Herbicidal compounds
Heterocyclic aromatic derivatives offer a solution to the challenges of weed control by providing effective herbicidal compositions that minimize environmental impact and resistance, improving crop yields.
Patent Information
- Application Number
- PCT/GB2026/050768
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Existing herbicides face challenges in effectively controlling weeds like Amaranthus retroflexus, which cause significant crop yield loss due to competition, allelopathic effects, and herbicide resistance, while also posing environmental risks and requiring large quantities for efficacy.
Development of heterocyclic aromatic derivatives and herbicidal compositions that can be applied as selective or non-selective herbicides, targeting weed growth through various application routes, minimizing environmental impact and resistance issues.
The heterocyclic derivatives provide effective weed control with reduced herbicide use, enhancing crop yields and minimizing environmental contamination, and reducing the development of resistant weeds.
Smart Images

Figure GB2026050768_12112026_PF_FP_ABST
Abstract
Description
[0001] 2026.05.07 DESCRIPTION P000685WO
[0002] HERBICIDAL COMPOUNDS
[0003] Field of the Invention
[0004] The present invention concerns the use of heterocyclic derivatives as herbicides. It further concerns herbicidal compositions which may be made using the heterocyclic derivatives and a method of controlling weeds at a locus.
[0005] Background of the Invention
[0006] The presence of undesired plants, for example weeds, increases demand on resources and effectively reduces the share of resources available to more useful plants, such as crops. This in turn reduces the yields of such crops affected by nearby weed growth. There exists a wide variety of plants commonly regarded as weeds in the context of crop growth, including broadleaf plants and grasses.
[0007] In addition to direct competition for resources, weeds are frequently allelopathic, i.e. they produce one or more biochemicals (often as secondary metabolites) which are capable of influencing the germination, growth, survival and reproduction of other organisms nearby. Such organisms can include other plant species or can include animal species. The process of allelopathy is a key element in the distribution of species and competition between them, and is also considered to be a significant weapon in the arsenal of many invasive species. Allelopathic weeds may be capable of inhibiting the growth of crop plants to a greater degree than by resource competition alone.
[0008] Agrochemicals, or agricultural chemicals, are those chemicals used for agricultural purposes. They are classified based on the role for which they are being used, e.g. pesticides for the controlling of pests, fungicides for the controlling of fungal growth, fertilisers for enhancing the nutrient content of the soil in which crops are grown, or herbicides, which are used to destroy unwanted vegetation.
[0009] Herbicides in particular may be selective or non-selective. The former are herbicides designed for use around desired plants / crops and seek to control weeds without damaging the desired plant / crop itself. The latter are herbicides which do not discriminate on variety of plant, but instead destroy all vegetation. Non-selective herbicides are therefore typically not used on crop fields during the growth of crops.
[0010] Herbicides may be applied by a variety of routes and may have a variety of mechanisms of action. They can be applied to the soil, to be absorbed by the roots / shoots of emerging weed2026.05.07 DESCRIPTION P000685WO
[0011] seedlings, or they can be applied to the leaves of existing plants. The choice of route can also dictate whether a herbicide is a pre-emergence herbicide (i.e. applied before the weed seedlings emerge at the surface) or a post-emergence herbicide (one which is applied after the weed seedlings have emerged through the soil surface). Each type of herbicide has particular considerations with respect to the method of application and how to achieve persistence in the soil.
[0012] The use of herbicides must be carefully managed. In general, herbicides are expensive substances and thus an economic motive exists for minimising their use. In addition, herbicide use can have undesirable environmental impact, for example in the contamination of groundwater, animal and human health concerns and in the development of herbicideresistant weeds. There is therefore an incentive to minimise the quantities of herbicides used in any one area needing weed control. This is not always easy, however, as the development of resistance to existing herbicides requires the use of ever larger quantities of herbicides.
[0013] The yields of crop plants can be significantly reduced by weed infestations. For example, redroot pigweed or Amaranthus retroflexus, is an aggressive and highly competitive weed in the growth of many crops. Its unchecked growth induces significant losses in the yields of soybeans, cotton, maize, sugar beet, sorghum among many others (Weaver et al., “The biology of Canadian weeds. 44. Amaranthus retroflexus L., A. powellii S. Wats, and A. hybridus L.”, Can. J. Plant. Sci., 1980, 60, 4, 1215-1234). The damage caused by A. retroflexus is not limited by geography either, indeed the weed is present globally. A. retroflexus has been reported to exhibit allelopathic effects on other weeds and crop plants, further reducing crop yields. It has also been implicated in harm to livestock, for example by facilitating the accumulation of harmful substances (e.g. nitrates and oxalates) in leaves and stems. In addition, A. retroflexus is known to be an additional vector for a range of crop pests and diseases, including parasitic weeds in tomato plants (Orobanche ramosa), aphids in orchards (Myzus persicae) and a cucumber mosaic virus in peppers (Weaver et al.). Many weeds, including A. retroflexus have developed resistance to existing herbicides (Francischini, A., et al. " Multiple-and Cross-Resistance of Amaranthus retroflexus to Acetolactate Synthase (ALS) and Photosystem II (PSII) Inhibiting Herbicides in Preemergence." Planta Daninha 37 (2019).) Similar problems and issues are encountered with many other weed species.
[0014] Accordingly, there is a strong incentive to develop new herbicides, to widen the range of available herbicides and to produce herbicides with superior properties, such as superior herbicidal performance or lower environmental impact. The compounds and compositions of the present invention represent a significant step forward in meeting these goals.2026.05.07 DESCRIPTION P000685WO
[0015] Summary of the Invention
[0016] The present invention relates to herbicidally active heterocyclic aromatic derivatives. The invention further extends to herbicidal compositions comprising such derivatives, as well as the use of such compounds and composition for controlling undesirable plant growth, such as weeds, and the method involved in such use.
[0017] The present invention provides in a first aspect a use of a compound as defined in claim 1 of general Formula (I) or an agriculturally acceptable salt thereof as a herbicide:
[0018]
[0019] In a second aspect the invention provides novel compounds or agriculturally acceptable salts thereof.
[0020] In a third aspect the invention provides a herbicidal composition, comprising a compound as defined in the first aspect of the invention or as provided in the second aspect of the invention and an agriculturally acceptable formulation adjuvant.
[0021] In a fourth aspect the invention provides a method of controlling weeds at a locus comprising application to the locus of a weed controlling amount of a composition according to the second aspect of the invention.
[0022] Brief Description of the Figure
[0023] Figure 1 shows the structures of some of the compounds from the Examples.
[0024] Detailed Description of the Invention
[0025] According to the present invention there is provided the use as a herbicide, of a compound of general Formula (I) or an agriculturally acceptable salt thereof:
[0026]
[0027] 2026.05.07 DESCRIPTION P000685WO
[0028] wherein Y is selected from O and S;
[0029] xi and X2 are independently selected from N and C;
[0030] X3 and X4 are independently selected from N, NR’”, CR’, C(=O), C(=S), O or S;
[0031] W is –(x5)n–;
[0032] each xs is independently selected from N, NRe, CR2, CR2R3, C(=O) and C(=S);
[0033] n is an integer in the range 1 to 4;
[0034] RA is absent or is selected from Re and R20;
[0035] R’ is selected from hydrogen, CN, nitro, halide, ORe, SRe, NReR?, NReOR?, NReNRyRs, ONReR?, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;
[0036] R’” is independently selected from Re and R20;
[0037] wherein group RA may form a cyclic structure with R’ or R’” on X3;
[0038] R1 is selected from C1.20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-20 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl and C5-20 heteroaryl, any of which may be optionally substituted;
[0039] wherein each R2 and R3 are independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NReR?, NReOR?, NReNR? Re, ONReR?, ON(=CRe), R20, OR20, SR20, NR6R20, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl and C5-20 heteroaryl, any of which may be optionally substituted;
[0040] wherein group R1 may form a cyclic structure with any of Re, R2 or R3 on adjacent unit X5;
[0041] RG, R? and Rs are independently selected from the group consisting of H, Ci-ealkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce-2o aryl, C5-20 heteroaryl which may be optionally substituted; wherein Re may independently or together with R? form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl, any of which may be optionally substituted;
[0042] R20 is selected from the group consisting of2026.05.07 DESCRIPTION P000685WO
[0043] C(=O)Re,
[0044] C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,
[0045] S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,
[0046] SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,
[0047] C(=S)R6, C(=S)OR6, C(=S)NR6R7,
[0048] CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).
[0049] In this invention, the optional substituents may be selected from cyano (CN), nitro (NO2), halogen, ORe, SRe, NR8R7, NR8OR7, NR8NR7R8, R2o, OR2o, SR2o, NR8R2o, C1-6 alkyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C8-2o aryl, Cs-2o heteroaryl, C2.8alkenyl and C2.8alkynyl, any of which may themselves be optionally substituted.
[0050] Alternatively, in this invention, the optional substituents may be selected from oxo, cyano (CN), nitro (NO2), halogen, ORe, SRe, NReR7, NReOR7, NReNR7R8, R2o, OR2o, SR2o, NReR2o, C1-6 alkyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce-2o aryl, Cs-2o heteroaryl, C2.6 alkenyl and C2.6 alkynyl, any of which may themselves be optionally substituted.
[0051] In this invention, where substituents are said to “include” certain groups, said groups are encompassed but not limiting.
[0052] Preferred optional substituents are selected from halo, cyano, nitro, OH, C1.4 alkyl, C1.4 haloalkyl, C1.4 alkoxy, C1.4 carboxyl, C1.4 alkylcarbonyl, C2.8alkenyl, C2.8alkynyl, C8-2o aryl, and Cs-2o heteroaryl. These substituents may themselves be optionally substituted, where applicable. For instance, C1.4 alkyl may be substituted with halide (to give C1.4 haloalkyl).
[0053] There may be more than one optional substituent. For instance, there may be one, two or three optional substituents.
[0054] The group R2o may be selected, along with the groups R8, R7and R8where appropriate to give the preferred compounds outlined herein.
[0055] Preferred groups for R2o include C(=O)R8, C(=O)OR8, C(=O)NR8R7, and S(=O)R8.2026.05.07 DESCRIPTION P000685WO
[0056] The above substituent groups may be chosen such that they include an ether, alkoxyamine, oxime, ester, carbonate, carbamate, sulphite, sulphide, sulphinyl, sulphonyl, sulphinic acid, sulphinamide, sulphonamide, sulphonimidamides, sulphilimine, sulphoximine, sulphenamide, thiolester, thiocarbonate, thiocarbamate, ketone, amide, imide, diketone, ketoacid, ketoamide, acetamide, thioaldehyde, thionoester, thioamide, imine, carboxi midate, enamine, azo, nitrile, isonitrile, cyanate or isocyanate.
[0057] Groups Re, R? and Rs are independently selected from the group consisting of H, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce-2oaryl, C5-20 heteroaryl which may be optionally substituted; wherein Re may independently or together with R? form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl which may be optionally substituted. Optional substituents may be chosen from those groups listed above.
[0058] Preferred groups for Re and R? and Rs include H, C1.4 alkyl and C1.4 haloalkyl. Haloalkyl is formed from a C1.4 alkyl group which may be optionally substituted with a halo group.
[0059] Preferably, in compounds of formula (I), Y is O and the formula (I) is therefore as follows:
[0060]
[0061] wherein groups R1, W, RA and X1-X4 are as defined above for formula (I).
[0062] In compounds described herein, W is -(xs)n- where each X5 is independently selected from N, NR6, CR2, CR2R3, C(=O) and C(=S).
[0063] In an embodiment, each X5 is independently selected from N, NRs, CR2, CR2R3, and C(=S).
[0064] n is an integer in the range 1 to 4, that is, n may be 1, 2, 3 or 4. In one embodiment, n is an integer in the range 2 to 4, that is, n is 2, 3 or 4.
[0065] The ring including W may be a 5 or 6 membered ring. Alternatively, the ring including W may be a 7 membered ring. The W group may contain heteroatoms such as N or O. It may alternatively contain other groups such as a ketone, C(=O), group. Depending on the choice2026.05.07 DESCRIPTION P000685WO
[0066] of substituents, the group W may create a ring that may be either aromatic or non-aromatic and have varying degrees of saturation.
[0067] For instance, W may be:
[0068] • -CR2R3- (forming a 5 membered ring)
[0069] • -CR2R3CR2R3- (forming a 6 membered ring)
[0070] • -CR2CR2- (forming a 6 membered ring)
[0071] • -CR2R3CR2R3CR2R3- (forming a 7 membered ring)
[0072] Preferably R3 (when present) is H and / or R2 is H.
[0073] R2 and R3 are typically H. Other groups for R2 and R3 include cyano (CN), nitro (NO2), halogen, ORe, SRe, NReR?, NReOR?, NReNRyRs, R20, OR20, SR20, NR6R20, C1-6 alkyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, C2-6 alkenyl and C2-6 alkynyl which may themselves be optionally substituted.
[0074] Alternatively, R2 and / or R3 may be C1.20 alkyl (typically C1.4 alkyl), C1.20 alkoxy, which may themselves be optionally substituted, halo, hydroxy, nitro, cyano or include a keto, ester, C2-6 alkenyl, C2-6 alkynyl or an amide group.
[0075] R2 and R3 in the same and / or adjacent units in -(xs)nmay be linked to form a cyclic structure. They may be linked, for instance, to form a cyclic, heterocyclic, or an aromatic ring.
[0076] Preferred groups for R2 include H, CN, nitro, OH and halide (particularly Cl and Br).
[0077] Compound of formula (I) may have formula:
[0078]
[0079] In these formulae:
[0080] Y is selected from O and S;
[0081] xi and X2 are independently selected from N and C;
[0082] X3 and X4 are independently selected from N, NR’”, CR’, C(=O), C(=S), O or S;2026.05.07 DESCRIPTION P000685WO
[0083] R’ is selected from hydrogen, CN, nitro, halide, ORe, SRe, NReR?, NReOR7, NReNR? Re, ONReR?, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;
[0084] R’” is selected from Re and R20;
[0085] RA is absent or is selected from Re and R20;
[0086] wherein group RA may form a cyclic structure with R’ or R’” on X3;
[0087] R1 is selected from C1.20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-20 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;
[0088] wherein group R1 may form a cyclic structure with any of R2 or R3;
[0089] wherein each R2 and each R3 are independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NReR?, NReOR?, NReNR? Re, ONReR?, ON(=CRe), R20, OR20, SR20, NR6R2O, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl any of which may be optionally substituted;
[0090] RG, R? and Rs are independently selected from the group consisting of H, Ci-ealkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted; wherein Re may independently or together with R? form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl any of which may be optionally substituted;
[0091] R20 is selected from the group consisting of
[0092] C(=O)Re,
[0093] C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,
[0094] S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R?, S(=O)2NR6R?, S(=O)2NR? COR6, S(=O)(=NR8)NR6R?, S(=O)(=NR6)R?, S(=NR6)R?,
[0095] SC(=O)R6, SC(=O)OR6, SC(=O)NR6R?,2026.05.07 DESCRIPTION P000685WO
[0096] C(=S)R6, C(=S)OR6, C(=S)NR6R7,
[0097] CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).
[0098] Each individual R2 and each individual R3 group may be different. Accordingly, the formulae of the compounds of the invention may be drawn as follows:
[0099]
[0100] wherein each R2A and R2B, R3Aand R3Bare independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NR6R7, NR6OR7, NR6NR7R8, ONR6R7, ON(=CR8), R20, OR20, SR20, NR6R2O,, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;
[0101] In these formulae, R2B is preferably H.
[0102] Preferably, R2A is H.
[0103] Preferably, R2A, R2B, RSA and RSB are all H.
[0104] The above recited formulae comprise a 5-membered aromatic heterocycle on the left hand side of the molecule as part of the bicyclic ring structure. Such heterocycles may comprise multiple isomers and tautomers.
[0105] On the right hand side of the molecule is a further cyclic structure preferably comprising a cyclic amide. The cyclic amide is substituted, i.e. there is a substituent R1 which is not H. There may be further substituents around the ring. In a preferred embodiment, the ring atoms in the alpha positions relative to the remainder of the molecule is not substituted, i.e. the alphacarbon bears at least one hydrogen.
[0106] In some compounds, RA is absent.
[0107] In preferred compounds, RA is selected from the group consisting of hydrogen, C1.10 alkyl, Ci- 10 haloalkyl, C2-10 alkene, C2-10 alkyne, keto or ester, any of which may be optionally substituted;2026.05.07 DESCRIPTION P000685WO
[0108] preferably wherein RA is selected from the group consisting of H, CMO alkyl, Ci-w haloalkyl, C2-10 alkene, C2-10 alkyne, any of which may be optionally substituted. RA IS preferably C1.4 alkyl or H, and is most preferably H.
[0109] In one embodiment, R1 is not optionally substituted C6-20 aryl. In one embodiment, R1 is not optionally substituted C5-20 heteroaryl. In a preferred embodiment, R1 is selected from C1.20 alkyl, C2-20 alkenyl, C2-2oalkynyl, C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-20 cycloalkenyl, C3-10 heterocycloalkenyl, any of which may be optionally substituted. In a further preferred embodiment, R1 is selected from C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-20 cycloalkenyl, C3-10 heterocycloalkenyl, any of which may be optionally substituted.
[0110] In one embodiment of the invention, R1 is -(CR”R ”)m-Alk wherein m is an integer in the range 0 to 4; each R” is independently selected from H and Ci-e alkyl which is optionally substituted and Aik is optionally substituted C1.10 alkyl or optionally substituted C3-10 cycloalkyl. Typically Aik is selected from optionally substituted cyclopentyl, cyclohexyl and cycloheptyl, m is preferably 1 and / or each R” is preferably H.
[0111] In a different embodiment of the invention, R1 is -(CR ”R ”)m-Aryl wherein m is an integer in the range 0 to 4; each R” is independently selected from H and Ci-e alkyl which is optionally substituted, and Aryl is C6-20 aryl or C5-20 heteroaryl which may be optionally substituted; preferably wherein Aryl is phenyl, which is optionally substituted in the ortho and / or para positions, preferably substituted with halide, m is preferably 1 and / or each R” is preferably H.
[0112] Typically, Aryl is phenyl, pyridine or pyrimidine, any of which may be optionally substituted.
[0113] The optional substituents on the Aik and Aryl may selected from one or more of the following: C O alkyl, CMO haloalkyl, halide, CN, nitro, hydroxyl and CMO alkoxy, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C6-20 aryl, C5-20 heteroaryl; wherein any of the alkyl or aryl groups may themselves be optionally substituted.
[0114] In one embodiment of the invention, R1 has the forrnula-(CH2)m-Z wherein m is an integer in the range 0-4 and Z is selected from Ci-e alkyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl and C5-20 heteroaryl, any of which may be optionally substituted. Typically Z is selected from C3-10 cycloalkyl, C3-6 heterocycloalkyl, C6-20 aryl and C5-20 heteroaryl, any of which may be optionally substituted. In this embodiment, the optional substituents are preferably selected from one of more of halide, OH, Ci-e alkoxy and2026.05.07 DESCRIPTION P000685WO
[0115] CN. The optional substituents are more preferably selected from halide, OH, OMe and CN. In a preferred embodiment, m = 0 or 1. Most preferably m is 1.
[0116] In a different embodiment, Ri is -(CH2)m-Z wherein Z is selected from C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, wherein Z may be optionally substituted and m is an integer in the range 1 to 4.
[0117] In one preferred embodiment of the invention, Z is selected from C3-10 cycloalkyl and C3-10 heterocycloalkyl, any of which may be optionally substituted. The rings may comprise one or more heteroatoms or contain within the ring one or more keto groups, C=O. The heterocyclyl groups may, for instance, comprise an N, S or an O atom as part of the ring. Suitable heterocyclyl groups are 5 or 6 membered rings containing one or more heteroatoms, the heteroatoms typically selected from N and O. Preferably there is one heteroatom present, for instance selected from N and O.
[0118] The cycloalkyl group for Z is typically selected from optionally substituted cyclopentyl, cyclohexyl and cycloheptyl.
[0119] In an embodiment, the heterocycloalkyl group forZ may be derived from one of the following: tetrahydrofuran, tetrahydropyran, 1,4 dioxane, pyrrolidine, piperidine, tetrahydrothiophene, tetrahydrothiopyran, morpholine, any of which may be optionally substituted.
[0120] The optional substituents on the any of the cyclic groups (such as the cycloalkyl or heterocycloalkyl) groups may be selected from one or more of the following: C1.10 alkyl (preferably, Ci-e alkyl), C1.10 haloalkyl, halide, CN, nitro, hydroxyl and C1.10 alkoxy, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C6-20 aryl, C5-20 heteroaryl; wherein any of the alkyl or aryl groups may themselves be optionally substituted.
[0121] The optional substituents are preferably selected from one of more of halide, OH, Ci-e alkoxy and CN. The optional substituents are more preferably selected from halide, OH, OMe and CN.
[0122] There may be more than one optional substituent on the group Z.
[0123] The optional substituents are preferably halide. There may be two or more halide substituents on the group R1.2026.05.07 DESCRIPTION P000685WO
[0124] The halide substituents are typically selected from F, Cl and Br. When there is more than one halide substituent, the halide substituents may be the same or different.
[0125] Some groups for Z are aromatic groups. For instance Z may be selected from Ce-2o aryl and C5-20 heteroaryl, either of which may be optionally substituted. For instance Z may be phenyl, pyridine or pyrimidine, any of which may be optionally substituted. When the group Z comprises an aromatic group, typically there is a linker CH2 group between the aromatic group and the rest of the molecule.
[0126] There may be more than one optional substituent on the group Z.
[0127] When Z is C6-20 aryl or C5-20 heteroaryl, the optional substituents are preferably halide. There may be two or more halide substituents on the group Z.
[0128] The halide substituents are typically selected from F, Cl and Br. When there is more than one halide substituent, the halide substituents may be the same or different.
[0129] In one embodiment of the invention, R1 is -(CHR)m-Aryl wherein m is in the range 0 to 4 and Aryl is selected from C6-20 aryl and C5-20 heteroaryl, either of which may be optionally substituted. Typically R may be selected from H orCi-ealkyl. Typically, m is not zero and hence m is in the range 1 to 4. Preferably, m=1.
[0130] Typically, in this embodiment, Aryl is phenyl, pyridine or pyrimidine; preferably which is optionally substituted, preferably wherein the optional substituents are selected from one or more of the following: C1.10 alkyl, C1.10 haloalkyl, halide, hydroxyl and C1.10 alkoxy.
[0131] In these embodiments wherein R1 is -(CH2)m-Z, -(CR”R”)m-Alk or -(CR”R”)m-Aryl, m is an integer in the range 0 to 4, that is, m may take any of the values 0,1, 2, 3 or 4. Preferably, m is an integer in the range 1 to 4, and is most preferably equal to 1.
[0132] xsand X4 are typically selected from N, NR’”, CR’, O and S.
[0133] In one embodiment of the invention, X3 is NR’”, wherein preferably R’” is selected from H, Ci- 4 alkyl, and C(=O)Re, typically wherein Reis Ci-e alkyl.2026.05.07 DESCRIPTION P000685WO
[0134] In one embodiment of the invention, X4 is CR’, wherein R’ is preferably selected from H, C1.4 alkyl and halide.
[0135] In an alternative embodiment of the invention, X3 orx4 is C(=O) or C(=S). Such a compound may for instance take the form:
[0136]
[0137] Such compounds may tautomerize into compounds containing an aromatic ring on the left hand side of the molecule, for instance the above compound may tautomerize as follows:
[0138]
[0139] Typical compounds useful in this invention have formulae comprising any one of substructures A to H, which may include any of the preferred groups or structures recited above. These compounds may be novel compounds in their own right. They can be incorporated into agricultural or herbicidal compositions of the invention as described below.
[0140]
[0141] 2026.05.07 DESCRIPTION P000685WO
[0142]
[0143] In one embodiment, the compound does not have substructure (A).
[0144] In one embodiment, the compound does not have substructure (B).
[0145] In one embodiment, the compound does not have substructure (C).
[0146] In one embodiment, the compound does not have substructure (D).
[0147] In one embodiment, the compound does not have substructure (E).
[0148] In one embodiment, the compound does not have substructure (F).
[0149] In one embodiment, the compound does not have substructure (G).
[0150] In one embodiment, the compound does not have substructure (H).
[0151] Substructure A
[0152] The compounds useful in this invention may have formula (IA):
[0153]
[0154] In compounds of formula IA,
[0155] Y is selected from O and S;
[0156] W is –(x5)n–;
[0157] each xs is independently selected from N, NRe, CR2, CR2R3, C(=O) and C(=S);
[0158] n is an integer in the range 1 to 4;
[0159] R1 is selected from C1-20 alkyl, C2-20 alkenyl, C2-2oalkynyl, C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-20 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl and C5-20 heteroaryl, any of which may be optionally substituted;
[0160] wherein group R1 may form a cyclic structure with any of Re, R2 or R3 on adjacent unit X5;
[0161] wherein each R2 and R3 are independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NReR?, NReOR?, NReNRyRs, ONReR?, ON(=CRe), R20, OR20, SR20, NR6R20, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-102026.05.07 DESCRIPTION P000685WO
[0162] cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20heteroaryl any of which may be optionally substituted;
[0163] R6, R7and R8are independently selected from the group consisting of H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20aryl, C5-20heteroaryl which may be optionally substituted; wherein R6may independently or together with R7form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-10aryl or C5-10 heteroaryl any of which may be optionally substituted;
[0164] R20 is selected from the group consisting of
[0165] C(=O)Re,
[0166] C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,
[0167] S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,
[0168] SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,
[0169] C(=S)R6, C(=S)OR6, C(=S)NR6R7,
[0170] CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).
[0171] In an embodiment of the invention, the compound is not any one of the following:
[0172]
[0173] 2026.05.07 DESCRIPTION P000685WO
[0174]
[0175] In an embodiment of the invention, the compound is not any one of the following:
[0176]
[0177] 2026.05.07 DESCRIPTION P000685WO
[0178]
[0179] In one embodiment, Ri is not optionally substituted C6-20 aryl. In one embodiment, R1 is not optionally substituted C5-20 heteroaryl. In a preferred embodiment, R1 is selected from C1.20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-20 cycloalkenyl, C3-10 heterocycloalkenyl, any of which may be optionally substituted. In a further preferred embodiment, R1 is selected from C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-20 cycloalkenyl, C3-10 heterocycloalkenyl, any of which may be optionally substituted.
[0180] The compound of formula (I) may have formula:
[0181]
[0182] In these formulae:
[0183] Y is selected from O and S.
[0184] Each individual R2 and each individual R3 group may be different. Accordingly, the formulae may be drawn as follows:
[0185]
[0186] 2026.05.07 DESCRIPTION P000685WO
[0187] wherein each R2A and R2B, R3Aand R3Bare independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NReR?, NReOR?, NReNRyRs, ONReR?, ON(=CRe), R20, OR20, SR20, NR6R2O,, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted.
[0188] Preferred groups for R2A and R2B include H, CN, nitro, OH and halide.
[0189] In these formulae, R2B is preferably H.
[0190] Preferred compounds of the invention have the following formulae (HA) or (111 A):
[0191]
[0192] wherein R1 is selected from C1.20 alkyl, C2-20 alkenyl, C2-2oalkynyl, C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-20 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;
[0193] wherein group R1 may form a cyclic structure with any of R2;
[0194] wherein each R2is independently selected from the group consisting of hydrogen, CN, nitro, halide, OR6, SR6, NR6R7, NR6OR7, NR6NR7R8, ONR6R7, ON(=CR6), R20, OR20, SR20, NR6R20, C1-6alkyl, C2-6 alkenyl, C2-6alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl any of which may be optionally substituted;
[0195] R6, R7and R8are independently selected from the group consisting of H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted; wherein R6may independently or together with R7form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-10aryl or C5-10 heteroaryl which may be optionally substituted;
[0196] R20 is selected from the group consisting of
[0197] C(=O)Re,2026.05.07 DESCRIPTION P000685WO
[0198] C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,
[0199] S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,
[0200] SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,
[0201] C(=S)R6, C(=S)OR6, C(=S)NR6R7,
[0202] CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).
[0203] Each R2 and R3 group may be different. Formulae (HA) and (111 A) may therefore be drawn as follows:
[0204]
[0205] wherein each R2Aand R2B, R3Aand R3Bare independently selected from the group consisting of hydrogen, CN, nitro, halide, OR6, SR6, NR6R7, NR6OR7, NR6NR7R8, ONR6R7, ON(=CR6), R20, OR20, SR20, NR6R20, C1-6alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted.
[0206] In one embodiment, formulae (HA) and (IIIA) may take one of the following forms:
[0207]
[0208] wherein each R2is independently selected from the group consisting of hydrogen, CN, nitro, halide, OR6, SR6, NR6R7, NR6OR7, NR6NR7R8, ONR6R7, ON(=CR6), R20, OR20, SR20, NR6R20, C1-6alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted;2026.05.07 DESCRIPTION P000685WO
[0209] RG, R? and Rs are independently selected from the group consisting of H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted; wherein Re may independently or together with R7form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl which may be optionally substituted;
[0210] R20 is selected from the group consisting of
[0211] C(=O)Re,
[0212] C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,
[0213] S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,
[0214] SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,
[0215] C(=S)R6, C(=S)OR6, C(=S)NR6R7,
[0216] CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).
[0217] The cycloalkyl groups on the above formulae are optionally substituted.
[0218] Preferably, in compounds of formula (I), Y is O and the formula (I) is therefore as follows:
[0219]
[0220] wherein groups R1 and W are as defined above for formula (I).
[0221] In preferred embodiments of the invention wherein the compound comprises substructure A, and the group R1 comprises an aromatic group, R1 comprises a linker CH2, connecting the aromatic group to the rest of the molecule.
[0222] R1 preferably has the formula-(CH2)m-Z wherein m is an integer in the range 1-4 and Z is selected from C1.20 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl and C5-20 heteroaryl, any of which may be optionally substituted. Preferably, m=1.
[0223] R1 more preferably has the formula-(CH2)m-Z wherein m is an integer in the range 1-4 and Z is selected from Ci-8alkyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-102026.05.07 DESCRIPTION P000685WO
[0224] heterocycloalkenyl, C6-20 aryl and C5-20 heteroaryl, any of which may be optionally substituted. Preferably, m=1.
[0225] Alternatively, R1 is preferably -(CH2)m-Z wherein Z is selected from C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, and C3-10 heterocycloalkenyl, wherein Z may be optionally substituted and m is an integer in the range 1 to 4. Preferably m=1.
[0226] R1 may be -(CH2)m-C3-io cycloalkyl wherein the cycloalkyl may be optionally substituted and m is an integer in the range 1 to 4. Preferably, m=1.
[0227] In one preferred embodiment of the invention, Z is selected from C3-10 cycloalkyl and C3-10 heterocycloalkyl. The cycloalkyl rings may comprise one or more heteroatoms or contain one or more keto groups, C=O. The cycloalkyl group is typically selected from optionally substituted cyclopentyl, cyclohexyl and cycloheptyl.
[0228] m is an integer in the range 1 to 4, that is, m may take any of the values 1, 2, 3 or 4.
[0229] Preferably, m is 1.
[0230] The optional substituents on the cycloalkyl may be selected from one or more of the following (in a non-exhaustive list): C1.10 alkyl, C1.10 haloalkyl, halide, CN, nitro, hydroxyl and Ci- alkoxy, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C6-20 aryl, C5-20 heteroaryl; wherein any of the alkyl or aryl groups may themselves be optionally substituted.
[0231] The optional substituents on the R1 group are preferably selected from one of more of halide, OH, C1.6 alkoxy and CN. The optional substituents are more preferably selected from halide, OH, OMe and CN.
[0232] There may be more than one optional substituent on the group R1.
[0233] The optional substituents are preferably halide. There may be two or more halide substituents on the group R1.
[0234] The halide substituents are typically selected from F, Cl and Br. When there is more than one halide substituent, the halide substituents may be the same or different.
[0235] Substructure B
[0236] The compounds useful in this invention may have formula (IB):2026.05.07 DESCRIPTION P000685WO
[0237]
[0238] In compounds of formula IB,
[0239] Y is selected from O and S;
[0240] RA is selected from Re and R20;
[0241] R’ is selected from hydrogen, CN, nitro, halide, ORe, SRe, NReR?, NReOR?, NReNRyRs, ONReR?, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;
[0242] W is –(x5)n–;
[0243] each X5 is independently selected from N, NRe, CR2, CR2R3, C(=O) and C(=S);
[0244] n is an integer in the range 1 to 4;
[0245] R1 is selected from C1.20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-20 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;
[0246] wherein group R1 may form a cyclic structure with any of Re, R2 or R3 on adjacent unit X5;
[0247] wherein each R2 and R3 are independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NReR?, NReOR?, NReNR? Re, ONReR?, ON(=CRe), R20, OR20, SR20, NR6R20, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;
[0248] RG, R? and Rs are independently selected from the group consisting of H, Ci-ealkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted; wherein Re may independently2026.05.07 DESCRIPTION P000685WO
[0249] or together with R7form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl which may be optionally substituted;
[0250] R20 is selected from the group consisting of
[0251] C(=O)Re,
[0252] C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,
[0253] S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,
[0254] SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,
[0255] C(=S)R6, C(=S)OR6, C(=S)NR6R7,
[0256] CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).
[0257] In preferred embodiments, R’ is selected from H, halo, and C1.4 alkyl.
[0258] Substructure C
[0259] The compounds useful in this invention may have formula (IC):
[0260]
[0261] In compounds of formula (IC):
[0262] Y is selected from O and S;
[0263] R’is selected from hydrogen, CN, nitro, halide, ORe, SRe, NR6R7, NR6OR7, NR6NR7R8, ONR6R7, ON(=CR8), R2O, OR2O, SR2O, NR8R2O, C1-6 alkyl, C2.8alkenyl, C2.8alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C8-2o aryl, Cs-2o heteroaryl, any of which may be optionally substituted;
[0264] R’” is selected from R8and R28;
[0265] W is –(x5)n–;
[0266] each X5 is independently selected from N, NR8, CR2, CR2R8, C(=O) and C(=S);
[0267] n is an integer in the range 1 to 4;2026.05.07 DESCRIPTION P000685WO
[0268] Ri is selected from C1-20 alkyl, C2-20 alkenyl, C2-2oalkynyl, C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-20 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;
[0269] wherein group R1 may form a cyclic structure with any of R8, R2 or R3 on adjacent unit x5;
[0270] wherein each R2 and R3 are independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NR6R7, NR6OR7, NR6NR7R8, ONR6R7, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;
[0271] RG, R7 and Rs are independently selected from the group consisting of H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted; wherein Re may independently or together with R7form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl which may be optionally substituted;
[0272] R20 is selected from the group consisting of
[0273] C(=O)Re,
[0274] C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,
[0275] S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,
[0276] SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,
[0277] C(=S)R6, C(=S)OR6, C(=S)NR6R7,
[0278] CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).
[0279] In preferred embodiments, R’ is selected from H, halo, and C1.4 alkyl.
[0280] Even more preferably, R’ is halo, and is typically Cl.
[0281] In one embodiment, R1 is -(CR2R3)m-Alk or -(CR2R3)n-Aryl;
[0282] wherein m is in the range 0 to 4, R2 and R3 are independently selected from H and Ci-8alkyl which is optionally substituted; Aik is selected from optionally substituted cyclopentyl, cyclohexyl and cycloheptyl; and Aryl is C6-20 aryl or C5-20 heteroaryl which may be optionally2026.05.07 DESCRIPTION P000685WO
[0283] substituted; preferably wherein Aryl is phenyl, which is optionally substituted in the ortho and / or para positions, preferably substituted with halide.
[0284] Typically, the compound is not:
[0285]
[0286] The compound is also typically not:
[0287]
[0288] or
[0289] R’” is typically selected from H and C1.4 alkyl.
[0290] Other possible substructures are as follows:
[0291] Substructure D
[0292] The compounds useful in this invention may have formula (ID):2026.05.07 DESCRIPTION P000685WO
[0293]
[0294] In compounds of formula (ID):
[0295] Y is selected from O and S;
[0296] W is –(x5)n–;
[0297] each X5 is independently selected from N, NR6, CR2, CR2R3, C(=O) and C(=S);
[0298] n is an integer in the range 1 to 4;
[0299] R1 is selected from C1-20 alkyl, C2-20 alkenyl, C2-2oalkynyl, C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-20 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;
[0300] wherein group R1 may form a cyclic structure with any of R6, R2 or R3 on adjacent unit X5;
[0301] wherein each R2 and R3 are independently selected from the group consisting of hydrogen, CN, nitro, halide, OR6, SR6, NR6R7, NR6OR7, NR6NR7R8, ONR6R7, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;
[0302] RG, R7 and Rs are independently selected from the group consisting of H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted; wherein Re may independently or together with R7form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl, any of which may be optionally substituted;
[0303] R20 is selected from the group consisting of
[0304] C(=O)Re,
[0305] C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,
[0306] S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,2026.05.07 DESCRIPTION P000685WO
[0307] SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,
[0308] C(=S)R6, C(=S)OR6, C(=S)NR6R7,
[0309] CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).
[0310] Substructure E
[0311] The compounds useful in this invention may have formula (IE):
[0312]
[0313] In compounds of formula (IE):
[0314] Y is selected from O and S;
[0315] RA is selected from R8and R20;
[0316] each R’is independently selected from hydrogen, CN, nitro, halide, OR8, SR8, NR6R7, NR6OR7, NR6NR7R8, ONR6R7, ON(=CR8), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-e alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;
[0317] W is –(x5)n–;
[0318] each X5 is independently selected from N, NR8, CR2, CR2R3, C(=O) and C(=S);
[0319] n is an integer in the range 1 to 4;
[0320] R1 is selected from C1.20 alkyl, C2-20 alkenyl, C2-2oalkynyl, C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-20 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;
[0321] wherein group R1 may form a cyclic structure with any of R8, R2 or R3 on adjacent unit x5;
[0322] wherein each R2 and R3 are independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NR6R7, NR6OR7, NR6NR7R8, ONR6R7, ON(=CR8), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;2026.05.07 DESCRIPTION P000685WO
[0323] RG, R? and Rs are independently selected from the group consisting of H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted; wherein Re may independently or together with R7form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl, any of which may be optionally substituted;
[0324] R20 is selected from the group consisting of
[0325] C(=O)Re,
[0326] C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,
[0327] S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,
[0328] SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,
[0329] C(=S)R6, C(=S)OR6, C(=S)NR6R7,
[0330] CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).
[0331] The groups R’ may be different. Accordingly the structure of formula (IE) may be as follows:
[0332]
[0333] wherein each R’ group R’Aand R’Bare independently selected from hydrogen, CN, nitro, halide, ORe, SRe, NR6R7, NR6OR7, NR6NR7R8, ONR6R7, ON(=CR8), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted.
[0334] In preferred embodiments, R’ is selected from H, halo, and C1.4 alkyl.
[0335] Substructure F
[0336] The compounds useful in this invention may have formula (IF):2026.05.07 DESCRIPTION P000685WO
[0337]
[0338] In compounds of formula (IF):
[0339] Y is selected from O and S;
[0340] each R’is independently selected from hydrogen, CN, nitro, halide, ORe, SRe, NReR?, NReOR?, NReNRyRs, ONReR?, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, 02-ealkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;
[0341] W is –(x5)n–;
[0342] each X5 is independently selected from N, NRe, CR2, CR2R3, C(=O) and C(=S);
[0343] n is an integer in the range 1 to 4;
[0344] R1 is selected from C1.20 alkyl, C2-20 alkenyl, C2-2oalkynyl, C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-20 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;
[0345] wherein group R1 may form a cyclic structure with any of Re, R2 or R3 on adjacent unit X5;
[0346] wherein each R2 and R3 are independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NReR?, NReOR?, NReNR? Re, ONReR?, ON(=CRe), R20, OR20, SR20, NR6R20, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted;
[0347] RG, R? and Rs are independently selected from the group consisting of H, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted; wherein Re may independently or together with R? form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl which may be optionally substituted;2026.05.07 DESCRIPTION P000685WO
[0348] R20 is selected from the group consisting of
[0349] C(=O)Re,
[0350] C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,
[0351] S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,
[0352] SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,
[0353] C(=S)R6, C(=S)OR6, C(=S)NR6R7,
[0354] CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).
[0355] The groups R’ may be different. Accordingly the structure of formula (IF) may be as follows:
[0356]
[0357] wherein each R’group R’Aand R’Bare independently selected from hydrogen, CN, nitro, halide, OR8, SR8, NR6R7, NR6OR7, NR6NR7R8, ONR6R7, ON(=CR8), R2o, OR2o, SR2o, NR8R2o, C1-6 alkyl, C2-6 alkenyl, C2.8alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C8-2o aryl, Cs-2o heteroaryl, any of which may be optionally substituted.
[0358] In preferred embodiments, R’ is selected from H, halo, and C1.4 alkyl.
[0359] Substructure G
[0360] The compounds useful in this invention may have formula (IG):
[0361]
[0362] In compounds of formula (IG):
[0363] Y is selected from O and S;
[0364] R’” is independently selected from R8and R28;2026.05.07 DESCRIPTION P000685WO
[0365] W is –(x5)n–;
[0366] each xs is independently selected from N, NR8, CR2, CR2R3, C(=O) and C(=S);
[0367] n is an integer in the range 1 to 4;
[0368] R1 is selected from C1-20 alkyl, C2-20 alkenyl, C2-2oalkynyl, C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-20 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;
[0369] wherein group R1 may form a cyclic structure with any of R8, R2 or R3 on adjacent unit x5;
[0370] wherein each R2 and R3 are independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NR6R7, NR6OR7, NR6NR7R8, ONR6R7, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl any of which may be optionally substituted;
[0371] R6, R7and R8are independently selected from the group consisting of H, C1-6alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted; wherein Re may independently or together with R7form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl any of which may be optionally substituted;
[0372] R20 is selected from the group consisting of
[0373] C(=O)Re,
[0374] C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,
[0375] S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,
[0376] SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,
[0377] C(=S)R6, C(=S)OR6, C(=S)NR6R7,
[0378] CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).
[0379] R’” is typically selected from H and C1.4 alkyl.
[0380] Substructure H
[0381] The compounds useful in this invention may have formula (IH):2026.05.07 DESCRIPTION P000685WO
[0382]
[0383] In compounds of formula (IH):
[0384] Y is selected from O and S;
[0385] RA is selected from Re and R20;
[0386] W is –(x5)n–;
[0387] each X5 is independently selected from N, NR6, CR2, CR2R3, C(=O) and C(=S);
[0388] n is an integer in the range 1 to 4;
[0389] R1 is selected from C1-20 alkyl, C2-20 alkenyl, C2-2oalkynyl, C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-20 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;
[0390] wherein group R1 may form a cyclic structure with any of R6, R2 or R3 on adjacent unit X5;
[0391] wherein each R2 and R3 are independently selected from the group consisting of hydrogen, CN, nitro, halide, OR6, SR6, NR6R7, NR6OR7, NR6NR7R8, ONR6R7, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted;
[0392] R6, R7and R8are independently selected from the group consisting of H, C1-6alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted; wherein Re may independently or together with R7form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl which may be optionally substituted;
[0393] R20 is selected from the group consisting of
[0394] C(=O)Re,
[0395] C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,2026.05.07 DESCRIPTION P000685WO
[0396] S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,
[0397] SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,
[0398] C(=S)R6, C(=S)OR6, C(=S)NR6R7,
[0399] CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).
[0400] The invention further provides agricultural (preferably, herbicidal) compositions comprising a compound of formula (I) or its preferred formulae (the various substructures and preferred embodiments as outlined above), together with an agriculturally acceptable formulation adjuvant. Also provided are such herbicidal compositions further comprising at least one additional herbicide. Further provided is a method of controlling weeds at a locus comprising application to the locus of a weed controlling amount of such a herbicidal composition.
[0401] Compounds of the invention have herbicidal activity.
[0402] By “herbicidal activity”, is meant the ability to kill or inhibit the growth of plants, plant cells, plant seeds or plant tissue or material, including but not limited to, weeds and seeds thereof.
[0403] A compound having herbicidal activity may be defined as having >0% (typically >5%, >10%, >15%, >20%, >25%, >30% or >35%) visual injury to AMARE & / or LOLMU, & / or POAAN, & / or ECHCG, & / or STEME, & / or CHEAL, and / or TRFPR at a rate of <1000 g / ha when applied pre emergence within a glasshouse environment.
[0404] A compound having herbicidal activity may be defined as having >40% visual injury to AMARE & / or LOLMU, & / or POAAN, & / or ECHCG, & / or STEME, & / or CHEAL, at a rate of <1000 g / ha when applied pre emergence within a glasshouse environment.
[0405] Alternatively, a compound having herbicide activity may be defined as causing >0% (typically >5%, >10%, >15%, >20%, >25%, >30%, >35%, >40% or >45%) visual injury to POAAN & / or ARBTH and / or PHLPR, at a concentration of 1 mM active ingredient when applied preemergence or at a concentration of 0.5 mM when applied post-emergence onto weeds grown on agar in 96 well plates.
[0406] Alternatively, a compound having herbicide activity may be defined as causing >50% visual injury to POAAN & / or ARBTH, at a concentration of 1 mM active ingredient when applied preemergence or at a concentration of 0.5 mM when applied post-emergence onto weeds grown on agar in 96 well plates.2026.05.07 DESCRIPTION P000685WO
[0407] Methods for measuring herbicidal activity are described later in the Examples.
[0408] Such activity is distinct from the crop protecting activity outlined in WO2018 / 116073 which uses 1,2,3-thiadiazole carboxamide and thioamide compounds to protect crops by fighting against undesired phytopathogenic microorganisms (such as fungal or nematodes or bacterial pathogens).
[0409] As used herein, a “weed” will be understood to refer to a plant growing in detrimental competition with the desired plants for any one or more of water, light, nutrients and / or space. Non-limiting characteristics of weeds include low or no economic value compared to the desired (e.g. cultivated) plants, the provision of ecological and / or economic damage, vigorous growth characteristics, and / or the production of large seed numbers.
[0410] As used herein, the term “plant material” refers to material derived from a plant. A plant is a living organism that grows in earth, in water or on other plants, and produces seeds. Plants include trees, shrubs, herbs, grasses, ferns, algae, mosses and weeds, including Arabidopsis.
[0411] As used herein, the terms “herbicide” and “herbicidal compound” refer to compounds or compositions capable of causing herbicidal activity as defined above.
[0412] The invention further provides agricultural compositions comprising a compound of formula (I) or its preferred formulae (the various substructures and preferred embodiments as outlined above), or the alternative formulae defined herein, together with an agriculturally acceptable formulation adjuvant. Further, the invention provides novel compounds of formula (I) or its preferred formulae (the various substructures and preferred embodiments as outlined above).
[0413] The invention further provides novel compounds, which can be designated with formula (I) or formula (X) as outlined in the claims. The novel compounds have herbicidal activity. They can be divided into groups A-G as outlined above. Group A compounds have formula A:
[0414]
[0415] 2026.05.07 DESCRIPTION P000685WO
[0416] wherein Y is selected from O and S;
[0417] W is –(x5)n–;
[0418] each x5is independently selected from N, NR6, CR2, CR2R3, C(=O) and C(=S);
[0419] n is an integer in the range 1 to 4;
[0420] wherein R1 is selected from C1.20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-20 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;
[0421] wherein each R2 and R3 are independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NReR7, NReOR7, NReNR7R8, ONReR7, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted;
[0422] Re, R7 and Rs are independently selected from the group consisting of H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted; wherein Re may independently or together with R7form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl which may be optionally substituted;
[0423] R20 is selected from the group consisting of
[0424] C(=O)Re,
[0425] C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,
[0426] S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,
[0427] SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,
[0428] C(=S)R6, C(=S)OR6, C(=S)NR6R7,
[0429] CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).
[0430] Typically, the compounds are not any one of the following:2026.05.07 DESCRIPTION P000685WO
[0431]
[0432] Preferably, Ri is not C6-20 aryl or C5-20 heteroaryl, which may be optionally substituted. Preferably, formula A has formula A(1) or A(2):
[0433]
[0434] wherein R1 is not C6-20 aryl or C5-20 heteroaryl, which may be optionally substituted.2026.05.07 DESCRIPTION P000685WO
[0435] In these formulae Ri is selected from C1-20 alkyl, C2-20 alkenyl, C2-2oalkynyl, C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-20 cycloalkenyl, C3-10 heterocycloalkenyl, any of which may be optionally substituted;
[0436] wherein each R2 is independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NR6R7, NR6OR7, NR6NR7R8, ONR6R7, ON(=CR6), R20, OR20, SR20, NR6R20, C1.6 alkyl, C2-6 alkenyl, C2-6alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted.
[0437] Re, R7, Rs and R20 are as defined above for formula (A).
[0438] Preferred groups for R2 include H, CN, nitro, OH and halide.
[0439] Preferred embodiments for compounds in group A are described above in relation to substructure A. Specific compounds are provided in the Examples.
[0440] Group B compounds have formula B:
[0441]
[0442] wherein Y is selected from O and S;
[0443] W is –(x5)n–;
[0444] each X5 is independently selected from N, NRe, CR2, CR2R3, C(=O) and C(=S);
[0445] n is an integer in the range 1 to 4;
[0446] RA is selected from Re and R20;
[0447] R’ is selected from hydrogen, CN, nitro, halide, ORe, SRe, NReR?, NReOR?, NReNR? Re, ONReR?, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;2026.05.07 DESCRIPTION P000685WO
[0448] wherein Ri is selected from C1.20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-20 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;
[0449] wherein each R2 and R3 are independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NR6R7, NR6OR7, NR6NR7R8, ONR6R7, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted;
[0450] Re, R7 and Rs are independently selected from the group consisting of H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted; wherein Re may independently or together with R7form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl which may be optionally substituted;
[0451] R20 is selected from the group consisting of
[0452] C(=O)Re,
[0453] C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,
[0454] S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,
[0455] SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,
[0456] C(=S)R6, C(=S)OR6, C(=S)NR6R7,
[0457] CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).
[0458] Preferred compounds of formula B have the following formulae:
[0459]
[0460] Substructure B(1) Substructure B(2)
[0461] RA, R’ and R1 are as defined above for formula (B).2026.05.07 DESCRIPTION P000685WO
[0462] Each R2 is independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NReR?, NReOR?, NReNRyRs, ONReR?, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted.
[0463] Group C compounds have Formula O’:
[0464]
[0465] wherein Y is selected from O and S;
[0466] W is –(x5)n–;
[0467] each X5 is independently selected from N, NRe, CR2, CR2R3, C(=O) and C(=S);
[0468] n is an integer in the range 1 to 4;
[0469] wherein each R2 and R3 are independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NReR?, NReOR?, NReNR? Re, ONReR?, ON(=CRe), R20, OR20, SR20, NR6R20, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted;
[0470] wherein R1 is selected from C1.20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-20 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;
[0471] R’ is selected from hydrogen, CN, nitro, halide, ORe, SRe, NReR?, NReOR?, NReNR? Re, ONReR?, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;
[0472] R’” is selected from Re and R20;2026.05.07 DESCRIPTION P000685WO
[0473] R6, R7and R8are independently selected from the group consisting of H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20aryl, C5-20heteroaryl which may be optionally substituted; wherein R6may independently or together with R7form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl which may be optionally substituted;
[0474] R20 is selected from the group consisting of
[0475] C(=O)Re,
[0476] C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,
[0477] S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,
[0478] SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,
[0479] C(=S)R6, C(=S)OR6, C(=S)NR6R7,
[0480] CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6);
[0481] with the proviso that the formula is not selected from one of the following:
[0482]
[0483] 2026.05.07 DESCRIPTION P000685WO
[0484] The compound is also typically not:
[0485]
[0486] or
[0487] Preferred compounds of Formula C’ have the following formulae:
[0488]
[0489] Substructure-C(l) Substructure-C(2)
[0490] Ri, R’ and R’” are as defined for formula (C) above. Preferably, R’ is halide, most typically Cl.
[0491] Each R2 is independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NReR?, NReOR?, NReNRyRs, ONReR?, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted.
[0492] Preferably, when the compound of group C has Formula C’(2):
[0493] R’ is halide and R1 is -(CR2R3)n-Alk or -(CR2R3)n-Aryl;
[0494] wherein n is in the range 0 to 4, R2 and R3 are independently selected from H and Ci-e alkyl which is optionally substituted; Aik is selected from optionally substituted cyclopentyl, cyclohexyl and cycloheptyl; and Aryl is C6-20 aryl or C5-20 heteroaryl which may be optionally substituted; preferably wherein Aryl is phenyl, which is optionally substituted in the ortho and / or para positions, preferably substituted with halide.
[0495] Typically, R’ is Cl.2026.05.07 DESCRIPTION P000685WO
[0496] The invention further provides a compound of general Formula (I’) or an agriculturally acceptable salt thereof:
[0497] zs. >7
[0498] N NW, N~RI
[0499] (I’)
[0500] wherein Y is selected from O and S;
[0501] W is –(x5)n–;
[0502] each xs is independently selected from N, NRe, CR2, CR2R3, C(=O) and C(=S);
[0503] n is an integer in the range 1 to 4;
[0504] R1 is -(CH2)m-Z wherein Z is selected from C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, and C3-10 heterocycloalkenyl, wherein Z may be optionally substituted and m is an integer in the range 1 to 4;
[0505] wherein each R2 and R3 are independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NReR7, NReOR7, NReNR7Rs, ONReR7, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;
[0506] wherein group R1 may form a cyclic structure with any of Re, R2 or R3 on adjacent unit X5;
[0507] R6, R7and R8are independently selected from the group consisting of H, C1-6alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted; wherein Re may independently or together with R7form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl, any of which may be optionally substituted;
[0508] R20 is selected from the group consisting of
[0509] C(=O)Re,
[0510] C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,
[0511] S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,2026.05.07 DESCRIPTION P000685WO
[0512] SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,
[0513] C(=S)R6, C(=S)OR6, C(=S)NR6R7,
[0514] CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).
[0515] In this invention, where substituents are said to “include” certain groups, said groups are encompassed but not limiting.
[0516] Preferred optional substituents are selected from halo, cyano, nitro, OH, C1.4 alkyl, C1.4 haloalkyl, C1.4 alkoxy, C1.4 carboxyl, C1.4 alkylcarbonyl, C2-3 alkenyl, C2-6 alkynyl, C6-20 aryl, and C5-20 heteroaryl. These substituents may themselves be optionally substituted, where applicable. For instance, C1.4 alkyl may be substituted with halide (to give C1.4 haloalkyl).
[0517] There may be more than one optional substituent. For instance, there may be one, two or three optional substituents.
[0518] The group R20 may be selected, along with the groups R6, R7and R8where appropriate to give the preferred compounds outlined herein.
[0519] Preferred groups for R20 include C(=O)R6, C(=O)OR6, C(=O)NR6R7, and S(=O)R6.
[0520] The above substituent groups may be chosen such that they include an ether, alkoxyamine, oxime, ester, carbonate, carbamate, sulphite, sulphide, sulphinyl, sulphonyl, sulphinic acid, sulphinamide, sulphonamide, sulphonimidamides, sulphilimine, sulphoximine, sulphenamide, thiolester, thiocarbonate, thiocarbamate, ketone, amide, imide, diketone, ketoacid, ketoamide, acetamide, thioaldehyde, thionoester, thioamide, imine, carboxi midate, enamine, azo, nitrile, isonitrile, cyanate or isocyanate.
[0521] Groups R6, R7and R8are independently selected from the group consisting of H, C1-6alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20aryl, C5-20 heteroaryl which may be optionally substituted; wherein R6may independently or together with R7form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-10aryl or C5-10 heteroaryl which may be optionally substituted. Optional substituents may be chosen from those groups listed above.
[0522] Preferred groups for R6and R7and R8include H, C1-4 alkyl and C1-4 haloalkyl. Haloalkyl is formed from a C1.4 alkyl group which may be optionally substituted with a halo group.2026.05.07 DESCRIPTION P000685WO
[0523] Preferably, in compounds of formula (I’), Y is O and the formula (I’) of the compound is therefore as follows:
[0524]
[0525] wherein groups Ri and W are as defined above for formula (I’).
[0526] In compounds described herein, W is -(xs)n- where each X5 is independently selected from N, NR6, CR2, CR2R3, C(=O) and C(=S).
[0527] In a preferred embodiment, each X5 is independently selected from N, NR6, CR2, CR2R3, and C(=S).
[0528] n is an integer in the range 1 to 4, that is, n may be 1, 2, 3 or 4. In one embodiment, n is an integer in the range 2 to 4, that is, n is 2, 3 or 4.
[0529] The ring including W may be a 5 or 6 membered ring. Alternatively, the ring including W may be a 7 membered ring. The W group may contain heteroatoms such as N or O. It may alternatively contain other groups such as a ketone, C(=O), group. Depending on the choice of substituents, the group W may create a ring that may be either aromatic or non-aromatic and have varying degrees of saturation.
[0530] For instance, W may be:
[0531] • -CR2R3- (forming a 5 membered ring)
[0532] • -CR2R3CR2R3- (forming a 6 membered ring)
[0533] • -CR2CR2- (forming a 6 membered ring)
[0534] • -CR2R3CR2R3CR2R3- (forming a 7 membered ring)
[0535] Preferably R3 (when present) is H and / or R2is H.
[0536] R2and R3 are typically H. Other groups for R2and R3 include cyano (CN), nitro (NO2), halogen, ORe, SRe, NR6R7, NR6OR7, NR6NR7R8, R20, OR20, SR20, NR6R20, C1-6 alkyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20aryl, C5-20heteroaryl, C2-
[0537] 6 alkenyl and C2.6 alkynyl which may themselves be optionally substituted.2026.05.07 DESCRIPTION P000685WO
[0538] Alternatively, R2 and / or R3 may be C1.20 alkyl (typically C1.4 alkyl), C1.20 alkoxy, which may themselves be optionally substituted, halo, hydroxy, nitro, cyano or include a keto, ester, C2-6 alkenyl, C2-6 alkynyl or an amide group.
[0539] Preferred groups for R2Aand / or R3include H, CN, nitro, OH and halide.
[0540] R2 and R3 in the same and / or adjacent units in -(xs)nmay be linked to form a cyclic structure. They may be linked, for instance, to form a cyclic, heterocyclic, or an aromatic ring.
[0541] Compound of formula (I’) may have formula:
[0542]
[0543] In these formulae:
[0544] Y is selected from O and S;
[0545] R1 is -(CH2)m-Z wherein Z is selected from C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, and C3-10 heterocycloalkenyl, wherein Z may be optionally substituted and m is an integer in the range 1 to 4.
[0546] Preferably, R1 is -(CH2)m-C3-io cycloalkyl wherein the cycloalkyl may be optionally substituted and m is an integer in the range 1 to 4.
[0547] m is preferably 1.
[0548] In these compounds, each R2 and each R3 are independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NR6R7, NR6OR7, NR6NR7R8, ONR6R7, ON(=CR6), R20, OR20, SR20, NR6R20, C1-6alkyl, C2-6 alkenyl, C2-6alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl any of which may be optionally substituted;
[0549] RG, R? and Rs are independently selected from the group consisting of H, Ci-ealkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl,2026.05.07 DESCRIPTION P000685WO
[0550] C6-20aryl, C5-20 heteroaryl which may be optionally substituted; wherein R6may independently or together with R7form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-10aryl or C5-10 heteroaryl any of which may be optionally substituted;
[0551] R20 is selected from the group consisting of
[0552] C(=O)Re,
[0553] C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,
[0554] S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,
[0555] SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,
[0556] C(=S)R6, C(=S)OR6, C(=S)NR6R7,
[0557] CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).
[0558] The preferred groups are the same as those for compounds of formula (I’) above.
[0559] Each individual R2 and each individual R3 group may be different. Accordingly, the formulae may be drawn as follows:
[0560]
[0561] wherein each R2A and R2B, R3Aand R3Bare independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NR6R7, NR6OR7, NR6NR7R8, ONR6R7, ON(=CR8), R20, OR20, SR20, NR6R2O,, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted.
[0562] In these formulae, R2B is preferably H.
[0563] Preferably, R2A is H.
[0564] Preferably, R2A, R2B, RSA and RSB are all H.2026.05.07 DESCRIPTION P000685WO
[0565] The above recited formulae comprise a 5-membered aromatic heterocycle on the left hand side of the molecule as part of the bicyclic ring structure. Such heterocycles may comprise multiple isomers and tautomers.
[0566] On the right hand side of the molecule is a further cyclic structure preferably comprising a cyclic amide. The cyclic amide is substituted, i.e. there is a substituent Ri which is not H. There may be further substituents around the ring. In a preferred embodiment, the ring atoms in the alpha positions relative to the remainder of the molecule is not substituted, i.e. the alphacarbon bears at least one hydrogen.
[0567] In the invention, Ri is -(CH2)m-Z wherein Z is selected from C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, wherein Z may be optionally substituted and m is an integer in the range 1 to 4.
[0568] In one preferred embodiment of the invention, Z is selected from C3-10 cycloalkyl and C3-10 heterocycloalkyl, any of which may be optionally substituted. The rings may comprise one or more heteroatoms or contain within the ring one or more keto groups, C=O. The heterocyclyl groups may, for instance, comprise an N, S or an O atom as part of the ring. Suitable heterocyclyl groups are 5 or 6 membered rings containing one or more heteroatoms, the heteroatoms typically selected from N and O. Preferably there is one heteroatom present, for instance selected from N and O.
[0569] The cycloalkyl group for Z is typically selected from optionally substituted cyclopentyl, cyclohexyl and cycloheptyl.
[0570] In an embodiment, the heterocycloalkyl group forZ may be derived from one of the following: tetrahydrofuran, tetrahydropyran, 1,4 dioxane, pyrrolidine, piperidine, tetrahydrothiophene, tetrahydrothiopyran, morpholine, any of which may be optionally substituted.
[0571] m is an integer in the range 1 to 4, that is, m may take any of the values 1, 2, 3 or 4.
[0572] Preferably, m is 1.
[0573] The optional substituents on the any of the cyclic groups (such as the cycloalkyl or heterocycloalkyl) groups may be selected from one or more of the following: C1.10 alkyl (preferably, Ci-e alkyl), C1.10 haloalkyl, halide, CN, nitro, hydroxyl and C1.10 alkoxy, C3-102026.05.07 DESCRIPTION P000685WO
[0574] cycloalkyl, C3-10 heterocycloalkyl, C6-20 aryl, C5-20 heteroaryl; wherein any of the alkyl or aryl groups may themselves be optionally substituted.
[0575] Typical optional substituents may be selected from: F, N(Me)Boc, NHBoc, CO2Me OCF3 NH2, NMe2, NHCOMe, N(Me)COMe, OH, OCOMe, Me, tBu, Et, phenyl, Cl substituted-phenyl, -(O-CH2-CH2-O)-, CF3, COCH3, (=O)2(forming e.g. a sulfonyl group), C=O, =CH2, -(CH2-CH2)-(spiro-cyclopropyl), -CH2CH=CH2.
[0576] The optional substituents are preferably selected from one of more of halide, OH, Ci-e alkoxy and CN. The optional substituents are more preferably selected from halide, OH, OMe and CN.
[0577] There may be more than one optional substituent on the group Z.
[0578] The optional substituents are preferably halide. There may be two or more halide substituents on the group Ri.
[0579] The halide substituents are typically selected from F, Cl and Br. When there is more than one halide substituent, the halide substituents may be the same or different.
[0580] Preferred compounds of the invention have the following formulae (HA) or (111 A):
[0581]
[0582] wherein R1 is -(CH2)m-Z, wherein Z is selected from C3-10 cycloalkyl, C3-10 heterocycloalkyl, Oslo cycloalkenyl, C3-10 heterocycloalkenyl, wherein Z may be optionally substituted and m is an integer in the range 1 to 4.
[0583] Preferably, R1 is -(CH2)m-C3-io cycloalkyl wherein the cycloalkyl may be optionally substituted and m is an integer in the range 1 to 4. Preferably, m=1.2026.05.07 DESCRIPTION P000685WO
[0584] In these compounds, each R2 is independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NReR7, NReOR7, NReNR7R8, ONReR7, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl any of which may be optionally substituted;
[0585] R6, R7and R8are independently selected from the group consisting of H, C1-6alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted; wherein Re may independently or together with R7form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl which may be optionally substituted;
[0586] R20 is selected from the group consisting of
[0587] C(=O)Re,
[0588] C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,
[0589] S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,
[0590] SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,
[0591] C(=S)R6, C(=S)OR6, C(=S)NR6R7,
[0592] CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).
[0593] Each R2 and R3 group may be different. Formulae (HA) and (111 A) may therefore be drawn as follows:
[0594]
[0595] wherein each R2A and R2B, R3Aand R3Bare independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NReR7, NReOR7, NReNR7R8, ONReR7, ON(=CRe), R20, OR20, SR20, NR6R2O,, CI-B alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted.2026.05.07 DESCRIPTION P000685WO
[0596] In one embodiment, formulae (IIA) and (111 A) may take one of the following forms:
[0597]
[0598] wherein each R2 is independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NR6R7, NR6OR7, NR6NR7R8, ONR6R7, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted;
[0599] RG, R7 and Rs are independently selected from the group consisting of H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted; wherein Re may independently or together with R7form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl which may be optionally substituted;
[0600] R20 is selected from the group consisting of
[0601] C(=O)Re,
[0602] C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,
[0603] S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,
[0604] SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,
[0605] C(=S)R6, C(=S)OR6, C(=S)NR6R7,
[0606] CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).
[0607] The invention further provides agricultural compositions comprising a compound of formula (I’) or its preferred formulae (the various substructures and preferred embodiments as outlined above), or any of the alternative formulae defined herein, together with an agriculturally acceptable formulation adjuvant. Further, the invention provides novel compounds of formula (I’) or its preferred formulae (the various substructures and preferred embodiments as outlined above).2026.05.07 DESCRIPTION P000685WO
[0608] The invention further provides herbicidal compositions comprising a compound of formula (I’) or its preferred formulae (the various substructures and preferred embodiments as outlined above), together with an agriculturally acceptable formulation adjuvant. Also provided are such herbicidal compositions further comprising at least one additional herbicide. Further provided is a method of controlling weeds at a locus comprising application to the locus of a weed controlling amount of such a herbicidal composition.
[0609] A further aspect of the invention is directed to use of a compound of general Formula (I’) (or any of its preferred embodiments as described above), or a salt thereof in agriculture, preferably as a herbicide.
[0610] These compounds typically have herbicidal activity. The meaning of herbicidal activity is given above with reference to compounds of formula (I).
[0611] As used herein, “Ci-ealk” is a diradical alkylene moiety having from 1 to 6 carbons, i.e., Cialk, C2alk, C3alk, C4alk, Csalk, or Cealk. As used herein, a Cialk is -CH2-. The diradical alkylene moiety can be a straight chain alkylene, for example, -CH2CH2CH2CH2CH2- (Csalk), -CH2CH2 CH2CH2- (C4alk), -CH2CH2CH2- (Csalk), CH2CH2- (C2alk). The diradical alkylene moiety can be also be a branched chain alkylene, for example, -CH(CH3)CH(CH3)CH2- (Csalk), -CH(CH3)C(CH3)2CH2- (Csalk), -CH2CH(CH3)CH2- (C4alk), -CH(CH3)CH2- (C3alk), -C(CH3)2-(C3alk), and the like.
[0612] Within the scope of the disclosure are compounds of formula XI and salts thereof:
[0613]
[0614] wherein
[0615] L is C1-6alk; and
[0616] R41 is substituted or unsubstituted Ci-ealkyl; substituted or unsubstituted Ce-2oaryl; substituted or unsubstituted Cs-2oheteroaryl; substituted or unsubstituted C3.iocycloalkyl, substituted or unsubstituted C3.iocycloalkenyl, substituted or unsubstituted C3.ioheterocycloalkyl, or substituted or unsubstituted C3.ioheterocycloalkenyl.2026.05.07 DESCRIPTION P000685WO
[0617] In preferred aspects of the disclosure are compounds of formula XI, L is Cialk (-CH2-). In other aspects, L is C2alk. In other aspects, L is Cealk. In other aspects, L is C4alk. In other aspects, L is Csalk. In other aspects, L is Cealk.
[0618] In some aspects of the disclosure are compounds of formula XI wherein R41 is substituted or unsubstituted Ci-ealkyL In some aspects, R41 is unsubstituted Ci-ealkyl, for example, unsubstituted methyl. In some aspects, R41 is unsubstituted ethyl. In some aspects, R41 is unsubstituted n-propyl. In some aspects, R41 is unsubstituted isopropyl. In some aspects, R41 is unsubstituted n-butyl. In some aspects, R41 is unsubstituted isobutyl. In some aspects, R41 is unsubstituted sec-butyl. In some aspects, R41 is unsubstituted tert-butyl. In some aspects, R41 is substituted Ci-ealkyl, for example, substituted methyl. In some aspects, R41 is substituted ethyl. In some aspects, R41 is substituted n-propyl. In some aspects, R41 is substituted isopropyl. In some aspects, R41 is substituted n-butyl. In some aspects, R41 is substituted isobutyl. In some aspects, R41 is substituted sec-butyl. In some aspects, R41 is substituted tert-butyl. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with one substituent. In some embodiments wherein R41 is substituted Ci- ealkyl, the Ci-ealkyl is substituted with two substituents that are the same or different. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with three substituents that are the same or different. In embodiments wherein R41 is substituted Ci- ealkyl, the Ci-ealkyl is substituted with more than three substituents that are the same or different. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with one substituent that is Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOC1. ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci. ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with two substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with three substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with more than three substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi.
[0619] ehaloalkyl.2026.05.07 DESCRIPTION P000685WO
[0620] In some aspects of the disclosure are compounds of formula XI wherein R41 is substituted or unsubstituted Ce-2oaryl. In some aspects, R41 is unsubstituted C6-2oaryl, for example, unsubstituted phenyl. In some aspects, R4I is unsubstituted tolyl. In some aspects, R4I is unsubstituted xylyl. In some aspects, R4I is unsubstituted naphthyl. In some aspects, R4I is substituted C6-2oaryl, for example, substituted phenyl. In some aspects, R4I is substituted tolyl. In some aspects, R4I is substituted xylyl. In some aspects, R4I is substituted naphthyl. In some embodiments wherein R4I is substituted C6-2oaryl, the C6-2oaryl is substituted with one substituent. In some embodiments wherein R4I is substituted C6-2oaryl, the C6-2oaryl is substituted with two substituents that are the same or different. In some embodiments wherein R4I is substituted Ce-2oaryl, the C6-2oaryl is substituted with three substituents that are the same or different. In some embodiments wherein R4I is substituted Ce-2oaryl, the Ce-2oaryl is substituted with more than three substituents that are the same or different. In some embodiments wherein R41 is substituted C6-20aryl, the C6-20aryl is substituted with one substituent that is C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl. In some embodiments wherein R41 is substituted C6-20aryl, the Ce-2oaryl is substituted with two substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl. In some embodiments wherein R4I is substituted Ce-2oaryl, the Ce-2oaryl is substituted with three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NC1. ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R4I is substituted Ce-2oaryl, the Ce-2oaryl is substituted with three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOC1. ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci. ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl.
[0621] In some aspects of the disclosure are compounds of formula XI wherein R4I is substituted or unsubstituted C5-2oheteroaryl. In some aspects, R4I is unsubstituted C5-2oheteroaryl, for example, unsubstituted pyridyl. In some aspects, R4I is unsubstituted pyrimidinyl. In some aspects, R4I is unsubstituted pyrazinyl. In some aspects, R4I is unsubstituted pyridazinyl. In some aspects, R4I is unsubstituted thienyl. In some aspects, R4I is unsubstituted furanyl. In some aspects, R4I is unsubstituted imidazolyl. In some aspects, R4I is unsubstituted pyrazolyl. In some aspects, R4I is unsubstituted triazolyl. In some aspects, R4I is unsubstituted quinolinyl. In some aspects, R4I is unsubstituted isoquinolinyl. In some aspects, R4I is substituted C5-2oheteroaryl, for example, substituted pyridyl. In some aspects,2026.05.07 DESCRIPTION P000685WO
[0622] R41 is substituted pyrimidinyl. In some aspects, R41 is substituted pyrazinyl. In some aspects, R41 is substituted pyridazinyl. In some aspects, R41 is substituted thienyl. In some aspects, R41 is substituted furanyl. In some aspects, R41 is substituted imidazolyl. In some aspects, R41 is substituted pyrazolyl. In some aspects, R41 is substituted triazolyl. In some aspects, R41 is substituted quinolinyl. In some aspects, R41 is substituted isoquinolinyl. In some embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with one substituent. In some embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with two substituents that are the same or different. In other embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with three substituents that are the same or different. In other embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with more than three substituents that are the same or different. In some embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with one substituent that is Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-6alkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with two substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl. In some embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with three substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl. In some embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with more than three substituents that are each independently Ci- ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl.
[0623] In some aspects of the disclosure are compounds of formula XI wherein R41 is substituted or unsubstituted Cs- cycloalkyl. In some aspects, R41 is unsubstituted Cs- cycloalkyl. For example, in some aspects, R41 is unsubstituted cyclopropyl. In some aspects, R41 is unsubstituted cyclobutyl. In some aspects, R41 is unsubstituted cyclopentyl. In some aspects, R41 is unsubstituted cyclohexyl. In some aspects, R41 is unsubstituted cycloheptanyl. In some aspects, R41 is unsubstituted cyclooctanyl. In some aspects, R41 is unsubstituted adamantanyl. In some aspects, R41 is unsubstituted bicyclo[2.2.1]heptanyl. In some aspects, R41 is unsubstituted bicyclo[2.2.2.octanyl. In some aspects, R41 is unsubstituted2026.05.07 DESCRIPTION P000685WO
[0624] spiro[3.3]heptanyl. In some aspects, R41 is unsubstituted spiro[4.4]nonanyl. In some aspects, R41 is unsubstituted spiro[2.4]heptanyl. In some aspects, R41 is unsubstituted spiro[3.4]octanyl. In some aspects, R41 is unsubstituted bicyclo[4.2.0]octanyl. In some aspects, R41 is unsubstituted bicyclo[4.3.0]nonanyl. In some aspects, R41 is unsubstituted bicyclo[4.4.0]decanyl. In some aspects, R41 is unsubstituted bicyclo[3.1.0]hexanyl. In some aspects, R41 is unsubstituted bicyclo[3.2.0]heptanyl. In some aspects, R41 is unsubstituted bicyclo[3.3.0]octanyl. In some aspects, R41 is unsubstituted bicyclo[4.1.0]heptanyl. In some aspects, R41 is unsubstituted tetrahydronapthalenyl. In some aspects, R41 is unsubstituted dihydroindenyl. In some aspects, R41 is substituted Cs- cycloalkyl. For example, in some aspects, R41 is substituted cyclopropyl. In some aspects, R41 is substituted cyclobutyl. In some aspects, R41 is substituted cyclopentyl. In some aspects, R41 is substituted cyclohexyl. In some aspects, R41 is substituted cycloheptanyl. In some aspects, R41 is substituted cyclooctanyl. In some aspects, R41 is substituted adamantanyl. In some aspects, R41 is substituted bicyclo[2.2.1]heptanyl. In some aspects, R41 is substituted bicyclo[2.2.2.octanyl. In some aspects, R41 is substituted spiro[3.3]heptanyl. In some aspects, R41 is substituted spiro[4.4]nonanyl. In some aspects, R41 is substituted spiro[2.4]heptanyl. In some aspects, R41 is substituted spiro[3.4]octanyl. In some aspects, R41 is substituted bicyclo[4.2.0]octanyl. In some aspects, R41 is substituted bicyclo[4.3.0]nonanyl. In some aspects, R41 is substituted bicyclo[4.4.0]decanyl. In some aspects, R41 is substituted bicyclo[3.1.0]hexanyl. In some aspects, R41 is substituted bicyclo[3.2.0]heptanyl. In some aspects, R41 is substituted bicyclo[3.3.0]octanyl. In some aspects, R41 is substituted bicyclo[4.1.0]heptanyl. In some aspects, R41 is substituted tetrahydronapthalenyl. In some embodiments wherein R41 is substituted Cs- cycloalkyl, the Cs- cycloalkyl is substituted with one substitutuent. In some embodiments wherein R41 is substituted Cs- cycloalkyl, the Cs- cycloalkyl is substituted with two substituents that are the same or different. In Some embodiments wherein R41 is substituted C3-10cycloalkyl, the C3-10cycloalkyl is substituted with three substituents that are the same or different. In Some embodiments wherein R41 is substituted C3-10cycloalkyl, the C3-10cycloalkyl is substituted with more than three substituents that are the same or different. In some aspects wherein the R41 is substituted with one substituent, the substituent is Ci- ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, and OC1-6haloalkyl. In some aspects wherein the R41 is substituted with two substituents, the substituents can be two substituents are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl. In some aspects wherein the R41 is substituted with three substituents, they are each indepenently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl,2026.05.07 DESCRIPTION P000685WO
[0625] Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-6alkyl)Ci.ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In other embodiments, when R41 is substituted C3- cycloalkyl, the Cs- cycloalkyl substituted with more than three substituents are are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci- ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci.ealkyl)Ci.ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl.
[0626] In some aspects of the disclosure are compounds of formula XI wherein R41 is substituted or unsubstituted Cs- cycloalkenyl. In some aspects, R41 is unsubstituted Cs- cycloalkenyl. In some aspects, R41 is unsubstituted cyclopropenyl. In some aspects, R41 is unsubstituted cyclobutenyl. In some aspects, R41 is unsubstituted cyclopentenyl. In some aspects, R41 is unsubstituted cyclohexenyl. In some aspects, R41 is unsubstituted cycloheptenyl. In some aspects, R41 is unsubstituted cyclooctenyl. In some aspects, R41 is unsubstituted adamantenyl. In some aspects, R41 is unsubstituted bicyclo[2.2.1]heptenyl. In some aspects, R41 is unsubstituted bicyclo[2.2.2.octenyl. In some aspects, R41 is unsubstituted spiro[3.3]heptenyl. In some aspects, R41 is unsubstituted spiro[4.4]nonenyl. In some aspects, R41 is unsubstituted spiro[2.4]heptenyl. In some aspects, R41 is unsubstituted spiro[3.4]octenyl. In some aspects, R41 is unsubstituted bicyclo[4.2.0]octenyl. In some aspects, R41 is unsubstituted bicyclo[4.3.0]nonenyl. In some aspects, R41 is unsubstituted bicyclo[4.4.0]decenyl. In some aspects, R41 is unsubstituted bicyclo[3.1.0]hexenyl. In some aspects, R41 is unsubstituted bicyclo[3.2.0]heptenyl. In some aspects, R41 is unsubstituted bicyclo[3.3.0]octenyl. In some aspects, R41 is unsubstituted bicyclo[4.1.0]heptenyl. In some aspects, R41 is unsubstituted dihydronapthalenyl. In some aspects, R41 is substituted C3-locycloalkenyl. In some aspects, R41 is substituted cyclopropenyl. In some aspects, R41 is substituted cyclobutenyl. In some aspects, R41 is substituted cyclopentenyl. In some aspects, R41 is substituted cyclohexenyl. In some aspects, R41 is substituted cycloheptenyl. In some aspects, R41 is substituted cyclooctenyl. In some aspects, R41 is substituted adamantenyl. In some aspects, R41 is substituted bicyclo[2.2.1]heptenyl. In some aspects, R41 is substituted bicyclo[2.2.2.octenyl. In some aspects, R41 is substituted spiro[3.3]heptenyl. In some aspects, the R41 is substituted spiro[4.4]nonenyl. In some aspects, the R41 is substituted spiro[2.4]heptenyl. In some aspects, R41 is substituted spiro[3.4]octenyl. In some aspects, R41 is substituted bicyclo[4.2.0]octenyl. In some aspects, R41 is substituted bicyclo[4.3.0]nonenyl. In some aspects, R41 is substituted bicyclo[4.4.0]decenyl. In some aspects, R41 is substituted bicyclo[3.1.0]hexenyl. In some aspects, R41 is substituted bicyclo[3.2.0]heptenyl. In some aspects, R41 is substituted bicyclo[3.3.0]octenyl. In some aspects, R41 is substituted bicyclo[4.1.0]heptenyl. In some aspects, R41 is substituted dihydronapthalenyl. In some embodiments wherein R41 is substituted Cs- cycloalkenyl, the2026.05.07 DESCRIPTION P000685WO
[0627] Cs-iocycloalkenyl is substituted with one substituent. In some embodiments wherein R41 is substituted Cs- cycloalkenyl, the Cs- cycloalkenyl is substituted with two substituents that are the same or different. In some embodiments wherein R41 is substituted Cs- cycloalkenyl, the Cs- cycloalkenyl is substituted with three substituents that are the same or different. In some embodiments wherein R4I is substituted Cs- cycloalkenyl, the Cs- cycloalkenyl is substituted with more than three substituents that are the same or different. When R4I is substituted Cs- cycloalkenyl, the substituent can be one substituent that is Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-6alkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OC1-ehaloalkyl. When R4I is substituted Cs- cycloalkenyl, the substituent can be two substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl. When R4I is substituted Cs- cycloalkenyl, the substituent can be three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NC1. ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl. When R4I is substituted Cs- cycloalkenyl, the substituent can be more than three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOC1. ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci. ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl.
[0628] In some aspects of the disclosure are compounds of formula XI wherein R4I is substituted or unsubstituted Cs-wheterocycloalkyl. In some aspects, R4I is unsubstituted C3-loheterocycloalkyl. In some aspects, R4I is unsubstituted aziridinyl. In some aspects, R4I is unsubstituted oxiranyl. In some aspects, R4I is unsubstituted thiiranyl. In some aspects, R4I is unsubstituted azetidinyl. In some aspects, R4I is unsubstituted diazetidinyl. In some aspects, R4I is unsubstituted oxetanyl. In some aspects, R4I is unsubstituted thietanyl. In some aspects, R4I is unsubstituted pyrrolidinyl. In some aspects, R4I is unsubstituted pyrazolidinyl. In some aspects, R4I is unsubstituted imidazolidinyl. In some aspects, R4I is unsubstituted tetrahydrofuranyl. In some aspects, R4I is unsubstituted dioxolanyl. In some aspects, R4I is unsubstituted tetrahydrothiophenyl. In some aspects, R4I is unsubstituted oxathiolanyl. In some aspects, R4I is unsubstituted sulfolanyl. In some aspects, R4I is unsubstituted piperiinyl. In some aspects, R4I is unsubstituted piperazinyl. In some aspects, R4I is unsubstituted tetrahydropyranyl. In some aspects, R4I is unsubstituted dioxanyl. In some aspects, R4I is unsubstituted thianyl. In some aspects, R4I is unsubstituted dithianyl. In some aspects, R4I is unsubstituted morpholinyl. In some aspects, R4I is unsubstituted thiomorpholinyl. In some aspects, R4I is unsubstituted thiomorpholinyl dioxide. In some2026.05.07 DESCRIPTION P000685WO
[0629] aspects, R41 is unsubstituted pyrrolizidinyl. In some aspects, R41 is unsubstituted decahydroisoquinolinyl. In some aspects, R41 is unsubstituted decahydroquinolinyl. In some aspects, R41 is unsubstituted tetrahydroquinolinyl. In some aspects, R41 is unsubstituted quinuclidinyl. In some aspects, R41 is unsubstituted azaadamantanyl. In some aspects, R41 is unsubstituted oxepanyl. In some aspects, R41 is unsubstituted oxaspiro[4.5]decanyl. In some aspects, R41 is unsubstituted dioxaspiro[3.4]octnyl. In some aspects, R41 is unsubstituted oxaazaspiro[3.5]nonanyl. In some aspects, R41 is unsubstituted dioxaazaspiro[4.4]nonanyl. In some aspects, R41 is substituted C3-10heterocycloalkyl. In some aspects, R41 is substituted aziridinyl. In some aspects, R41 is substituted oxiranyl. In some aspects, R41 is substituted thiiranyl. In some aspects, R41 is substituted azetidinyl. In some aspects, R41 is substituted diazetidinyl. In some aspects, R41 is substituted oxetanyl. In some aspects, R41 is substituted thietanyl. In some aspects, R41 is substituted pyrrolidinyl. In some aspects, R41 is substituted pyrazolidinyl. In some aspects, R41 is substituted imidazolidinyl. In some aspects, R41 is substituted tetrahydrofuranyl. In some aspects, R41 is substituted dioxolanyl. In some aspects, R41 is substituted tetrahydrothiophenyl. In some aspects, R41 is substituted oxathiolanyl. In some aspects, R41 is substituted sulfolanyl. In some aspects, R41 is substituted piperiinyl. In some aspects, R41 is substituted piperazinyl. In some aspects, R41 is substituted tetrahydropyranyl. In some aspects, R41 is substituted dioxanyl. In some aspects, R41 is substituted thianyl. In some aspects, R41 is substituted dithianyl. In some aspects, R41 is substituted morpholinyl. In some aspects, R41 is substituted thiomorpholinyl. In some aspects, R41 is substituted thiomorpholinyl dioxide. In some aspects, R41 is substituted pyrrolizidinyl. In some aspects, R41 is substituted decahydroisoquinolinyl. In some aspects, R41 is substituted decahydroquinolinyl. In some aspects, R41 is substituted tetrahydroquinolinyl. In some aspects, R41 is substituted quinuclidinyl. In some aspects, R41 is substituted azaadamantanyl. In some aspects, R41 is substituted oxepanyl. In some aspects, R41 is substituted oxaspiro[4.5]decanyl. In some aspects, R41 is substituted dioxaspiro[3.4]octnyl. In some aspects, R41 is substituted oxaazaspiro[3.5]nonanyl. In some aspects, R41 is substituted dioxaazaspiro[4.4]nonanyl. In those embodiments wherein R41 is substituted Cs-wheterocycloalkyl, the Cs-wheterocycloalkyl is substituted with one substitutent. In some embodiments wherein R41 is substituted Cs-wheterocycloalkyl, the C3-loheterocycloalkyl is substituted with two substituents that are the same or different. In some embodiments wherein R41 is substituted Cs-wheterocycloalkyl, the Cs-wheterocycloalkyl is substituted with three substituents that are the same or different. In some embodiments wherein R41 is substituted Cs-wheterocycloalkyl, the Cs-wheterocycloalkyl is substituted with more than three substituents that are the same or different. When R41 is substituted C3-loheterocycloalkyl, the substituent can be one substituent that is Ci-ealkyl, C2.ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NC1-2026.05.07 DESCRIPTION P000685WO
[0630] ealkylCOOCi-ealkyl, -N(Ci-6alkyl)Ci-6alkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. When R41 is substituted Cs-wheterocycloalkyl, the substituents can be two substituents that are each independently Ci-ealkyl, C2.ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci- ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-6alkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. When R41 is substituted Cs-wheterocycloalkyl, the substituents can be three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NC1. ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. When R41 is substituted Cs-wheterocycloalkyl, the substituents can be more than three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOC1. ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci. ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl.
[0631] In some aspects of the disclosure are compounds of formula XI wherein R41 is substituted or unsubstituted Cs- heterocycloalkenyl. According to the disclosure, a Cs-wheterocycloalkenyl moiety is a Cs-wheterocycloalkyl moiety with one or more double bonds. In some aspects, Cs-ioheterocycloalkenyl is a aziridinyl, oxiranyl, thiiranyl, azetidinyl, diazetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, dioxolanyl, tetrahydrothiophenyl, oxathiolanyl, sulfolanyl, piperiinyl, piperazinyl, tetrahydropyranyl, dioxanyl, thianyl, dithianyl, morpholinyl, thiomorpholinyl, thiomorpholinyl dioxide, pyrrolizidinyl, decahydroisoquinolinyl, decahydroquinolinyl, tetrahydroquinolinyl, quinuclidinyl, azaadamantanyl, oxepanyl, oxaspiro[4.5]decanyl, dioxaspiro[3.4]octnyl, oxaazaspiro[3.5]nonanyl, or dioxaazaspiro[4.4]nonanyl with one double bond. In some aspects, Cs-ioheterocycloalkenyl is a aziridinyl, oxiranyl, thiiranyl, azetidinyl, diazetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, dioxolanyl, tetrahydrothiophenyl, oxathiolanyl, sulfolanyl, piperiinyl, piperazinyl, tetrahydropyranyl, dioxanyl, thianyl, dithianyl, morpholinyl, thiomorpholinyl, thiomorpholinyl dioxide, pyrrolizidinyl, decahydroisoquinolinyl, decahydroquinolinyl, tetrahydroquinolinyl, quinuclidinyl, azaadamantanyl, oxepanyl, oxaspiro[4.5]decanyl, dioxaspiro[3.4]octnyl, oxaazaspiro[3.5]nonanyl, or dioxaazaspiro[4.4]nonanyl with two double bonds. In some aspects, R41 is unsubstituted C3-10heterocycloalkenyl. In some aspects, R41 is substituted C3-10heterocycloalkenyl. In some aspects, the substituted C3-10heterocycloalkenyl is substituted with one substituent. In some aspects, the substituted C3-10heterocycloalkenyl is substituted with two substituents that are the same or different. In some aspects, the substituted C3-10heterocycloalkenyl is substituted with three substituents that are the same or different. In some aspects, the substituted C3-10heterocycloalkenyl is substituted with more than three substituents that are the same or different. When fR₄₁ is substituted C₃-₁₀heterocycloalkenyl,2026.05.07 DESCRIPTION P000685WO
[0632] the substituent can be one substituent that is Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. When R4I is substituted Cs-ioheterocycloalkenyl, the substituent can be two substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl. When R4I is substituted Cs- heterocycloalkenyl, the substituent can be three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. When R4I is substituted Cs-ioheterocycloalkenyl, the substituent can be more than three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci- ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl.
[0633] Within the scope of the disclosure are compounds of formula Xl-A and salts thereof:
[0634]
[0635] wherein
[0636] L is C1-6alk; and
[0637] R4I is substituted or unsubstituted Ci-ealkyl; substituted or unsubstituted Ce-2oaryl; substituted or unsubstituted C5-2oheteroaryl; substituted or unsubstituted Cs- cycloalkyl, substituted or unsubstituted Cs- cycloalkenyl, substituted or unsubstituted Cs-wheterocycloalkyl, or substituted or unsubstituted Cs- heterocycloalkenyl.
[0638] In preferred aspects of the disclosure are compounds of formula Xl-A, L is Cialk (-CH2-). In other aspects, L is C2alk. In other aspects, L is Csalk. In other aspects, L is C4alk. In other aspects, L is Csalk. In other aspects, L is Cealk.
[0639] In some aspects of the disclosure are compounds of formula Xl-A wherein R41 is substituted or unsubstituted Ci-ealkyl. In some aspects, R41 is unsubstituted Ci-ealkyl, for example, unsubstituted methyl. In some aspects, R4I is unsubstituted ethyl. In some aspects, R4I is unsubstituted n-propyl. In some aspects, R4I is unsubstituted isopropyl. In some aspects, R4I is unsubstituted n-butyl. In some aspects, R4I is unsubstituted isobutyl. In some aspects, R4I2026.05.07 DESCRIPTION P000685WO
[0640] is unsubstituted sec-butyl. In some aspects, R41 is unsubstituted tert-butyl. In some aspects, R41 is substituted Ci-ealkyl, for example, substituted methyl. In some aspects, R41 is substituted ethyl. In some aspects, R41 is substituted n-propyl. In some aspects, R41 is substituted isopropyl. In some aspects, R41 is substituted n-butyl. In some aspects, R41 is substituted isobutyl. In some aspects, R41 is substituted sec-butyl. In some aspects, R41 is substituted tert-butyl. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with one substituent. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with two substituents that are the same or different. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with three substituents that are the same or different. In embodiments wherein R41 is substituted Ci- ealkyl, the Ci-ealkyl is substituted with more than three substituents that are the same or different. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with one substituent that is Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOC1. ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci. ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with two substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with three substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with more than three substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl.
[0641] In some aspects of the disclosure are compounds of formula Xl-A wherein R41 is substituted or unsubstituted Ce-2oaryl. In some aspects, R41 is unsubstituted Ce-2oaryl, for example, unsubstituted phenyl. In some aspects, R41 is unsubstituted tolyl. In some aspects, R41 is unsubstituted xylyl. In some aspects, R41 is unsubstituted naphthyl. In some aspects, R41 is substituted Ce-2oaryl, for example, substituted phenyl. In some aspects, R41 is substituted tolyl. In some aspects, R41 is substituted xylyl. In some aspects, R41 is substituted naphthyl. In some embodiments wherein R41 is substituted Ce-2oaryl, the C6-2oaryl is substituted with one substituent. In some embodiments wherein R41 is substituted C6-2oaryl, the C6-2oaryl is substituted with two substituents that are the same or different. In some embodiments2026.05.07 DESCRIPTION P000685WO
[0642] wherein R41 is substituted Ce-2oaryl, the Ce-2oaryl is substituted with three substituents that are the same or different. In some embodiments wherein R41 is substituted Ce-2oaryl, the Ce-2oaryl is substituted with more than three substituents that are the same or different. In some embodiments wherein R41 is substituted C6-20aryl, the C6-20aryl is substituted with one substituent that is C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl. In some embodiments wherein R41 is substituted C6-20aryl, the Ce-2oaryl is substituted with two substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl. In some embodiments wherein R4I is substituted Ce-2oaryl, the Ce-2oaryl is substituted with three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NC1. ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R4I is substituted Ce-2oaryl, the Ce-2oaryl is substituted with three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOC1. ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci. ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl.
[0643] In some aspects of the disclosure are compounds of formula XI-A wherein R41 is substituted or unsubstituted C5-20heteroaryl. In some aspects, R41 is unsubstituted C5-20heteroaryl, for example, unsubstituted pyridyl. In some aspects, R41 is unsubstituted pyrimidinyl. In some aspects, R41 is unsubstituted pyrazinyl. In some aspects, R41 is unsubstituted pyridazinyl. In some aspects, R41 is unsubstituted thienyl. In some aspects, R41 is unsubstituted furanyl. In some aspects, R41 is unsubstituted imidazolyl. In some aspects, R41 is unsubstituted pyrazolyl. In some aspects, R41 is unsubstituted triazolyl. In some aspects, R41 is unsubstituted quinolinyl. In some aspects, R41 is unsubstituted isoquinolinyl. In some aspects, R41 is substituted C5-20heteroaryl, for example, substituted pyridyl. In some aspects, R41 is substituted pyrimidinyl. In some aspects, R41 is substituted pyrazinyl. In some aspects, R41 is substituted pyridazinyl. In some aspects, R41 is substituted thienyl. In some aspects, R41 is substituted furanyl. In some aspects, R41 is substituted imidazolyl. In some aspects, R41 is substituted pyrazolyl. In some aspects, R41 is substituted triazolyl. In some aspects, R41 is substituted quinolinyl. In some aspects, R41 is substituted isoquinolinyl. In some embodiments wherein R41 is substituted C5-20heteroaryl, the C5-20heteroaryl is substituted with one substituent. In some embodiments wherein R41 is substituted C5-20heteroaryl, the C5-20heteroaryl is substituted with two substituents that are the same or different. In other embodiments wherein R41 is substituted C5-20heteroaryl, the C5-20heteroaryl is substituted2026.05.07 DESCRIPTION P000685WO
[0644] with three substituents that are the same or different. In other embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with more than three substituents that are the same or different. In some embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with one substituent that is Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-6alkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted C5-20heteroaryl, the C5-20heteroaryl is substituted with two substituents that are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl. In some embodiments wherein R41 is substituted C5-20heteroaryl, the C5-20heteroaryl is substituted with three substituents that are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl. In some embodiments wherein R41 is substituted C5-20heteroaryl, the C5-20heteroaryl is substituted with more than three substituents that are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl.
[0645] In some aspects of the disclosure are compounds of formula XI-A wherein R41 is substituted or unsubstituted C3-10cycloalkyl. In some aspects, R41 is unsubstituted C3-10cycloalkyl. For example, in some aspects, R41 is unsubstituted cyclopropyl. In some aspects, R41 is unsubstituted cyclobutyl. In some aspects, R41 is unsubstituted cyclopentyl. In some aspects, R41 is unsubstituted cyclohexyl. In some aspects, R41 is unsubstituted cycloheptanyl. In some aspects, R41 is unsubstituted cyclooctanyl. In some aspects, R41 is unsubstituted adamantanyl. In some aspects, R41 is unsubstituted bicyclo[2.2.1]heptanyl. In some aspects, R41 is unsubstituted bicyclo[2.2.2.octanyl. In some aspects, R41 is unsubstituted spiro[3.3]heptanyl. In some aspects, R41 is unsubstituted spiro[4.4]nonanyl. In some aspects, R41 is unsubstituted spiro[2.4]heptanyl. In some aspects, R41 is unsubstituted spiro[3.4]octanyl. In some aspects, R41 is unsubstituted bicyclo[4.2.0]octanyl. In some aspects, R41 is unsubstituted bicyclo[4.3.0]nonanyl. In some aspects, R41 is unsubstituted bicyclo[4.4.0]decanyl. In some aspects, R41 is unsubstituted bicyclo[3.1.0]hexanyl. In some aspects, R41 is unsubstituted bicyclo[3.2.0]heptanyl. In some aspects, R41 is unsubstituted bicyclo[3.3.0]octanyl. In some aspects, R41 is unsubstituted bicyclo[4.1.0]heptanyl. In some aspects, R41 is unsubstituted tetrahydronapthalenyl. In some aspects, R41 is unsubstituted dihydroindenyl. In some aspects, R41 is substituted C3-10cycloalkyl. For example, in some2026.05.07 DESCRIPTION P000685WO
[0646] aspects, R41 is substituted cyclopropyl. In some aspects, R41 is substituted cyclobutyl. In some aspects, R41 is substituted cyclopentyl. In some aspects, R41 is substituted cyclohexyl. In some aspects, R41 is substituted cycloheptanyl. In some aspects, R41 is substituted cyclooctanyl. In some aspects, R41 is substituted adamantanyl. In some aspects, R41 is substituted bicyclo[2.2.1]heptanyl. In some aspects, R41 is substituted bicyclo[2.2.2.octanyl. In some aspects, R41 is substituted spiro[3.3]heptanyl. In some aspects, R41 is substituted spiro[4.4]nonanyl. In some aspects, R41 is substituted spiro[2.4]heptanyl. In some aspects, R41 is substituted spiro[3.4]octanyl. In some aspects, R41 is substituted bicyclo[4.2.0]octanyl. In some aspects, R41 is substituted bicyclo[4.3.0]nonanyl. In some aspects, R41 is substituted bicyclo[4.4.0]decanyl. In some aspects, R41 is substituted bicyclo[3.1.0]hexanyl. In some aspects, R41 is substituted bicyclo[3.2.0]heptanyl. In some aspects, R41 is substituted bicyclo[3.3.0]octanyl. In some aspects, R41 is substituted bicyclo[4.1.0]heptanyl. In some aspects, R41 is substituted tetrahydronapthalenyl. In some embodiments wherein R41 is substituted Cs- cycloalkyl, the Cs- cycloalkyl is substituted with one substitutuent. In some embodiments wherein R41 is substituted Cs- cycloalkyl, the Cs- cycloalkyl is substituted with two substituents that are the same or different. In some embodiments wherein R41 is substituted C3-10cycloalkyl, the C3-10cycloalkyl is substituted with three substituents that are the same or different. In Some embodiments wherein R41 is substituted C3-10cycloalkyl, the C3-10cycloalkyl is substituted with more than three substituents that are the same or different. In some aspects wherein the R41 is substituted with one substituent, the substituent is Ci- ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, and OC1-6haloalkyl. In some aspects wherein the R41 is substituted with two substituents, the substituents can be two substituents are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl. In some aspects wherein the R41 is substituted with three substituents, they are each indepenently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In other embodiments, when R41 is substituted C3- cycloalkyl, the Cs- cycloalkyl substituted with more than three substituents are are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci- ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl.
[0647] In some aspects of the disclosure are compounds of formula Xl-A wherein R41 is substituted or unsubstituted Cs- cycloalkenyl. In some aspects, R41 is unsubstituted Cs- cycloalkenyl. In2026.05.07 DESCRIPTION P000685WO
[0648] some aspects, R41 is unsubstituted cyclopropenyl. In some aspects, R41 is unsubstituted cyclobutenyl. In some aspects, R4I is unsubstituted cyclopentenyl. In some aspects, R4I is unsubstituted cyclohexenyl. In some aspects, R4I is unsubstituted cycloheptenyl. In some aspects, R4I is unsubstituted cyclooctenyl. In some aspects, R4I is unsubstituted adamantenyl. In some aspects, R4I is unsubstituted bicyclo[2.2.1]heptenyl. In some aspects, R4I is unsubstituted bicyclo[2.2.2.octenyl. In some aspects, R4I is unsubstituted spiro[3.3]heptenyl. In some aspects, R4I is unsubstituted spiro[4.4]nonenyl. In some aspects, R4I is unsubstituted spiro[2.4]heptenyl. In some aspects, R4I is unsubstituted spiro[3.4]octenyl. In some aspects, R4I is unsubstituted bicyclo[4.2.0]octenyl. In some aspects, R4I is unsubstituted bicyclo[4.3.0]nonenyl. In some aspects, R4I is unsubstituted bicyclo[4.4.0]decenyl. In some aspects, R4I is unsubstituted bicyclo[3.1.0]hexenyl. In some aspects, R4I is unsubstituted bicyclo[3.2.0]heptenyl. In some aspects, R4I is unsubstituted bicyclo[3.3.0]octenyl. In some aspects, R4I is unsubstituted bicyclo[4.1.0]heptenyl. In some aspects, R4I is unsubstituted dihydronapthalenyl. In some aspects, R41 is substituted C3-10cycloalkenyl. In some aspects, R41 is substituted cyclopropenyl. In some aspects, R41 is substituted cyclobutenyl. In some aspects, R41 is substituted cyclopentenyl. In some aspects, R41 is substituted cyclohexenyl. In some aspects, R41 is substituted cycloheptenyl. In some aspects, R41 is substituted cyclooctenyl. In some aspects, R41 is substituted adamantenyl. In some aspects, R41 is substituted bicyclo[2.2.1]heptenyl. In some aspects, R41 is substituted bicyclo[2.2.2.octenyl. In some aspects, R41 is substituted spiro[3.3]heptenyl. In some aspects, the R41 is substituted spiro[4.4]nonenyl. In some aspects, the R41 is substituted spiro[2.4]heptenyl. In some aspects, R41 is substituted spiro[3.4]octenyl. In some aspects, R41 is substituted bicyclo[4.2.0]octenyl. In some aspects, R41 is substituted bicyclo[4.3.0]nonenyl. In some aspects, R41 is substituted bicyclo[4.4.0]decenyl. In some aspects, R41 is substituted bicyclo[3.1.0]hexenyl. In some aspects, R41 is substituted bicyclo[3.2.0]heptenyl. In some aspects, R41 is substituted bicyclo[3.3.0]octenyl. In some aspects, R41 is substituted bicyclo[4.1.0]heptenyl. In some aspects, R41 is substituted dihydronapthalenyl. In some embodiments wherein R41 is substituted C3-10cycloalkenyl, the C3-10cycloalkenyl is substituted with one substituent. In some embodiments wherein R41 is substituted C3-10cycloalkenyl, the C3-10cycloalkenyl is substituted with two substituents that are the same or different. In some embodiments wherein R41 is substituted C3-10cycloalkenyl, the C3-10cycloalkenyl is substituted with three substituents that are the same or different. In some embodiments wherein R41 is substituted C3-10cycloalkenyl, the C3-10cycloalkenyl is substituted with more than three substituents that are the same or different. When R41 is substituted C3-10cycloalkenyl, the substituent can be one substituent that is C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, OC1-2026.05.07 DESCRIPTION P000685WO
[0649] ehaloalkyl. When R41 is substituted Cs- cycloalkenyl, the substituent can be two substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci.ealkyl)Ci.ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl. When R41 is substituted Cs- cycloalkenyl, the substituent can be three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NC1. ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl. When R41 is substituted Cs- cycloalkenyl, the substituent can be more than three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOC1. ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci. ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl.
[0650] In some aspects of the disclosure are compounds of formula Xl-A wherein R41 is substituted or unsubstituted Cs-wheterocycloalkyl. In some aspects, R41 is unsubstituted C3-loheterocycloalkyl. In some aspects, R41 is unsubstituted aziridinyl. In some aspects, R41 is unsubstituted oxiranyl. In some aspects, R41 is unsubstituted thiiranyl. In some aspects, R41 is unsubstituted azetidinyl. In some aspects, R41 is unsubstituted diazetidinyl. In some aspects, R41 is unsubstituted oxetanyl. In some aspects, R41 is unsubstituted thietanyl. In some aspects, R41 is unsubstituted pyrrolidinyl. In some aspects, R41 is unsubstituted pyrazolidinyl. In some aspects, R41 is unsubstituted imidazolidinyl. In some aspects, R41 is unsubstituted tetrahydrofuranyl. In some aspects, R41 is unsubstituted dioxolanyl. In some aspects, R41 is unsubstituted tetrahydrothiophenyl. In some aspects, R41 is unsubstituted oxathiolanyl. In some aspects, R41 is unsubstituted sulfolanyl. In some aspects, R41 is unsubstituted piperiinyl. In some aspects, R41 is unsubstituted piperazinyl. In some aspects, R41 is unsubstituted tetrahydropyranyl. In some aspects, R41 is unsubstituted dioxanyl. In some aspects, R41 is unsubstituted thianyl. In some aspects, R41 is unsubstituted dithianyl. In some aspects, R41 is unsubstituted morpholinyl. In some aspects, R41 is unsubstituted thiomorpholinyl. In some aspects, R41 is unsubstituted thiomorpholinyl dioxide. In some aspects, R41 is unsubstituted pyrrolizidinyl. In some aspects, R41 is unsubstituted decahydroisoquinolinyl. In some aspects, R41 is unsubstituted decahydroquinolinyl. In some aspects, R41 is unsubstituted tetrahydroquinolinyl. In some aspects, R41 is unsubstituted quinuclidinyl. In some aspects, R41 is unsubstituted azaadamantanyl. In some aspects, R41 is unsubstituted oxepanyl. In some aspects, R41 is unsubstituted oxaspiro[4.5]decanyl. In some aspects, R41 is unsubstituted dioxaspiro[3.4]octnyl. In some aspects, R41 is unsubstituted oxaazaspiro[3.5]nonanyl. In some aspects, R41 is unsubstituted dioxaazaspiro[4.4]nonanyl. In some aspects, R41 is substituted C3-10heterocycloalkyl. In some aspects, R41 is substituted aziridinyl. In some aspects, R41 is substituted oxiranyl. In some aspects, R41 is substituted2026.05.07 DESCRIPTION P000685WO
[0651] thiiranyl. In some aspects, R41 is substituted azetidinyl. In some aspects, R41 is substituted diazetidinyl. In some aspects, R41 is substituted oxetanyl. In some aspects, R41 is substituted thietanyl. In some aspects, R41 is substituted pyrrolidinyl. In some aspects, R41 is substituted pyrazolidinyl. In some aspects, R41 is substituted imidazolidinyl. In some aspects, R41 is substituted tetrahydrofuranyl. In some aspects, R41 is substituted dioxolanyl. In some aspects, R41 is substituted tetrahydrothiophenyl. In some aspects, R41 is substituted oxathiolanyl. In some aspects, R41 is substituted sulfolanyl. In some aspects, R41 is substituted piperiinyl. In some aspects, R41 is substituted piperazinyl. In some aspects, R41 is substituted tetrahydropyranyl. In some aspects, R41 is substituted dioxanyl. In some aspects, R41 is substituted thianyl. In some aspects, R41 is substituted dithianyl. In some aspects, R41 is substituted morpholinyl. In some aspects, R41 is substituted thiomorpholinyl. In some aspects, R41 is substituted thiomorpholinyl dioxide. In some aspects, R41 is substituted pyrrolizidinyl. In some aspects, R41 is substituted decahydroisoquinolinyl. In some aspects, R41 is substituted decahydroquinolinyl. In some aspects, R41 is substituted tetrahydroquinolinyl. In some aspects, R41 is substituted quinuclidinyl. In some aspects, R41 is substituted azaadamantanyl. In some aspects, R41 is substituted oxepanyl. In some aspects, R41 is substituted oxaspiro[4.5]decanyl. In some aspects, R41 is substituted dioxaspiro[3.4]octnyl. In some aspects, R41 is substituted oxaazaspiro[3.5]nonanyl. In some aspects, R41 is substituted dioxaazaspiro[4.4]nonanyl. In those embodiments wherein R41 is substituted C3-10heterocycloalkyl, the C3-10heterocycloalkyl is substituted with one substitutent. In some embodiments wherein R41 is substituted C3-10heterocycloalkyl, the C3-10heterocycloalkyl is substituted with two substituents that are the same or different. In some embodiments wherein R41 is substituted C3-10heterocycloalkyl, the C3-10heterocycloalkyl is substituted with three substituents that are the same or different. In some embodiments wherein R41 is substituted C3-10heterocycloalkyl, the C3-10heterocycloalkyl is substituted with more than three substituents that are the same or different. When R41 is substituted C3-10heterocycloalkyl, the substituent can be one substituent that is C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl. When R41 is substituted C3-10heterocycloalkyl, the substituents can be two substituents that are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl. When R41 is substituted C3-10heterocycloalkyl, the substituents can be three substituents that are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl. When R41 is substituted C3-10heterocycloalkyl, the substituents can be more than three2026.05.07 DESCRIPTION P000685WO
[0652] substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi. ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl.
[0653] In some aspects of the disclosure are compounds of formula Xl-A wherein R41 is substituted or unsubstituted Cs-wheterocycloalkenyl. According to the disclosure, a C3-loheterocycloalkenyl moiety is a Cs-wheterocycloalkyl moiety with one or more double bonds. In some aspects, Cs-wheterocycloalkenyl is a aziridinyl, oxiranyl, thiiranyl, azetidinyl, diazetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, dioxolanyl, tetrahydrothiophenyl, oxathiolanyl, sulfolanyl, piperiinyl, piperazinyl, tetrahydropyranyl, dioxanyl, thianyl, dithianyl, morpholinyl, thiomorpholinyl, thiomorpholinyl dioxide, pyrrolizidinyl, decahydroisoquinolinyl, decahydroquinolinyl, tetrahydroquinolinyl, quinuclidinyl, azaadamantanyl, oxepanyl, oxaspiro[4.5]decanyl, dioxaspiro[3.4]octnyl, oxaazaspiro[3.5]nonanyl, or dioxaazaspiro[4.4]nonanyl with one double bond. In some aspects, Cs-wheterocycloalkenyl is a aziridinyl, oxiranyl, thiiranyl, azetidinyl, diazetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, dioxolanyl, tetrahydrothiophenyl, oxathiolanyl, sulfolanyl, piperiinyl, piperazinyl, tetrahydropyranyl, dioxanyl, thianyl, dithianyl, morpholinyl, thiomorpholinyl, thiomorpholinyl dioxide, pyrrolizidinyl, decahydroisoquinolinyl, decahydroquinolinyl, tetrahydroquinolinyl, quinuclidinyl, azaadamantanyl, oxepanyl, oxaspiro[4.5]decanyl, dioxaspiro[3.4]octnyl, oxaazaspiro[3.5]nonanyl, or dioxaazaspiro[4.4]nonanyl with two double bonds. In some aspects, R41 is unsubstituted Cs-wheterocycloalkenyl. In some aspects, R41 is substituted Cs-wheterocycloalkenyl. In some aspects, the substituted Cs-wheterocycloalkenyl is substituted with one substituent. In some aspects, the substituted Cs-wheterocycloalkenyl is substituted with two substituents that are the same or different. In some aspects, the substituted Cs-wheterocycloalkenyl is substituted with three substituents that are the same or different. In some aspects, the substituted Cs-wheterocycloalkenyl is substituted with more than three substituents that are the same or different. When fR4i is substituted Cs-wheterocycloalkenyl, the substituent can be one substituent that is Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. When R41 is substituted Cs-wheterocycloalkenyl, the substituent can be two substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl. When R41 is substituted C3-10heterocycloalkenyl, the substituent can be three substituents that are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -2026.05.07 DESCRIPTION P000685WO
[0654] N(Ci-6alkyl)Ci-6alkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. When R41 is substituted Cs-wheterocycloalkenyl, the substituent can be more than three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci- ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-6alkyl)Ci.ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl.
[0655] Within the scope of the disclosure are compounds of formula XII and salts thereof:
[0656]
[0657] wherein
[0658] L is C1-6alk; and
[0659] R41 is substituted or unsubstituted Ci-ealkyl; substituted or unsubstituted Ce-2oaryl; substituted or unsubstituted C5-2oheteroaryl; substituted or unsubstituted Cs- cycloalkyl, substituted or unsubstituted Cs- cycloalkenyl, substituted or unsubstituted Cs-wheterocycloalkyl, or substituted or unsubstituted Cs-wheterocycloalkenyl.
[0660] In preferred aspects of the disclosure are compounds of formula XII, L is Cialk (-CH2-). In other aspects, L is C2alk. In other aspects, L is Csalk. In other aspects, L is C4alk. In other aspects, L is Csalk. In other aspects, L is Cealk.
[0661] In some aspects of the disclosure are compounds of formula XII wherein R41 is substituted or unsubstituted Ci-ealkyl. In some aspects, R41 is unsubstituted Ci-ealkyl, for example, unsubstituted methyl. In some aspects, R41 is unsubstituted ethyl. In some aspects, R41 is unsubstituted n-propyl. In some aspects, R41 is unsubstituted isopropyl. In some aspects, R41 is unsubstituted n-butyl. In some aspects, R41 is unsubstituted isobutyl. In some aspects, R41 is unsubstituted sec-butyl. In some aspects, R41 is unsubstituted tert-butyl. In some aspects, R41 is substituted Ci-ealkyl, for example, substituted methyl. In some aspects, R41 is substituted ethyl. In some aspects, R41 is substituted n-propyl. In some aspects, R41 is substituted isopropyl. In some aspects, R41 is substituted n-butyl. In some aspects, R41 is substituted isobutyl. In some aspects, R41 is substituted sec-butyl. In some aspects, R41 is substituted tert-butyl. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with one substituent. In some embodiments wherein R41 is substituted Ci- ealkyl, the Ci-ealkyl is substituted with two substituents that are the same or different. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with three substituents that are the same or different. In embodiments wherein R41 is substituted Ci-2026.05.07 DESCRIPTION P000685WO
[0662] ealkyl, the Ci-ealkyl is substituted with more than three substituents that are the same or different. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with one substituent that is Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi. ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci. ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with two substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with three substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with more than three substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl.
[0663] In some aspects of the disclosure are compounds of formula XII wherein R41 is substituted or unsubstituted Ce-2oaryl. In some aspects, R41 is unsubstituted Ce-2oaryl, for example, unsubstituted phenyl. In some aspects, R41 is unsubstituted tolyl. In some aspects, R41 is unsubstituted xylyl. In some aspects, R41 is unsubstituted naphthyl. In some aspects, R41 is substituted C6-2oaryl, for example, substituted phenyl. In some aspects, R41 is substituted tolyl. In some aspects, R41 is substituted xylyl. In some aspects, R41 is substituted naphthyl. In some embodiments wherein R41 is substituted Ce-2oaryl, the C6-2oaryl is substituted with one substituent. In some embodiments wherein R41 is substituted C6-2oaryl, the C6-2oaryl is substituted with two substituents that are the same or different. In some embodiments wherein R41 is substituted Ce-2oaryl, the C6-2oaryl is substituted with three substituents that are the same or different. In some embodiments wherein R41 is substituted Ce-2oaryl, the Ce-2oaryl is substituted with more than three substituents that are the same or different. In some embodiments wherein R41 is substituted Ce-2oaryl, the C6-2oaryl is substituted with one substituent that is Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted Ce-2oaryl, the Ce-2oaryl is substituted with two substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi.2026.05.07 DESCRIPTION P000685WO
[0664] ehaloalkyl. In some embodiments wherein R41 is substituted Ce-2oaryl, the Ce-2oaryl is substituted with three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi. ealkylCOOCi-ealkyl, -N(Ci.ealkyl)Ci.ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted Ce-2oaryl, the Ce-2oaryl is substituted with three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOC1. ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci. ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl.
[0665] In some aspects of the disclosure are compounds of formula XII wherein R41 is substituted or unsubstituted C5-2oheteroaryl. In some aspects, R41 is unsubstituted C5-2oheteroaryl, for example, unsubstituted pyridyl. In some aspects, R41 is unsubstituted pyrimidinyl. In some aspects, R41 is unsubstituted pyrazinyl. In some aspects, R41 is unsubstituted pyridazinyl. In some aspects, R41 is unsubstituted thienyl. In some aspects, R41 is unsubstituted furanyl. In some aspects, R41 is unsubstituted imidazolyl. In some aspects, R41 is unsubstituted pyrazolyl. In some aspects, R41 is unsubstituted triazolyl. In some aspects, R41 is unsubstituted quinolinyl. In some aspects, R41 is unsubstituted isoquinolinyl. In some aspects, R41 is substituted C5-2oheteroaryl, for example, substituted pyridyl. In some aspects, R41 is substituted pyrimidinyl. In some aspects, R41 is substituted pyrazinyl. In some aspects, R41 is substituted pyridazinyl. In some aspects, R41 is substituted thienyl. In some aspects, R41 is substituted furanyl. In some aspects, R41 is substituted imidazolyl. In some aspects, R41 is substituted pyrazolyl. In some aspects, R41 is substituted triazolyl. In some aspects, R41 is substituted quinolinyl. In some aspects, R41 is substituted isoquinolinyl. In some embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with one substituent. In some embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with two substituents that are the same or different. In other embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with three substituents that are the same or different. In other embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with more than three substituents that are the same or different. In some embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with one substituent that is Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl. In some embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with two substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi.2026.05.07 DESCRIPTION P000685WO
[0666] ehaloalkyl. In some embodiments wherein R41 is substituted C5-2oheteroaryl, the Cs-2oheteroaryl is substituted with three substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-6alkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with more than three substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl.
[0667] In some aspects of the disclosure are compounds of formula XII wherein R41 is substituted or unsubstituted Cs- cycloalkyl. In some aspects, R41 is unsubstituted Cs- cycloalkyl. For example, in some aspects, R41 is unsubstituted cyclopropyl. In some aspects, R41 is unsubstituted cyclobutyl. In some aspects, R41 is unsubstituted cyclopentyl. In some aspects, R41 is unsubstituted cyclohexyl. In some aspects, R41 is unsubstituted cycloheptanyl. In some aspects, R41 is unsubstituted cyclooctanyl. In some aspects, R41 is unsubstituted adamantanyl. In some aspects, R41 is unsubstituted bicyclo[2.2.1]heptanyl. In some aspects, R41 is unsubstituted bicyclo[2.2.2.octanyl. In some aspects, R41 is unsubstituted spiro[3.3]heptanyl. In some aspects, R41 is unsubstituted spiro[4.4]nonanyl. In some aspects, R41 is unsubstituted spiro[2.4]heptanyl. In some aspects, R41 is unsubstituted spiro[3.4]octanyl. In some aspects, R41 is unsubstituted bicyclo[4.2.0]octanyl. In some aspects, R41 is unsubstituted bicyclo[4.3.0]nonanyl. In some aspects, R41 is unsubstituted bicyclo[4.4.0]decanyl. In some aspects, R41 is unsubstituted bicyclo[3.1.0]hexanyl. In some aspects, R41 is unsubstituted bicyclo[3.2.0]heptanyl. In some aspects, R41 is unsubstituted bicyclo[3.3.0]octanyl. In some aspects, R41 is unsubstituted bicyclo[4.1.0]heptanyl. In some aspects, R41 is unsubstituted tetrahydronapthalenyl. In some aspects, R41 is unsubstituted dihydroindenyl. In some aspects, R41 is substituted Cs- cycloalkyl. For example, in some aspects, R41 is substituted cyclopropyl. In some aspects, R41 is substituted cyclobutyl. In some aspects, R41 is substituted cyclopentyl. In some aspects, R41 is substituted cyclohexyl. In some aspects, R41 is substituted cycloheptanyl. In some aspects, R41 is substituted cyclooctanyl. In some aspects, R41 is substituted adamantanyl. In some aspects, R41 is substituted bicyclo[2.2.1]heptanyl. In some aspects, R41 is substituted bicyclo[2.2.2.octanyl. In some aspects, R41 is substituted spiro[3.3]heptanyl. In some aspects, R41 is substituted spiro[4.4]nonanyl. In some aspects, R41 is substituted spiro[2.4]heptanyl. In some aspects, R41 is substituted spiro[3.4]octanyl. In some aspects, R41 is substituted bicyclo[4.2.0]octanyl. In some aspects, R41 is substituted bicyclo[4.3.0]nonanyl. In some aspects, R41 is substituted bicyclo[4.4.0]decanyl. In some aspects, R41 is substituted bicyclo[3.1.0]hexanyl. In some2026.05.07 DESCRIPTION P000685WO
[0668] aspects, R41 is substituted bicyclo[3.2.0]heptanyl. In some aspects, R41 is substituted bicyclo[3.3.0]octanyl. In some aspects, R41 is substituted bicyclo[4.1.0]heptanyl. In some aspects, R41 is substituted tetrahydronapthalenyl. In some embodiments wherein R41 is substituted Cs- cycloalkyl, the Cs- cycloalkyl is substituted with one substitutuent. In some embodiments wherein R41 is substituted Cs- cycloalkyl, the Cs- cycloalkyl is substituted with two substituents that are the same or different. In some embodiments wherein R41 is substituted C3-10cycloalkyl, the C3-10cycloalkyl is substituted with three substituents that are the same or different. In Some embodiments wherein R41 is substituted C3-10cycloalkyl, the C3-10cycloalkyl is substituted with more than three substituents that are the same or different. In some aspects wherein the R41 is substituted with one substituent, the substituent is Ci- ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, and OC1-6haloalkyl. In some aspects wherein the R41 is substituted with two substituents, the substituents can be two substituents are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl. In some aspects wherein the R41 is substituted with three substituents, they are each indepenently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In other embodiments, when R41 is substituted C3- cycloalkyl, the Cs- cycloalkyl substituted with more than three substituents are are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci- ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl.
[0669] In some aspects of the disclosure are compounds of formula XII wherein R41 is substituted or unsubstituted Cs- cycloalkenyl. In some aspects, R41 is unsubstituted Cs- cycloalkenyl. In some aspects, R41 is unsubstituted cyclopropenyl. In some aspects, R41 is unsubstituted cyclobutenyl. In some aspects, R41 is unsubstituted cyclopentenyl. In some aspects, R41 is unsubstituted cyclohexenyl. In some aspects, R41 is unsubstituted cycloheptenyl. In some aspects, R41 is unsubstituted cyclooctenyl. In some aspects, R41 is unsubstituted adamantenyl. In some aspects, R41 is unsubstituted bicyclo[2.2.1]heptenyl. In some aspects, R41 is unsubstituted bicyclo[2.2.2.octenyl. In some aspects, R41 is unsubstituted spiro[3.3]heptenyl. In some aspects, R41 is unsubstituted spiro[4.4]nonenyl. In some aspects, R41 is unsubstituted spiro[2.4]heptenyl. In some aspects, R41 is unsubstituted spiro[3.4]octenyl. In some aspects, R41 is unsubstituted bicyclo[4.2.0]octenyl. In some aspects, R41 is unsubstituted bicyclo[4.3.0]nonenyl. In some aspects, R41 is unsubstituted2026.05.07 DESCRIPTION P000685WO
[0670] bicyclo[4.4.0]decenyl. In some aspects, R41 is unsubstituted bicyclo[3.1.0]hexenyl. In some aspects, R41 is unsubstituted bicyclo[3.2.0]heptenyl. In some aspects, R41 is unsubstituted bicyclo[3.3.0]octenyl. In some aspects, R41 is unsubstituted bicyclo[4.1.0]heptenyl. In some aspects, R41 is unsubstituted dihydronapthalenyl. In some aspects, R41 is substituted C3-locycloalkenyl. In some aspects, R41 is substituted cyclopropenyl. In some aspects, R41 is substituted cyclobutenyl. In some aspects, R41 is substituted cyclopentenyl. In some aspects, R41 is substituted cyclohexenyl. In some aspects, R41 is substituted cycloheptenyl. In some aspects, R41 is substituted cyclooctenyl. In some aspects, R41 is substituted adamantenyl. In some aspects, R41 is substituted bicyclo[2.2.1]heptenyl. In some aspects, R41 is substituted bicyclo[2.2.2.octenyl. In some aspects, R41 is substituted spiro[3.3]heptenyl. In some aspects, the R41 is substituted spiro[4.4]nonenyl. In some aspects, the R41 is substituted spiro[2.4]heptenyl. In some aspects, R41 is substituted spiro[3.4]octenyl. In some aspects, R41 is substituted bicyclo[4.2.0]octenyl. In some aspects, R41 is substituted bicyclo[4.3.0]nonenyl. In some aspects, R41 is substituted bicyclo[4.4.0]decenyl. In some aspects, R41 is substituted bicyclo[3.1.0]hexenyl. In some aspects, R41 is substituted bicyclo[3.2.0]heptenyl. In some aspects, R41 is substituted bicyclo[3.3.0]octenyl. In some aspects, R41 is substituted bicyclo[4.1.0]heptenyl. In some aspects, R41 is substituted dihydronapthalenyl. In some embodiments wherein R41 is substituted Cs- cycloalkenyl, the Cs- cycloalkenyl is substituted with one substituent. In some embodiments wherein R41 is substituted Cs- cycloalkenyl, the Cs- cycloalkenyl is substituted with two substituents that are the same or different. In some embodiments wherein R41 is substituted Cs- cycloalkenyl, the Cs- cycloalkenyl is substituted with three substituents that are the same or different. In some embodiments wherein R41 is substituted Cs- cycloalkenyl, the Cs- cycloalkenyl is substituted with more than three substituents that are the same or different. When R41 is substituted Cs- cycloalkenyl, the substituent can be one substituent that is Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci.ealkyl)Ci.ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OC1-ehaloalkyl. When R41 is substituted Cs- cycloalkenyl, the substituent can be two substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl. When R41 is substituted Cs- cycloalkenyl, the substituent can be three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NC1. ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl. When R41 is substituted Cs- cycloalkenyl, the substituent can be more than three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOC1.2026.05.07 DESCRIPTION P000685WO
[0671] ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci.
[0672] 6alkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl.
[0673] In some aspects of the disclosure are compounds of formula XII wherein R41 is substituted or unsubstituted Cs-wheterocycloalkyl. In some aspects, R41 is unsubstituted C3-loheterocycloalkyl. In some aspects, R41 is unsubstituted aziridinyl. In some aspects, R41 is unsubstituted oxiranyl. In some aspects, R41 is unsubstituted thiiranyl. In some aspects, R41 is unsubstituted azetidinyl. In some aspects, R41 is unsubstituted diazetidinyl. In some aspects, R41 is unsubstituted oxetanyl. In some aspects, R41 is unsubstituted thietanyl. In some aspects, R41 is unsubstituted pyrrolidinyl. In some aspects, R41 is unsubstituted pyrazolidinyl. In some aspects, R41 is unsubstituted imidazolidinyl. In some aspects, R41 is unsubstituted tetrahydrofuranyl. In some aspects, R41 is unsubstituted dioxolanyl. In some aspects, R41 is unsubstituted tetrahydrothiophenyl. In some aspects, R41 is unsubstituted oxathiolanyl. In some aspects, R41 is unsubstituted sulfolanyl. In some aspects, R41 is unsubstituted piperiinyl. In some aspects, R41 is unsubstituted piperazinyl. In some aspects, R41 is unsubstituted tetrahydropyranyl. In some aspects, R41 is unsubstituted dioxanyl. In some aspects, R41 is unsubstituted thianyl. In some aspects, R41 is unsubstituted dithianyl. In some aspects, R41 is unsubstituted morpholinyl. In some aspects, R41 is unsubstituted thiomorpholinyl. In some aspects, R41 is unsubstituted thiomorpholinyl dioxide. In some aspects, R41 is unsubstituted pyrrolizidinyl. In some aspects, R41 is unsubstituted decahydroisoquinolinyl. In some aspects, R41 is unsubstituted decahydroquinolinyl. In some aspects, R41 is unsubstituted tetrahydroquinolinyl. In some aspects, R41 is unsubstituted quinuclidinyl. In some aspects, R41 is unsubstituted azaadamantanyl. In some aspects, R41 is unsubstituted oxepanyl. In some aspects, R41 is unsubstituted oxaspiro[4.5]decanyl. In some aspects, R41 is unsubstituted dioxaspiro[3.4]octnyl. In some aspects, R41 is unsubstituted oxaazaspiro[3.5]nonanyl. In some aspects, R41 is unsubstituted dioxaazaspiro[4.4]nonanyl. In some aspects, R41 is substituted C3-10heterocycloalkyl. In some aspects, R41 is substituted aziridinyl. In some aspects, R41 is substituted oxiranyl. In some aspects, R41 is substituted thiiranyl. In some aspects, R41 is substituted azetidinyl. In some aspects, R41 is substituted diazetidinyl. In some aspects, R41 is substituted oxetanyl. In some aspects, R41 is substituted thietanyl. In some aspects, R41 is substituted pyrrolidinyl. In some aspects, R41 is substituted pyrazolidinyl. In some aspects, R41 is substituted imidazolidinyl. In some aspects, R41 is substituted tetrahydrofuranyl. In some aspects, R41 is substituted dioxolanyl. In some aspects, R41 is substituted tetrahydrothiophenyl. In some aspects, R41 is substituted oxathiolanyl. In some aspects, R41 is substituted sulfolanyl. In some aspects, R41 is substituted piperiinyl. In some aspects, R41 is substituted piperazinyl. In some aspects, R41 is substituted tetrahydropyranyl. In some aspects, R41 is substituted dioxanyl. In some aspects,2026.05.07 DESCRIPTION P000685WO
[0674] R41 is substituted thianyl. In some aspects, R41 is substituted dithianyl. In some aspects, R41 is substituted morpholinyl. In some aspects, R41 is substituted thiomorpholinyl. In some aspects, R41 is substituted thiomorpholinyl dioxide. In some aspects, R41 is substituted pyrrolizidinyl. In some aspects, R41 is substituted decahydroisoquinolinyl. In some aspects, R41 is substituted decahydroquinolinyl. In some aspects, R41 is substituted tetrahydroquinolinyl. In some aspects, R41 is substituted quinuclidinyl. In some aspects, R41 is substituted azaadamantanyl. In some aspects, R41 is substituted oxepanyl. In some aspects, R41 is substituted oxaspiro[4.5]decanyl. In some aspects, R41 is substituted dioxaspiro[3.4]octnyl. In some aspects, R41 is substituted oxaazaspiro[3.5]nonanyl. In some aspects, R41 is substituted dioxaazaspiro[4.4]nonanyl. In those embodiments wherein R41 is substituted C3-10heterocycloalkyl, the C3-10heterocycloalkyl is substituted with one substitutent. In some embodiments wherein R41 is substituted C3-10heterocycloalkyl, the C3-10heterocycloalkyl is substituted with two substituents that are the same or different. In some embodiments wherein R41 is substituted C3-10heterocycloalkyl, the C3-10heterocycloalkyl is substituted with three substituents that are the same or different. In some embodiments wherein R41 is substituted C3-10heterocycloalkyl, the C3-10heterocycloalkyl is substituted with more than three substituents that are the same or different. When R41 is substituted C3-10heterocycloalkyl, the substituent can be one substituent that is Ci-ealkyl, C2.ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NC1. ealkylCOOCi-ealkyl, -N(Ci.ealkyl)Ci.ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. When R41 is substituted Cs-wheterocycloalkyl, the substituents can be two substituents that are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl. When R41 is substituted C3-10heterocycloalkyl, the substituents can be three substituents that are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi. ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. When R41 is substituted Cs-wheterocycloalkyl, the substituents can be more than three substituents that are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl.
[0675] In some aspects of the disclosure are compounds of formula XII wherein R41 is substituted or unsubstituted Cs-wheterocycloalkenyl. According to the disclosure, a Cs-wheterocycloalkenyl moiety is a Cs-wheterocycloalkyl moiety with one or more double bonds. In some aspects, Cs-wheterocycloalkenyl is a aziridinyl, oxiranyl, thiiranyl, azetidinyl, diazetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, dioxolanyl,2026.05.07 DESCRIPTION P000685WO
[0676] tetrahydrothiophenyl, oxathiolanyl, sulfolanyl, piperiinyl, piperazinyl, tetrahydropyranyl, dioxanyl, thianyl, dithianyl, morpholinyl, thiomorpholinyl, thiomorpholinyl dioxide, pyrrolizidinyl, decahydroisoquinolinyl, decahydroquinolinyl, tetrahydroquinolinyl, quinuclidinyl, azaadamantanyl, oxepanyl, oxaspiro[4.5]decanyl, dioxaspiro[3.4]octnyl, oxaazaspiro[3.5]nonanyl, or dioxaazaspiro[4.4]nonanyl with one double bond. In some aspects, Cs-ioheterocycloalkenyl is a aziridinyl, oxiranyl, thiiranyl, azetidinyl, diazetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, dioxolanyl, tetrahydrothiophenyl, oxathiolanyl, sulfolanyl, piperiinyl, piperazinyl, tetrahydropyranyl, dioxanyl, thianyl, dithianyl, morpholinyl, thiomorpholinyl, thiomorpholinyl dioxide, pyrrolizidinyl, decahydroisoquinolinyl, decahydroquinolinyl, tetrahydroquinolinyl, quinuclidinyl, azaadamantanyl, oxepanyl, oxaspiro[4.5]decanyl, dioxaspiro[3.4]octnyl, oxaazaspiro[3.5]nonanyl, or dioxaazaspiro[4.4]nonanyl with two double bonds. In some aspects, R41 is unsubstituted C3-10heterocycloalkenyl. In some aspects, R41 is substituted C3-10heterocycloalkenyl. In some aspects, the substituted C3-10heterocycloalkenyl is substituted with one substituent. In some aspects, the substituted C3-10heterocycloalkenyl is substituted with two substituents that are the same or different. In some aspects, the substituted C3-10heterocycloalkenyl is substituted with three substituents that are the same or different. In some aspects, the substituted C3-10heterocycloalkenyl is substituted with more than three substituents that are the same or different. When fR₄₁ is substituted C₃-₁₀heterocycloalkenyl, the substituent can be one substituent that is Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. When R41 is substituted Cs-ioheterocycloalkenyl, the substituent can be two substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl. When R41 is substituted Cs- heterocycloalkenyl, the substituent can be three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. When R41 is substituted C3-10heterocycloalkenyl, the substituent can be more than three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci- ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl.
[0677] Within the scope of the disclosure are compounds of formula XIII and salts thereof:2026.05.07 DESCRIPTION P000685WO
[0678]
[0679] wherein
[0680] L is C1-6alk; and
[0681] R41 is substituted or unsubstituted C1-6alkyl; substituted or unsubstituted C6-20aryl; substituted or unsubstituted C5-20heteroaryl; substituted or unsubstituted C3-10cycloalkyl, substituted or unsubstituted C3-10cycloalkenyl, substituted or unsubstituted C3-10heterocycloalkyl, or substituted or unsubstituted C3-10heterocycloalkenyl.
[0682] In preferred aspects of the disclosure are compounds of formula XIII, L is Cialk (-CH2-). In other aspects, L is C2alk. In other aspects, L is Cealk. In other aspects, L is C4alk. In other aspects, L is Csalk. In other aspects, L is Cealk.
[0683] In some aspects of the disclosure are compounds of formula XIII wherein R41 is substituted or unsubstituted Ci-ealkyl. In some aspects, R41 is unsubstituted Ci-ealkyl, for example, unsubstituted methyl. In some aspects, R41 is unsubstituted ethyl. In some aspects, R41 is unsubstituted n-propyl. In some aspects, R41 is unsubstituted isopropyl. In some aspects, R41 is unsubstituted n-butyl. In some aspects, R41 is unsubstituted isobutyl. In some aspects, R41 is unsubstituted sec-butyl. In some aspects, R41 is unsubstituted tert-butyl. In some aspects, R41 is substituted Ci-ealkyl, for example, substituted methyl. In some aspects, R41 is substituted ethyl. In some aspects, R41 is substituted n-propyl. In some aspects, R41 is substituted isopropyl. In some aspects, R41 is substituted n-butyl. In some aspects, R41 is substituted isobutyl. In some aspects, R41 is substituted sec-butyl. In some aspects, R41 is substituted tert-butyl. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with one substituent. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with two substituents that are the same or different. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with three substituents that are the same or different. In embodiments wherein R41 is substituted Ci- ealkyl, the Ci-ealkyl is substituted with more than three substituents that are the same or different. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with one substituent that is Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOC1. ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci. ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with two substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl,2026.05.07 DESCRIPTION P000685WO
[0684] Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci.ealkyl)Ci.ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with three substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with more than three substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl.
[0685] In some aspects of the disclosure are compounds of formula XIII wherein R41 is substituted or unsubstituted Ce-2oaryl. In some aspects, R41 is unsubstituted Ce-2oaryl, for example, unsubstituted phenyl. In some aspects, R41 is unsubstituted tolyl. In some aspects, R41 is unsubstituted xylyl. In some aspects, R41 is unsubstituted naphthyl. In some aspects, R41 is substituted C6-2oaryl, for example, substituted phenyl. In some aspects, R41 is substituted tolyl. In some aspects, R41 is substituted xylyl. In some aspects, R41 is substituted naphthyl. In some embodiments wherein R41 is substituted Ce-2oaryl, the C6-2oaryl is substituted with one substituent. In some embodiments wherein R41 is substituted C6-2oaryl, the C6-2oaryl is substituted with two substituents that are the same or different. In some embodiments wherein R41 is substituted Ce-2oaryl, the C6-2oaryl is substituted with three substituents that are the same or different. In some embodiments wherein R41 is substituted Ce-2oaryl, the Ce-2oaryl is substituted with more than three substituents that are the same or different. In some embodiments wherein R41 is substituted Ce-2oaryl, the C6-2oaryl is substituted with one substituent that is Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted Ce-2oaryl, the Ce-2oaryl is substituted with two substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl. In some embodiments wherein R41 is substituted Ce-2oaryl, the Ce-2oaryl is substituted with three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NC1. ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted Ce-2oaryl, the Ce-2oaryl is substituted with three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOC1.2026.05.07 DESCRIPTION P000685WO
[0686] ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci.
[0687] 6alkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl.
[0688] In some aspects of the disclosure are compounds of formula XIII wherein R41 is substituted or unsubstituted C5-2oheteroaryl. In some aspects, R41 is unsubstituted C5-2oheteroaryl, for example, unsubstituted pyridyl. In some aspects, R41 is unsubstituted pyrimidinyl. In some aspects, R41 is unsubstituted pyrazinyl. In some aspects, R41 is unsubstituted pyridazinyl. In some aspects, R41 is unsubstituted thienyl. In some aspects, R41 is unsubstituted furanyl. In some aspects, R41 is unsubstituted imidazolyl. In some aspects, R41 is unsubstituted pyrazolyl. In some aspects, R41 is unsubstituted triazolyl. In some aspects, R41 is unsubstituted quinolinyl. In some aspects, R41 is unsubstituted isoquinolinyl. In some aspects, R41 is substituted C5-2oheteroaryl, for example, substituted pyridyl. In some aspects, R41 is substituted pyrimidinyl. In some aspects, R41 is substituted pyrazinyl. In some aspects, R41 is substituted pyridazinyl. In some aspects, R41 is substituted thienyl. In some aspects, R41 is substituted furanyl. In some aspects, R41 is substituted imidazolyl. In some aspects, R41 is substituted pyrazolyl. In some aspects, R41 is substituted triazolyl. In some aspects, R41 is substituted quinolinyl. In some aspects, R41 is substituted isoquinolinyl. In some embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with one substituent. In some embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with two substituents that are the same or different. In other embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with three substituents that are the same or different. In other embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with more than three substituents that are the same or different. In some embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with one substituent that is Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with two substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with three substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with more than three substituents that are each independently Ci-2026.05.07 DESCRIPTION P000685WO
[0689] ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-6alkyl)Ci-6alkyl, -NHC1-6alkyl, NH2, OCi- ealkyl, or OCi-ehaloalkyl.
[0690] In some aspects of the disclosure are compounds of formula XIII wherein R41 is substituted or unsubstituted C3-10cycloalkyl. In some aspects, R41 is unsubstituted C3-10cycloalkyl. For example, in some aspects, R41 is unsubstituted cyclopropyl. In some aspects, R4I is unsubstituted cyclobutyl. In some aspects, R4I is unsubstituted cyclopentyl. In some aspects, R4I is unsubstituted cyclohexyl. In some aspects, R4I is unsubstituted cycloheptanyl. In some aspects, R4I is unsubstituted cyclooctanyl. In some aspects, R4I is unsubstituted adamantanyl. In some aspects, R4I is unsubstituted bicyclo[2.2.1]heptanyl. In some aspects, R4I is unsubstituted bicyclo[2.2.2.octanyl. In some aspects, R4I is unsubstituted spiro[3.3]heptanyl. In some aspects, R4I is unsubstituted spiro[4.4]nonanyl. In some aspects, R4I is unsubstituted spiro[2.4]heptanyl. In some aspects, R4I is unsubstituted spiro[3.4]octanyl. In some aspects, R4I is unsubstituted bicyclo[4.2.0]octanyl. In some aspects, R4I is unsubstituted bicyclo[4.3.0]nonanyl. In some aspects, R4I is unsubstituted bicyclo[4.4.0]decanyl. In some aspects, R4I is unsubstituted bicyclo[3.1.0]hexanyl. In some aspects, R4I is unsubstituted bicyclo[3.2.0]heptanyl. In some aspects, R4I is unsubstituted bicyclo[3.3.0]octanyl. In some aspects, R4I is unsubstituted bicyclo[4.1.0]heptanyl. In some aspects, R4I is unsubstituted tetrahydronapthalenyl. In some aspects, R4I is unsubstituted dihydroindenyl. In some aspects, R4I is substituted Cs- cycloalkyl. For example, in some aspects, R4I is substituted cyclopropyl. In some aspects, R4I is substituted cyclobutyl. In some aspects, R4I is substituted cyclopentyl. In some aspects, R4I is substituted cyclohexyl. In some aspects, R4I is substituted cycloheptanyl. In some aspects, R4I is substituted cyclooctanyl. In some aspects, R4I is substituted adamantanyl. In some aspects, R4I is substituted bicyclo[2.2.1]heptanyl. In some aspects, R4I is substituted bicyclo[2.2.2.octanyl. In some aspects, R4I is substituted spiro[3.3]heptanyl. In some aspects, R4I is substituted spiro[4.4]nonanyl. In some aspects, R4I is substituted spiro[2.4]heptanyl. In some aspects, R4I is substituted spiro[3.4]octanyl. In some aspects, R4I is substituted bicyclo[4.2.0]octanyl. In some aspects, R4I is substituted bicyclo[4.3.0]nonanyl. In some aspects, R4I is substituted bicyclo[4.4.0]decanyl. In some aspects, R4I is substituted bicyclo[3.1.0]hexanyl. In some aspects, R4I is substituted bicyclo[3.2.0]heptanyl. In some aspects, R4I is substituted bicyclo[3.3.0]octanyl. In some aspects, R4I is substituted bicyclo[4.1.0]heptanyl. In some aspects, R4I is substituted tetrahydronapthalenyl. In some embodiments wherein R4I is substituted C3-10cycloalkyl, the C3-10cycloalkyl is substituted with one substitutuent. In some embodiments wherein R41 is substituted C3-10cycloalkyl, the C3-10cycloalkyl is substituted with two substituents that are the same or different. In some embodiments wherein R4I is2026.05.07 DESCRIPTION P000685WO
[0691] substituted C3-10cycloalkyl, the C3-10cycloalkyl is substituted with three substituents that are the same or different. In Some embodiments wherein R41 is substituted C3-10cycloalkyl, the C3-10cycloalkyl is substituted with more than three substituents that are the same or different. In some aspects wherein the R41 is substituted with one substituent, the substituent is Ci- ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, and OC1-6haloalkyl. In some aspects wherein the R4I is substituted with two substituents, the substituents can be two substituents are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl. In some aspects wherein the R4I is substituted with three substituents, they are each indepenently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In other embodiments, when R4I is substituted C3- cycloalkyl, the Cs- cycloalkyl substituted with more than three substituents are are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci- ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl.
[0692] In some aspects of the disclosure are compounds of formula XIII wherein R41 is substituted or unsubstituted C3-10cycloalkenyl. In some aspects, R41 is unsubstituted C3-10cycloalkenyl. In some aspects, R4I is unsubstituted cyclopropenyl. In some aspects, R4I is unsubstituted cyclobutenyl. In some aspects, R4I is unsubstituted cyclopentenyl. In some aspects, R4I is unsubstituted cyclohexenyl. In some aspects, R4I is unsubstituted cycloheptenyl. In some aspects, R4I is unsubstituted cyclooctenyl. In some aspects, R4I is unsubstituted adamantenyl. In some aspects, R4I is unsubstituted bicyclo[2.2.1]heptenyl. In some aspects, R4I is unsubstituted bicyclo[2.2.2.octenyl. In some aspects, R4I is unsubstituted spiro[3.3]heptenyl. In some aspects, R4I is unsubstituted spiro[4.4]nonenyl. In some aspects, R4I is unsubstituted spiro[2.4]heptenyl. In some aspects, R4I is unsubstituted spiro[3.4]octenyl. In some aspects, R4I is unsubstituted bicyclo[4.2.0]octenyl. In some aspects, R4I is unsubstituted bicyclo[4.3.0]nonenyl. In some aspects, R4I is unsubstituted bicyclo[4.4.0]decenyl. In some aspects, R4I is unsubstituted bicyclo[3.1.0]hexenyl. In some aspects, R4I is unsubstituted bicyclo[3.2.0]heptenyl. In some aspects, R4I is unsubstituted bicyclo[3.3.0]octenyl. In some aspects, R4I is unsubstituted bicyclo[4.1.0]heptenyl. In some aspects, R4I is unsubstituted dihydronapthalenyl. In some aspects, R41 is substituted C3-10cycloalkenyl. In some aspects, R4I is substituted cyclopropenyl. In some aspects, R4I is substituted cyclobutenyl. In some aspects, R4I is substituted cyclopentenyl. In some aspects,2026.05.07 DESCRIPTION P000685WO
[0693] R41 is substituted cyclohexenyl. In some aspects, R41 is substituted cycloheptenyl. In some aspects, R41 is substituted cyclooctenyl. In some aspects, R41 is substituted adamantenyl. In some aspects, R41 is substituted bicyclo[2.2.1]heptenyl. In some aspects, R41 is substituted bicyclo[2.2.2.octenyl. In some aspects, R41 is substituted spiro[3.3]heptenyl. In some aspects, the R41 is substituted spiro[4.4]nonenyl. In some aspects, the R41 is substituted spiro[2.4]heptenyl. In some aspects, R41 is substituted spiro[3.4]octenyl. In some aspects, R41 is substituted bicyclo[4.2.0]octenyl. In some aspects, R41 is substituted bicyclo[4.3.0]nonenyl. In some aspects, R41 is substituted bicyclo[4.4.0]decenyl. In some aspects, R41 is substituted bicyclo[3.1.0]hexenyl. In some aspects, R41 is substituted bicyclo[3.2.0]heptenyl. In some aspects, R41 is substituted bicyclo[3.3.0]octenyl. In some aspects, R41 is substituted bicyclo[4.1.0]heptenyl. In some aspects, R41 is substituted dihydronapthalenyl. In some embodiments wherein R41 is substituted Cs- cycloalkenyl, the Cs- cycloalkenyl is substituted with one substituent. In some embodiments wherein R41 is substituted Cs- cycloalkenyl, the Cs- cycloalkenyl is substituted with two substituents that are the same or different. In some embodiments wherein R41 is substituted Cs- cycloalkenyl, the Cs- cycloalkenyl is substituted with three substituents that are the same or different. In some embodiments wherein R41 is substituted Cs- cycloalkenyl, the Cs- cycloalkenyl is substituted with more than three substituents that are the same or different. When R41 is substituted Cs- cycloalkenyl, the substituent can be one substituent that is Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci.ealkyl)Ci.ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OC1-ehaloalkyl. When R41 is substituted Cs- cycloalkenyl, the substituent can be two substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl. When R41 is substituted Cs- cycloalkenyl, the substituent can be three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NC1. ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl. When R41 is substituted Cs- cycloalkenyl, the substituent can be more than three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOC1. ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci. ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl.
[0694] In some aspects of the disclosure are compounds of formula XIII wherein R41 is substituted or unsubstituted C3-10heterocycloalkyl. In some aspects, R41 is unsubstituted C3-10heterocycloalkyl. In some aspects, R41 is unsubstituted aziridinyl. In some aspects, R41 is unsubstituted oxiranyl. In some aspects, R41 is unsubstituted thiiranyl. In some aspects, R412026.05.07 DESCRIPTION P000685WO
[0695] is unsubstituted azetidinyl. In some aspects, R41 is unsubstituted diazetidinyl. In some aspects, R41 is unsubstituted oxetanyl. In some aspects, R41 is unsubstituted thietanyl. In some aspects, R41 is unsubstituted pyrrolidinyl. In some aspects, R41 is unsubstituted pyrazolidinyl. In some aspects, R41 is unsubstituted imidazolidinyl. In some aspects, R41 is unsubstituted tetrahydrofuranyl. In some aspects, R41 is unsubstituted dioxolanyl. In some aspects, R41 is unsubstituted tetrahydrothiophenyl. In some aspects, R41 is unsubstituted oxathiolanyl. In some aspects, R41 is unsubstituted sulfolanyl. In some aspects, R41 is unsubstituted piperiinyl. In some aspects, R41 is unsubstituted piperazinyl. In some aspects, R41 is unsubstituted tetrahydropyranyl. In some aspects, R41 is unsubstituted dioxanyl. In some aspects, R41 is unsubstituted thianyl. In some aspects, R41 is unsubstituted dithianyl. In some aspects, R41 is unsubstituted morpholinyl. In some aspects, R41 is unsubstituted thiomorpholinyl. In some aspects, R41 is unsubstituted thiomorpholinyl dioxide. In some aspects, R41 is unsubstituted pyrrolizidinyl. In some aspects, R41 is unsubstituted decahydroisoquinolinyl. In some aspects, R41 is unsubstituted decahydroquinolinyl. In some aspects, R41 is unsubstituted tetrahydroquinolinyl. In some aspects, R41 is unsubstituted quinuclidinyl. In some aspects, R41 is unsubstituted azaadamantanyl. In some aspects, R41 is unsubstituted oxepanyl. In some aspects, R41 is unsubstituted oxaspiro[4.5]decanyl. In some aspects, R41 is unsubstituted dioxaspiro[3.4]octnyl. In some aspects, R41 is unsubstituted oxaazaspiro[3.5]nonanyl. In some aspects, R41 is unsubstituted dioxaazaspiro[4.4]nonanyl. In some aspects, R41 is substituted C3-10heterocycloalkyl. In some aspects, R41 is substituted aziridinyl. In some aspects, R41 is substituted oxiranyl. In some aspects, R41 is substituted thiiranyl. In some aspects, R41 is substituted azetidinyl. In some aspects, R41 is substituted diazetidinyl. In some aspects, R41 is substituted oxetanyl. In some aspects, R41 is substituted thietanyl. In some aspects, R41 is substituted pyrrolidinyl. In some aspects, R41 is substituted pyrazolidinyl. In some aspects, R41 is substituted imidazolidinyl. In some aspects, R41 is substituted tetrahydrofuranyl. In some aspects, R41 is substituted dioxolanyl. In some aspects, R41 is substituted tetrahydrothiophenyl. In some aspects, R41 is substituted oxathiolanyl. In some aspects, R41 is substituted sulfolanyl. In some aspects, R41 is substituted piperiinyl. In some aspects, R41 is substituted piperazinyl. In some aspects, R41 is substituted tetrahydropyranyl. In some aspects, R41 is substituted dioxanyl. In some aspects, R41 is substituted thianyl. In some aspects, R41 is substituted dithianyl. In some aspects, R41 is substituted morpholinyl. In some aspects, R41 is substituted thiomorpholinyl. In some aspects, R41 is substituted thiomorpholinyl dioxide. In some aspects, R41 is substituted pyrrolizidinyl. In some aspects, R41 is substituted decahydroisoquinolinyl. In some aspects, R41 is substituted decahydroquinolinyl. In some aspects, R41 is substituted tetrahydroquinolinyl. In some aspects, R41 is substituted quinuclidinyl. In some aspects, R41 is substituted azaadamantanyl. In some aspects, R41 is substituted oxepanyl. In some aspects,2026.05.07 DESCRIPTION P000685WO
[0696] R41 is substituted oxaspiro[4.5]decanyl. In some aspects, R41 is substituted dioxaspiro[3.4]octnyl. In some aspects, R41 is substituted oxaazaspiro[3.5]nonanyl. In some aspects, R41 is substituted dioxaazaspiro[4.4]nonanyl. In those embodiments wherein R41 is substituted C3-10heterocycloalkyl, the C3-10heterocycloalkyl is substituted with one substitutent. In some embodiments wherein R41 is substituted C3-10heterocycloalkyl, the C3-10heterocycloalkyl is substituted with two substituents that are the same or different. In some embodiments wherein R41 is substituted C3-10heterocycloalkyl, the C3-10heterocycloalkyl is substituted with three substituents that are the same or different. In some embodiments wherein R41 is substituted C3-10heterocycloalkyl, the C3-10heterocycloalkyl is substituted with more than three substituents that are the same or different. When R41 is substituted C3-10heterocycloalkyl, the substituent can be one substituent that is C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl. When R41 is substituted C3-10heterocycloalkyl, the substituents can be two substituents that are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO C1- ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. When R41 is substituted Cs-wheterocycloalkyl, the substituents can be three substituents that are each independently Ci-ealkyl, 02-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi. ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. When R41 is substituted Cs-wheterocycloalkyl, the substituents can be more than three substituents that are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl.
[0697] In some aspects of the disclosure are compounds of formula XIII wherein R41 is substituted or unsubstituted C3-10heterocycloalkenyl. According to the disclosure, a C3-10heterocycloalkenyl moiety is a C3-10heterocycloalkyl moiety with one or more double bonds. In some aspects, C3-10heterocycloalkenyl is a aziridinyl, oxiranyl, thiiranyl, azetidinyl, diazetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, dioxolanyl, tetrahydrothiophenyl, oxathiolanyl, sulfolanyl, piperiinyl, piperazinyl, tetrahydropyranyl, dioxanyl, thianyl, dithianyl, morpholinyl, thiomorpholinyl, thiomorpholinyl dioxide, pyrrolizidinyl, decahydroisoquinolinyl, decahydroquinolinyl, tetrahydroquinolinyl, quinuclidinyl, azaadamantanyl, oxepanyl, oxaspiro[4.5]decanyl, dioxaspiro[3.4]octnyl, oxaazaspiro[3.5]nonanyl, or dioxaazaspiro[4.4]nonanyl with one double bond. In some aspects, Cs-wheterocycloalkenyl is a aziridinyl, oxiranyl, thiiranyl, azetidinyl, diazetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, dioxolanyl,2026.05.07 DESCRIPTION P000685WO
[0698] tetrahydrothiophenyl, oxathiolanyl, sulfolanyl, piperiinyl, piperazinyl, tetrahydropyranyl, dioxanyl, thianyl, dithianyl, morpholinyl, thiomorpholinyl, thiomorpholinyl dioxide, pyrrolizidinyl, decahydroisoquinolinyl, decahydroquinolinyl, tetrahydroquinolinyl, quinuclidinyl, azaadamantanyl, oxepanyl, oxaspiro[4.5]decanyl, dioxaspiro[3.4]octnyl, oxaazaspiro[3.5]nonanyl, or dioxaazaspiro[4.4]nonanyl with two double bonds. In some aspects, R41 is unsubstituted C3-10heterocycloalkenyl. In some aspects, R41 is substituted C3-10heterocycloalkenyl. In some aspects, the substituted C3-10heterocycloalkenyl is substituted with one substituent. In some aspects, the substituted C3-10heterocycloalkenyl is substituted with two substituents that are the same or different. In some aspects, the substituted C3-10heterocycloalkenyl is substituted with three substituents that are the same or different. In some aspects, the substituted C3-10heterocycloalkenyl is substituted with more than three substituents that are the same or different. When fR₄₁ is substituted C₃-₁₀heterocycloalkenyl, the substituent can be one substituent that is Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. When R41 is substituted Cs-ioheterocycloalkenyl, the substituent can be two substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl. When R41 is substituted Cs- heterocycloalkenyl, the substituent can be three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. When R41 is substituted C3-10heterocycloalkenyl, the substituent can be more than three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci- ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl.
[0699] Within the scope of the disclosure are compounds of formula XIV and salts thereof:
[0700]
[0701] wherein
[0702] L is C1-6alk; and2026.05.07 DESCRIPTION P000685WO
[0703] R41 is substituted or unsubstituted C1-6alkyl; substituted or unsubstituted C6-20aryl; substituted or unsubstituted C5-20heteroaryl; substituted or unsubstituted C3-10cycloalkyl, substituted or unsubstituted C3-10cycloalkenyl, substituted or unsubstituted C3-10heterocycloalkyl, or substituted or unsubstituted C3-10heterocycloalkenyl.
[0704] In preferred aspects of the disclosure are compounds of formula XIV, L is C1alk (-CH2-). In other aspects, L is C2alk. In other aspects, L is C3alk. In other aspects, L is C4alk. In other aspects, L is C5alk. In other aspects, L is C6alk.
[0705] In some aspects of the disclosure are compounds of formula XIV wherein R41 is substituted or unsubstituted Ci-ealkyl. In some aspects, R41 is unsubstituted Ci-ealkyl, for example, unsubstituted methyl. In some aspects, R41 is unsubstituted ethyl. In some aspects, R41 is unsubstituted n-propyl. In some aspects, R41 is unsubstituted isopropyl. In some aspects, R41 is unsubstituted n-butyl. In some aspects, R41 is unsubstituted isobutyl. In some aspects, R41 is unsubstituted sec-butyl. In some aspects, R41 is unsubstituted tert-butyl. In some aspects, R41 is substituted Ci-ealkyl, for example, substituted methyl. In some aspects, R41 is substituted ethyl. In some aspects, R41 is substituted n-propyl. In some aspects, R41 is substituted isopropyl. In some aspects, R41 is substituted n-butyl. In some aspects, R41 is substituted isobutyl. In some aspects, R41 is substituted sec-butyl. In some aspects, R41 is substituted tert-butyl. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with one substituent. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with two substituents that are the same or different. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with three substituents that are the same or different. In embodiments wherein R41 is substituted Ci- ealkyl, the Ci-ealkyl is substituted with more than three substituents that are the same or different. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with one substituent that is Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOC1. ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci. ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with two substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with three substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with more than three substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -2026.05.07 DESCRIPTION P000685WO
[0706] NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl.
[0707] In some aspects of the disclosure are compounds of formula XIV wherein R41 is substituted or unsubstituted Ce-2oaryl. In some aspects, R41 is unsubstituted C6-2oaryl, for example, unsubstituted phenyl. In some aspects, R41 is unsubstituted tolyl. In some aspects, R41 is unsubstituted xylyl. In some aspects, R41 is unsubstituted naphthyl. In some aspects, R41 is substituted C6-2oaryl, for example, substituted phenyl. In some aspects, R41 is substituted tolyl. In some aspects, R41 is substituted xylyl. In some aspects, R41 is substituted naphthyl. In some embodiments wherein R41 is substituted C6-2oaryl, the C6-2oaryl is substituted with one substituent. In some embodiments wherein R41 is substituted C6-2oaryl, the C6-2oaryl is substituted with two substituents that are the same or different. In some embodiments wherein R41 is substituted Ce-2oaryl, the C6-2oaryl is substituted with three substituents that are the same or different. In some embodiments wherein R41 is substituted Ce-2oaryl, the Ce-2oaryl is substituted with more than three substituents that are the same or different. In some embodiments wherein R41 is substituted Ce-2oaryl, the C6-2oaryl is substituted with one substituent that is Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci.ealkyl)Ci.ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted Ce-2oaryl, the Ce-2oaryl is substituted with two substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl. In some embodiments wherein R41 is substituted Ce-2oaryl, the Ce-2oaryl is substituted with three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NC1. ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted Ce-2oaryl, the Ce-2oaryl is substituted with three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOC1. ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci. ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl.
[0708] In some aspects of the disclosure are compounds of formula XIV wherein R41 is substituted or unsubstituted C5-2oheteroaryl. In some aspects, R41 is unsubstituted C5-2oheteroaryl, for example, unsubstituted pyridyl. In some aspects, R41 is unsubstituted pyrimidinyl. In some aspects, R41 is unsubstituted pyrazinyl. In some aspects, R41 is unsubstituted pyridazinyl. In some aspects, R41 is unsubstituted thienyl. In some aspects, R41 is unsubstituted furanyl. In some aspects, R41 is unsubstituted imidazolyl. In some aspects, R41 is unsubstituted2026.05.07 DESCRIPTION P000685WO
[0709] pyrazolyl. In some aspects, R41 is unsubstituted triazolyl. In some aspects, R41 is unsubstituted quinolinyl. In some aspects, R4I is unsubstituted isoquinolinyl. In some aspects, R4I is substituted C5-2oheteroaryl, for example, substituted pyridyl. In some aspects, R4I is substituted pyrimidinyl. In some aspects, R4I is substituted pyrazinyl. In some aspects, R4I is substituted pyridazinyl. In some aspects, R4I is substituted thienyl. In some aspects, R4I is substituted furanyl. In some aspects, R4I is substituted imidazolyl. In some aspects, R4I is substituted pyrazolyl. In some aspects, R4I is substituted triazolyl. In some aspects, R4I is substituted quinolinyl. In some aspects, R4I is substituted isoquinolinyl. In some embodiments wherein R4I is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with one substituent. In some embodiments wherein R4I is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with two substituents that are the same or different. In other embodiments wherein R4I is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with three substituents that are the same or different. In other embodiments wherein R4I is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with more than three substituents that are the same or different. In some embodiments wherein R4I is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with one substituent that is Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-6alkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted C5-20heteroaryl, the C5-20heteroaryl is substituted with two substituents that are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl. In some embodiments wherein R41 is substituted C5-20heteroaryl, the C5-20heteroaryl is substituted with three substituents that are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl. In some embodiments wherein R41 is substituted C5-20heteroaryl, the C5-20heteroaryl is substituted with more than three substituents that are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl.
[0710] In some aspects of the disclosure are compounds of formula XIV wherein R4I is substituted or unsubstituted Cs- cycloalkyl. In some aspects, R4I is unsubstituted Cs- cycloalkyl. For example, in some aspects, R4I is unsubstituted cyclopropyl. In some aspects, R4I is unsubstituted cyclobutyl. In some aspects, R4I is unsubstituted cyclopentyl. In some aspects, R4I is unsubstituted cyclohexyl. In some aspects, R4I is unsubstituted cycloheptanyl. In2026.05.07 DESCRIPTION P000685WO
[0711] some aspects, R41 is unsubstituted cyclooctanyl. In some aspects, R41 is unsubstituted adamantanyl. In some aspects, R41 is unsubstituted bicyclo[2.2.1]heptanyl. In some aspects, R4I is unsubstituted bicyclo[2.2.2.octanyl. In some aspects, R4I is unsubstituted spiro[3.3]heptanyl. In some aspects, R4I is unsubstituted spiro[4.4]nonanyl. In some aspects, R4I is unsubstituted spiro[2.4]heptanyl. In some aspects, R4I is unsubstituted spiro[3.4]octanyl. In some aspects, R4I is unsubstituted bicyclo[4.2.0]octanyl. In some aspects, R4I is unsubstituted bicyclo[4.3.0]nonanyl. In some aspects, R4I is unsubstituted bicyclo[4.4.0]decanyl. In some aspects, R4I is unsubstituted bicyclo[3.1.0]hexanyl. In some aspects, R4I is unsubstituted bicyclo[3.2.0]heptanyl. In some aspects, R4I is unsubstituted bicyclo[3.3.0]octanyl. In some aspects, R4I is unsubstituted bicyclo[4.1.0]heptanyl. In some aspects, R4I is unsubstituted tetrahydronapthalenyl. In some aspects, R4I is unsubstituted dihydroindenyl. In some aspects, R4I is substituted Cs- cycloalkyl. For example, in some aspects, R4I is substituted cyclopropyl. In some aspects, R4I is substituted cyclobutyl. In some aspects, R4I is substituted cyclopentyl. In some aspects, R4I is substituted cyclohexyl. In some aspects, R4I is substituted cycloheptanyl. In some aspects, R4I is substituted cyclooctanyl. In some aspects, R4I is substituted adamantanyl. In some aspects, R4I is substituted bicyclo[2.2.1]heptanyl. In some aspects, R4I is substituted bicyclo[2.2.2.octanyl. In some aspects, R4I is substituted spiro[3.3]heptanyl. In some aspects, R4I is substituted spiro[4.4]nonanyl. In some aspects, R4I is substituted spiro[2.4]heptanyl. In some aspects, R4I is substituted spiro[3.4]octanyl. In some aspects, R4I is substituted bicyclo[4.2.0]octanyl. In some aspects, R4I is substituted bicyclo[4.3.0]nonanyl. In some aspects, R4I is substituted bicyclo[4.4.0]decanyl. In some aspects, R4I is substituted bicyclo[3.1.0]hexanyl. In some aspects, R4I is substituted bicyclo[3.2.0]heptanyl. In some aspects, R4I is substituted bicyclo[3.3.0]octanyl. In some aspects, R4I is substituted bicyclo[4.1.0]heptanyl. In some aspects, R4I is substituted tetrahydronapthalenyl. In some embodiments wherein R4I is substituted C3-10cycloalkyl, the C3-10cycloalkyl is substituted with one substitutuent. In some embodiments wherein R41 is substituted C3-10cycloalkyl, the C3-10cycloalkyl is substituted with two substituents that are the same or different. In some embodiments wherein R4I is substituted Cs- cycloalkyl, the Cs- cycloalkyl is substituted with three substituents that are the same or different. In Some embodiments wherein R4I is substituted Cs- cycloalkyl, the Cs- cycloalkyl is substituted with more than three substituents that are the same or different. In some aspects wherein the R4I is substituted with one substituent, the substituent is Ci- ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, and OC1-6haloalkyl. In some aspects wherein the R4I is substituted with two substituents, the substituents can be two substituents are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -2026.05.07 DESCRIPTION P000685WO
[0712] NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl. In some aspects wherein the R41 is substituted with three substituents, they are each indepenently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci.ealkyl)Ci.ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In other embodiments, when R41 is substituted C3- cycloalkyl, the Cs- cycloalkyl substituted with more than three substituents are are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci- ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl.
[0713] In some aspects of the disclosure are compounds of formula XIV wherein R41 is substituted or unsubstituted Cs- cycloalkenyl. In some aspects, R41 is unsubstituted Cs- cycloalkenyl. In some aspects, R41 is unsubstituted cyclopropenyl. In some aspects, R41 is unsubstituted cyclobutenyl. In some aspects, R41 is unsubstituted cyclopentenyl. In some aspects, R41 is unsubstituted cyclohexenyl. In some aspects, R41 is unsubstituted cycloheptenyl. In some aspects, R41 is unsubstituted cyclooctenyl. In some aspects, R41 is unsubstituted adamantenyl. In some aspects, R41 is unsubstituted bicyclo[2.2.1]heptenyl. In some aspects, R41 is unsubstituted bicyclo[2.2.2.octenyl. In some aspects, R41 is unsubstituted spiro[3.3]heptenyl. In some aspects, R41 is unsubstituted spiro[4.4]nonenyl. In some aspects, R41 is unsubstituted spiro[2.4]heptenyl. In some aspects, R41 is unsubstituted spiro[3.4]octenyl. In some aspects, R41 is unsubstituted bicyclo[4.2.0]octenyl. In some aspects, R41 is unsubstituted bicyclo[4.3.0]nonenyl. In some aspects, R41 is unsubstituted bicyclo[4.4.0]decenyl. In some aspects, R41 is unsubstituted bicyclo[3.1.0]hexenyl. In some aspects, R41 is unsubstituted bicyclo[3.2.0]heptenyl. In some aspects, R41 is unsubstituted bicyclo[3.3.0]octenyl. In some aspects, R41 is unsubstituted bicyclo[4.1.0]heptenyl. In some aspects, R41 is unsubstituted dihydronapthalenyl. In some aspects, R41 is substituted C3-locycloalkenyl. In some aspects, R41 is substituted cyclopropenyl. In some aspects, R41 is substituted cyclobutenyl. In some aspects, R41 is substituted cyclopentenyl. In some aspects, R41 is substituted cyclohexenyl. In some aspects, R41 is substituted cycloheptenyl. In some aspects, R41 is substituted cyclooctenyl. In some aspects, R41 is substituted adamantenyl. In some aspects, R41 is substituted bicyclo[2.2.1]heptenyl. In some aspects, R41 is substituted bicyclo[2.2.2.octenyl. In some aspects, R41 is substituted spiro[3.3]heptenyl. In some aspects, the R41 is substituted spiro[4.4]nonenyl. In some aspects, the R41 is substituted spiro[2.4]heptenyl. In some aspects, R41 is substituted spiro[3.4]octenyl. In some aspects, R41 is substituted bicyclo[4.2.0]octenyl. In some aspects, R41 is substituted bicyclo[4.3.0]nonenyl. In some aspects, R41 is substituted bicyclo[4.4.0]decenyl. In some aspects, R41 is substituted bicyclo[3.1.0]hexenyl. In some aspects, R41 is substituted2026.05.07 DESCRIPTION P000685WO
[0714] bicyclo[3.2.0]heptenyl. In some aspects, R41 is substituted bicyclo[3.3.0]octenyl. In some aspects, R41 is substituted bicyclo[4.1.0]heptenyl. In some aspects, R41 is substituted dihydronapthalenyl. In some embodiments wherein R41 is substituted Cs- cycloalkenyl, the Cs- cycloalkenyl is substituted with one substituent. In some embodiments wherein R41 is substituted Cs- cycloalkenyl, the Cs- cycloalkenyl is substituted with two substituents that are the same or different. In some embodiments wherein R41 is substituted Cs- cycloalkenyl, the Cs- cycloalkenyl is substituted with three substituents that are the same or different. In some embodiments wherein R41 is substituted Cs- cycloalkenyl, the Cs- cycloalkenyl is substituted with more than three substituents that are the same or different. When R41 is substituted Cs- cycloalkenyl, the substituent can be one substituent that is Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-6alkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OC1-ehaloalkyl. When R41 is substituted Cs- cycloalkenyl, the substituent can be two substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl. When R41 is substituted Cs- cycloalkenyl, the substituent can be three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NC1. ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl. When R41 is substituted Cs- cycloalkenyl, the substituent can be more than three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOC1. ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci. ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl.
[0715] In some aspects of the disclosure are compounds of formula XIV wherein R41 is substituted or unsubstituted Cs-wheterocycloalkyl. In some aspects, R41 is unsubstituted C3-loheterocycloalkyl. In some aspects, R41 is unsubstituted aziridinyl. In some aspects, R41 is unsubstituted oxiranyl. In some aspects, R41 is unsubstituted thiiranyl. In some aspects, R41 is unsubstituted azetidinyl. In some aspects, R41 is unsubstituted diazetidinyl. In some aspects, R41 is unsubstituted oxetanyl. In some aspects, R41 is unsubstituted thietanyl. In some aspects, R41 is unsubstituted pyrrolidinyl. In some aspects, R41 is unsubstituted pyrazolidinyl. In some aspects, R41 is unsubstituted imidazolidinyl. In some aspects, R41 is unsubstituted tetrahydrofuranyl. In some aspects, R41 is unsubstituted dioxolanyl. In some aspects, R41 is unsubstituted tetrahydrothiophenyl. In some aspects, R41 is unsubstituted oxathiolanyl. In some aspects, R41 is unsubstituted sulfolanyl. In some aspects, R41 is unsubstituted piperiinyl. In some aspects, R41 is unsubstituted piperazinyl. In some aspects, R41 is unsubstituted tetrahydropyranyl. In some aspects, R41 is unsubstituted dioxanyl. In some aspects, R41 is unsubstituted thianyl. In some aspects, R41 is unsubstituted dithianyl. In2026.05.07 DESCRIPTION P000685WO
[0716] some aspects, R41 is unsubstituted morpholinyl. In some aspects, R41 is unsubstituted thiomorpholinyl. In some aspects, R41 is unsubstituted thiomorpholinyl dioxide. In some aspects, R41 is unsubstituted pyrrolizidinyl. In some aspects, R41 is unsubstituted decahydroisoquinolinyl. In some aspects, R41 is unsubstituted decahydroquinolinyl. In some aspects, R41 is unsubstituted tetrahydroquinolinyl. In some aspects, R41 is unsubstituted quinuclidinyl. In some aspects, R41 is unsubstituted azaadamantanyl. In some aspects, R41 is unsubstituted oxepanyl. In some aspects, R41 is unsubstituted oxaspiro[4.5]decanyl. In some aspects, R41 is unsubstituted dioxaspiro[3.4]octnyl. In some aspects, R41 is unsubstituted oxaazaspiro[3.5]nonanyl. In some aspects, R41 is unsubstituted dioxaazaspiro[4.4]nonanyl. In some aspects, R41 is substituted Cs-wheterocycloalkyl. In some aspects, R41 is substituted aziridinyl. In some aspects, R41 is substituted oxiranyl. In some aspects, R41 is substituted thiiranyl. In some aspects, R41 is substituted azetidinyl. In some aspects, R41 is substituted diazetidinyl. In some aspects, R41 is substituted oxetanyl. In some aspects, R41 is substituted thietanyl. In some aspects, R41 is substituted pyrrolidinyl. In some aspects, R41 is substituted pyrazolidinyl. In some aspects, R41 is substituted imidazolidinyl. In some aspects, R41 is substituted tetrahydrofuranyl. In some aspects, R41 is substituted dioxolanyl. In some aspects, R41 is substituted tetrahydrothiophenyl. In some aspects, R41 is substituted oxathiolanyl. In some aspects, R41 is substituted sulfolanyl. In some aspects, R41 is substituted piperiinyl. In some aspects, R41 is substituted piperazinyl. In some aspects, R41 is substituted tetrahydropyranyl. In some aspects, R41 is substituted dioxanyl. In some aspects, R41 is substituted thianyl. In some aspects, R41 is substituted dithianyl. In some aspects, R41 is substituted morpholinyl. In some aspects, R41 is substituted thiomorpholinyl. In some aspects, R41 is substituted thiomorpholinyl dioxide. In some aspects, R41 is substituted pyrrolizidinyl. In some aspects, R41 is substituted decahydroisoquinolinyl. In some aspects, R41 is substituted decahydroquinolinyl. In some aspects, R41 is substituted tetrahydroquinolinyl. In some aspects, R41 is substituted quinuclidinyl. In some aspects, R41 is substituted azaadamantanyl. In some aspects, R41 is substituted oxepanyl. In some aspects, R41 is substituted oxaspiro[4.5]decanyl. In some aspects, R41 is substituted dioxaspiro[3.4]octnyl. In some aspects, R41 is substituted oxaazaspiro[3.5]nonanyl. In some aspects, R41 is substituted dioxaazaspiro[4.4]nonanyl. In those embodiments wherein R41 is substituted Cs-wheterocycloalkyl, the Cs-wheterocycloalkyl is substituted with one substitutent. In some embodiments wherein R41 is substituted Cs-wheterocycloalkyl, the C3-loheterocycloalkyl is substituted with two substituents that are the same or different. In some embodiments wherein R41 is substituted Cs-wheterocycloalkyl, the Cs-wheterocycloalkyl is substituted with three substituents that are the same or different. In some embodiments wherein R41 is substituted Cs-wheterocycloalkyl, the Cs-wheterocycloalkyl is substituted with more than three substituents that are the same or different. When R41 is substituted C3-2026.05.07 DESCRIPTION P000685WO
[0717] wheterocycloalkyl, the substituent can be one substituent that is Ci-ealkyl, C2.ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi. ealkylCOOCi-ealkyl, -N(Ci-6alkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. When R41 is substituted Cs-wheterocycloalkyl, the substituents can be two substituents that are each independently Ci-ealkyl, 02-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci- ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. When R41 is substituted Cs-wheterocycloalkyl, the substituents can be three substituents that are each independently Ci-ealkyl, 02-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi. ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. When R41 is substituted Cs-wheterocycloalkyl, the substituents can be more than three substituents that are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl.
[0718] In some aspects of the disclosure are compounds of formula XIV wherein R41 is substituted or unsubstituted Cs-wheterocycloalkenyl. According to the disclosure, a C3-loheterocycloalkenyl moiety is a Cs-wheterocycloalkyl moiety with one or more double bonds. In some aspects, Cs-wheterocycloalkenyl is a aziridinyl, oxiranyl, thiiranyl, azetidinyl, diazetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, dioxolanyl, tetrahydrothiophenyl, oxathiolanyl, sulfolanyl, piperiinyl, piperazinyl, tetrahydropyranyl, dioxanyl, thianyl, dithianyl, morpholinyl, thiomorpholinyl, thiomorpholinyl dioxide, pyrrolizidinyl, decahydroisoquinolinyl, decahydroquinolinyl, tetrahydroquinolinyl, quinuclidinyl, azaadamantanyl, oxepanyl, oxaspiro[4.5]decanyl, dioxaspiro[3.4]octnyl, oxaazaspiro[3.5]nonanyl, or dioxaazaspiro[4.4]nonanyl with one double bond. In some aspects, Cs-wheterocycloalkenyl is a aziridinyl, oxiranyl, thiiranyl, azetidinyl, diazetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, dioxolanyl, tetrahydrothiophenyl, oxathiolanyl, sulfolanyl, piperiinyl, piperazinyl, tetrahydropyranyl, dioxanyl, thianyl, dithianyl, morpholinyl, thiomorpholinyl, thiomorpholinyl dioxide, pyrrolizidinyl, decahydroisoquinolinyl, decahydroquinolinyl, tetrahydroquinolinyl, quinuclidinyl, azaadamantanyl, oxepanyl, oxaspiro[4.5]decanyl, dioxaspiro[3.4]octnyl, oxaazaspiro[3.5]nonanyl, or dioxaazaspiro[4.4]nonanyl with two double bonds. In some aspects, R41 is unsubstituted Cs-wheterocycloalkenyl. In some aspects, R41 is substituted Cs-wheterocycloalkenyl. In some aspects, the substituted Cs-wheterocycloalkenyl is substituted with one substituent. In some aspects, the substituted Cs-wheterocycloalkenyl is substituted with two substituents that are the same or different. In some aspects, the substituted Cs-wheterocycloalkenyl is substituted with three substituents that are the same or different. In2026.05.07 DESCRIPTION P000685WO
[0719] some aspects, the substituted Cs- heterocycloalkenyl is substituted with more than three substituents that are the same or different. When fR₄₁ is substituted C₃-₁₀heterocycloalkenyl, the substituent can be one substituent that is Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. When R41 is substituted Cs-ioheterocycloalkenyl, the substituent can be two substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl. When R41 is substituted Cs- heterocycloalkenyl, the substituent can be three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. When R41 is substituted C3-10heterocycloalkenyl, the substituent can be more than three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci- ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl.
[0720] Within the scope of the disclosure are compounds of formula XV and salts thereof:
[0721]
[0722] wherein
[0723] L is C1-6alk; and
[0724] R41 is substituted or unsubstituted Ci-ealkyl; substituted or unsubstituted Ce-2oaryl; substituted or unsubstituted C5-2oheteroaryl; substituted or unsubstituted Cs- cycloalkyl, substituted or unsubstituted Cs- cycloalkenyl, substituted or unsubstituted Cs-wheterocycloalkyl, or substituted or unsubstituted Cs- heterocycloalkenyl.
[0725] In preferred aspects of the disclosure are compounds of formula XV, L is Cialk (-CH2-). In other aspects, L is C2alk. In other aspects, L is Csalk. In other aspects, L is C4alk. In other aspects, L is Csalk. In other aspects, L is Cealk.
[0726] In some aspects of the disclosure are compounds of formula XV wherein R41 is substituted or unsubstituted Ci-ealkyl. In some aspects, R41 is unsubstituted Ci-ealkyl, for example, unsubstituted methyl. In some aspects, R41 is unsubstituted ethyl. In some aspects, R41 is2026.05.07 DESCRIPTION P000685WO
[0727] unsubstituted n-propyl. In some aspects, R41 is unsubstituted isopropyl. In some aspects, R41 is unsubstituted n-butyl. In some aspects, R41 is unsubstituted isobutyl. In some aspects, R41 is unsubstituted sec-butyl. In some aspects, R41 is unsubstituted tert-butyl. In some aspects, R41 is substituted Ci-ealkyl, for example, substituted methyl. In some aspects, R41 is substituted ethyl. In some aspects, R41 is substituted n-propyl. In some aspects, R41 is substituted isopropyl. In some aspects, R41 is substituted n-butyl. In some aspects, R41 is substituted isobutyl. In some aspects, R41 is substituted sec-butyl. In some aspects, R41 is substituted tert-butyl. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with one substituent. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with two substituents that are the same or different. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with three substituents that are the same or different. In embodiments wherein R41 is substituted Ci- ealkyl, the Ci-ealkyl is substituted with more than three substituents that are the same or different. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with one substituent that is Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi. ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci. ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with two substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with three substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with more than three substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl.
[0728] In some aspects of the disclosure are compounds of formula XV wherein R41 is substituted or unsubstituted Ce-2oaryl. In some aspects, R41 is unsubstituted Ce-2oaryl, for example, unsubstituted phenyl. In some aspects, R41 is unsubstituted tolyl. In some aspects, R41 is unsubstituted xylyl. In some aspects, R41 is unsubstituted naphthyl. In some aspects, R41 is substituted Ce-2oaryl, for example, substituted phenyl. In some aspects, R41 is substituted tolyl. In some aspects, R41 is substituted xylyl. In some aspects, R41 is substituted naphthyl. In some embodiments wherein R41 is substituted Ce-2oaryl, the C6-2oaryl is substituted with2026.05.07 DESCRIPTION P000685WO
[0729] one substituent. In some embodiments wherein R41 is substituted C6-2oaryl, the Ce-2oaryl is substituted with two substituents that are the same or different. In some embodiments wherein R41 is substituted Ce-2oaryl, the C6-2oaryl is substituted with three substituents that are the same or different. In some embodiments wherein R4I is substituted Ce-2oaryl, the Ce-2oaryl is substituted with more than three substituents that are the same or different. In some embodiments wherein R41 is substituted C6-20aryl, the C6-20aryl is substituted with one substituent that is C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl. In some embodiments wherein R41 is substituted C6-20aryl, the Ce-2oaryl is substituted with two substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl. In some embodiments wherein R4I is substituted Ce-2oaryl, the Ce-2oaryl is substituted with three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NC1. ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R4I is substituted Ce-2oaryl, the Ce-2oaryl is substituted with three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOC1. ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci. ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl.
[0730] In some aspects of the disclosure are compounds of formula XV wherein R41 is substituted or unsubstituted C5-2oheteroaryl. In some aspects, R41 is unsubstituted C5-2oheteroaryl, for example, unsubstituted pyridyl. In some aspects, R41 is unsubstituted pyrimidinyl. In some aspects, R41 is unsubstituted pyrazinyl. In some aspects, R41 is unsubstituted pyridazinyl. In some aspects, R41 is unsubstituted thienyl. In some aspects, R41 is unsubstituted furanyl. In some aspects, R41 is unsubstituted imidazolyl. In some aspects, R41 is unsubstituted pyrazolyl. In some aspects, R41 is unsubstituted triazolyl. In some aspects, R41 is unsubstituted quinolinyl. In some aspects, R41 is unsubstituted isoquinolinyl. In some aspects, R41 is substituted C5-2oheteroaryl, for example, substituted pyridyl. In some aspects, R41 is substituted pyrimidinyl. In some aspects, R41 is substituted pyrazinyl. In some aspects, R41 is substituted pyridazinyl. In some aspects, R41 is substituted thienyl. In some aspects, R41 is substituted furanyl. In some aspects, R41 is substituted imidazolyl. In some aspects, R41 is substituted pyrazolyl. In some aspects, R41 is substituted triazolyl. In some aspects, R41 is substituted quinolinyl. In some aspects, R41 is substituted isoquinolinyl. In some embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with one substituent. In some embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with two substituents that are the same or different. In other2026.05.07 DESCRIPTION P000685WO
[0731] embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with three substituents that are the same or different. In other embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with more than three substituents that are the same or different. In some embodiments wherein R4I is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with one substituent that is Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-6alkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted C5-20heteroaryl, the C5-20heteroaryl is substituted with two substituents that are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl. In some embodiments wherein R41 is substituted C5-20heteroaryl, the C5-20heteroaryl is substituted with three substituents that are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl. In some embodiments wherein R41 is substituted C5-20heteroaryl, the C5-20heteroaryl is substituted with more than three substituents that are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl.
[0732] In some aspects of the disclosure are compounds of formula XV wherein R41 is substituted or unsubstituted Cs- cycloalkyl. In some aspects, R41 is unsubstituted Cs- cycloalkyl. For example, in some aspects, R41 is unsubstituted cyclopropyl. In some aspects, R41 is unsubstituted cyclobutyl. In some aspects, R41 is unsubstituted cyclopentyl. In some aspects, R41 is unsubstituted cyclohexyl. In some aspects, R41 is unsubstituted cycloheptanyl. In some aspects, R41 is unsubstituted cyclooctanyl. In some aspects, R41 is unsubstituted adamantanyl. In some aspects, R41 is unsubstituted bicyclo[2.2.1]heptanyl. In some aspects, R41 is unsubstituted bicyclo[2.2.2.octanyl. In some aspects, R41 is unsubstituted spiro[3.3]heptanyl. In some aspects, R41 is unsubstituted spiro[4.4]nonanyl. In some aspects, R41 is unsubstituted spiro[2.4]heptanyl. In some aspects, R41 is unsubstituted spiro[3.4]octanyl. In some aspects, R41 is unsubstituted bicyclo[4.2.0]octanyl. In some aspects, R41 is unsubstituted bicyclo[4.3.0]nonanyl. In some aspects, R41 is unsubstituted bicyclo[4.4.0]decanyl. In some aspects, R41 is unsubstituted bicyclo[3.1.0]hexanyl. In some aspects, R41 is unsubstituted bicyclo[3.2.0]heptanyl. In some aspects, R41 is unsubstituted bicyclo[3.3.0]octanyl. In some aspects, R41 is unsubstituted bicyclo[4.1.0]heptanyl. In some aspects, R41 is unsubstituted tetrahydronapthalenyl. In some aspects, R41 is unsubstituted2026.05.07 DESCRIPTION P000685WO
[0733] dihydroindenyl. In some aspects, R41 is substituted Cs- cycloalkyl. For example, in some aspects, R41 is substituted cyclopropyl. In some aspects, R41 is substituted cyclobutyl. In some aspects, R41 is substituted cyclopentyl. In some aspects, R41 is substituted cyclohexyl. In some aspects, R41 is substituted cycloheptanyl. In some aspects, R41 is substituted cyclooctanyl. In some aspects, R41 is substituted adamantanyl. In some aspects, R41 is substituted bicyclo[2.2.1]heptanyl. In some aspects, R41 is substituted bicyclo[2.2.2.octanyl. In some aspects, R41 is substituted spiro[3.3]heptanyl. In some aspects, R41 is substituted spiro[4.4]nonanyl. In some aspects, R41 is substituted spiro[2.4]heptanyl. In some aspects, R41 is substituted spiro[3.4]octanyl. In some aspects, R41 is substituted bicyclo[4.2.0]octanyl. In some aspects, R41 is substituted bicyclo[4.3.0]nonanyl. In some aspects, R41 is substituted bicyclo[4.4.0]decanyl. In some aspects, R41 is substituted bicyclo[3.1.0]hexanyl. In some aspects, R41 is substituted bicyclo[3.2.0]heptanyl. In some aspects, R41 is substituted bicyclo[3.3.0]octanyl. In some aspects, R41 is substituted bicyclo[4.1.0]heptanyl. In some aspects, R41 is substituted tetrahydronapthalenyl. In some embodiments wherein R41 is substituted Cs- cycloalkyl, the Cs- cycloalkyl is substituted with one substitutuent. In some embodiments wherein R41 is substituted Cs- cycloalkyl, the Cs- cycloalkyl is substituted with two substituents that are the same or different. In some embodiments wherein R41 is substituted C3-10cycloalkyl, the C3-10cycloalkyl is substituted with three substituents that are the same or different. In Some embodiments wherein R41 is substituted C3-10cycloalkyl, the C3-10cycloalkyl is substituted with more than three substituents that are the same or different. In some aspects wherein the R41 is substituted with one substituent, the substituent is Ci- ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, and OC1-6haloalkyl. In some aspects wherein the R41 is substituted with two substituents, the substituents can be two substituents are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl. In some aspects wherein the R41 is substituted with three substituents, they are each indepenently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In other embodiments, when R41 is substituted C3- cycloalkyl, the Cs- cycloalkyl substituted with more than three substituents are are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci- ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl.2026.05.07 DESCRIPTION P000685WO
[0734] In some aspects of the disclosure are compounds of formula XV wherein R41 is substituted or unsubstituted Cs- cycloalkenyl. In some aspects, R41 is unsubstituted Cs- cycloalkenyl. In some aspects, R4I is unsubstituted cyclopropenyl. In some aspects, R4I is unsubstituted cyclobutenyl. In some aspects, R4I is unsubstituted cyclopentenyl. In some aspects, R4I is unsubstituted cyclohexenyl. In some aspects, R4I is unsubstituted cycloheptenyl. In some aspects, R4I is unsubstituted cyclooctenyl. In some aspects, R4I is unsubstituted adamantenyl. In some aspects, R4I is unsubstituted bicyclo[2.2.1]heptenyl. In some aspects, R4I is unsubstituted bicyclo[2.2.2.octenyl. In some aspects, R4I is unsubstituted spiro[3.3]heptenyl. In some aspects, R4I is unsubstituted spiro[4.4]nonenyl. In some aspects, R4I is unsubstituted spiro[2.4]heptenyl. In some aspects, R4I is unsubstituted spiro[3.4]octenyl. In some aspects, R4I is unsubstituted bicyclo[4.2.0]octenyl. In some aspects, R4I is unsubstituted bicyclo[4.3.0]nonenyl. In some aspects, R4I is unsubstituted bicyclo[4.4.0]decenyl. In some aspects, R4I is unsubstituted bicyclo[3.1.0]hexenyl. In some aspects, R4I is unsubstituted bicyclo[3.2.0]heptenyl. In some aspects, R4I is unsubstituted bicyclo[3.3.0]octenyl. In some aspects, R4I is unsubstituted bicyclo[4.1.0]heptenyl. In some aspects, R4I is unsubstituted dihydronapthalenyl. In some aspects, R41 is substituted C3-10cycloalkenyl. In some aspects, R4I is substituted cyclopropenyl. In some aspects, R4I is substituted cyclobutenyl. In some aspects, R4I is substituted cyclopentenyl. In some aspects, R4I is substituted cyclohexenyl. In some aspects, R4I is substituted cycloheptenyl. In some aspects, R4I is substituted cyclooctenyl. In some aspects, R4I is substituted adamantenyl. In some aspects, R4I is substituted bicyclo[2.2.1]heptenyl. In some aspects, R4I is substituted bicyclo[2.2.2.octenyl. In some aspects, R4I is substituted spiro[3.3]heptenyl. In some aspects, the R4I is substituted spiro[4.4]nonenyl. In some aspects, the R4I is substituted spiro[2.4]heptenyl. In some aspects, R4I is substituted spiro[3.4]octenyl. In some aspects, R4I is substituted bicyclo[4.2.0]octenyl. In some aspects, R4I is substituted bicyclo[4.3.0]nonenyl. In some aspects, R4I is substituted bicyclo[4.4.0]decenyl. In some aspects, R4I is substituted bicyclo[3.1.0]hexenyl. In some aspects, R4I is substituted bicyclo[3.2.0]heptenyl. In some aspects, R4I is substituted bicyclo[3.3.0]octenyl. In some aspects, R4I is substituted bicyclo[4.1.0]heptenyl. In some aspects, R4I is substituted dihydronapthalenyl. In some embodiments wherein R4I is substituted Cs- cycloalkenyl, the Cs- cycloalkenyl is substituted with one substituent. In some embodiments wherein R4I is substituted Cs- cycloalkenyl, the Cs- cycloalkenyl is substituted with two substituents that are the same or different. In some embodiments wherein R4I is substituted Cs- cycloalkenyl, the Cs- cycloalkenyl is substituted with three substituents that are the same or different. In some embodiments wherein R4I is substituted Cs- cycloalkenyl, the Cs- cycloalkenyl is substituted with more than three substituents that are the same or different. When R4I is substituted Cs- cycloalkenyl, the substituent can be one substituent that is Ci-ealkyl, C2-2026.05.07 DESCRIPTION P000685WO
[0735] ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-6alkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OC1. ehaloalkyl. When R41 is substituted Cs- cycloalkenyl, the substituent can be two substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl. When R41 is substituted Cs- cycloalkenyl, the substituent can be three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NC1. ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl. When R41 is substituted Cs- cycloalkenyl, the substituent can be more than three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOC1. ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci. ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl.
[0736] In some aspects of the disclosure are compounds of formula XV wherein R41 is substituted or unsubstituted Cs-wheterocycloalkyl. In some aspects, R41 is unsubstituted C3-loheterocycloalkyl. In some aspects, R41 is unsubstituted aziridinyl. In some aspects, R41 is unsubstituted oxiranyl. In some aspects, R41 is unsubstituted thiiranyl. In some aspects, R41 is unsubstituted azetidinyl. In some aspects, R41 is unsubstituted diazetidinyl. In some aspects, R41 is unsubstituted oxetanyl. In some aspects, R41 is unsubstituted thietanyl. In some aspects, R41 is unsubstituted pyrrolidinyl. In some aspects, R41 is unsubstituted pyrazolidinyl. In some aspects, R41 is unsubstituted imidazolidinyl. In some aspects, R41 is unsubstituted tetrahydrofuranyl. In some aspects, R41 is unsubstituted dioxolanyl. In some aspects, R41 is unsubstituted tetrahydrothiophenyl. In some aspects, R41 is unsubstituted oxathiolanyl. In some aspects, R41 is unsubstituted sulfolanyl. In some aspects, R41 is unsubstituted piperiinyl. In some aspects, R41 is unsubstituted piperazinyl. In some aspects, R41 is unsubstituted tetrahydropyranyl. In some aspects, R41 is unsubstituted dioxanyl. In some aspects, R41 is unsubstituted thianyl. In some aspects, R41 is unsubstituted dithianyl. In some aspects, R41 is unsubstituted morpholinyl. In some aspects, R41 is unsubstituted thiomorpholinyl. In some aspects, R41 is unsubstituted thiomorpholinyl dioxide. In some aspects, R41 is unsubstituted pyrrolizidinyl. In some aspects, R41 is unsubstituted decahydroisoquinolinyl. In some aspects, R41 is unsubstituted decahydroquinolinyl. In some aspects, R41 is unsubstituted tetrahydroquinolinyl. In some aspects, R41 is unsubstituted quinuclidinyl. In some aspects, R41 is unsubstituted azaadamantanyl. In some aspects, R41 is unsubstituted oxepanyl. In some aspects, R41 is unsubstituted oxaspiro[4.5]decanyl. In some aspects, R41 is unsubstituted dioxaspiro[3.4]octnyl. In some aspects, R41 is unsubstituted oxaazaspiro[3.5]nonanyl. In some aspects, R41 is unsubstituted dioxaazaspiro[4.4]nonanyl.2026.05.07 DESCRIPTION P000685WO
[0737] In some aspects, R41 is substituted C3-10heterocycloalkyl. In some aspects, R41 is substituted aziridinyl. In some aspects, R41is substituted oxiranyl. In some aspects, R41is substituted thiiranyl. In some aspects, R41is substituted azetidinyl. In some aspects, R41is substituted diazetidinyl. In some aspects, R41is substituted oxetanyl. In some aspects, R41is substituted thietanyl. In some aspects, R41is substituted pyrrolidinyl. In some aspects, R41is substituted pyrazolidinyl. In some aspects, R41is substituted imidazolidinyl. In some aspects, R41is substituted tetrahydrofuranyl. In some aspects, R41is substituted dioxolanyl. In some aspects, R41is substituted tetrahydrothiophenyl. In some aspects, R41is substituted oxathiolanyl. In some aspects, R41is substituted sulfolanyl. In some aspects, R41is substituted piperiinyl. In some aspects, R41is substituted piperazinyl. In some aspects, R41is substituted tetrahydropyranyl. In some aspects, R41is substituted dioxanyl. In some aspects, R41is substituted thianyl. In some aspects, R41is substituted dithianyl. In some aspects, R41is substituted morpholinyl. In some aspects, R41is substituted thiomorpholinyl. In some aspects, R41is substituted thiomorpholinyl dioxide. In some aspects, R41is substituted pyrrolizidinyl. In some aspects, R41is substituted decahydroisoquinolinyl. In some aspects, R41is substituted decahydroquinolinyl. In some aspects, R41is substituted tetrahydroquinolinyl. In some aspects, R41is substituted quinuclidinyl. In some aspects, R41is substituted azaadamantanyl. In some aspects, R41is substituted oxepanyl. In some aspects, R41is substituted oxaspiro[4.5]decanyl. In some aspects, R41is substituted dioxaspiro[3.4]octnyl. In some aspects, R41is substituted oxaazaspiro[3.5]nonanyl. In some aspects, R41is substituted dioxaazaspiro[4.4]nonanyl. In those embodiments wherein R41is substituted C3-10heterocycloalkyl, the C3-10heterocycloalkyl is substituted with one substitutent. In some embodiments wherein R41is substituted C3-10heterocycloalkyl, the C3-10heterocycloalkyl is substituted with two substituents that are the same or different. In some embodiments wherein R41is substituted C3-10heterocycloalkyl, the C3-10heterocycloalkyl is substituted with three substituents that are the same or different. In some embodiments wherein R41is substituted C3-10heterocycloalkyl, the C3-10heterocycloalkyl is substituted with more than three substituents that are the same or different. When R41is substituted C3-10heterocycloalkyl, the substituent can be one substituent that is C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl. When R41is substituted C3-10heterocycloalkyl, the substituents can be two substituents that are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl. When R41is substituted C3-10heterocycloalkyl, the substituents can be three substituents that are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-62026.05.07 DESCRIPTION P000685WO
[0738] ealkylCOOCi-ealkyl, -N(Ci.ealkyl)Ci.ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. When R41 is substituted Cs-wheterocycloalkyl, the substituents can be more than three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOC1. ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl.
[0739] In some aspects of the disclosure are compounds of formula XV wherein R41 is substituted or unsubstituted Cs-wheterocycloalkenyl. According to the disclosure, a C3-loheterocycloalkenyl moiety is a Cs-wheterocycloalkyl moiety with one or more double bonds. In some aspects, Cs-wheterocycloalkenyl is a aziridinyl, oxiranyl, thiiranyl, azetidinyl, diazetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, dioxolanyl, tetrahydrothiophenyl, oxathiolanyl, sulfolanyl, piperiinyl, piperazinyl, tetrahydropyranyl, dioxanyl, thianyl, dithianyl, morpholinyl, thiomorpholinyl, thiomorpholinyl dioxide, pyrrolizidinyl, decahydroisoquinolinyl, decahydroquinolinyl, tetrahydroquinolinyl, quinuclidinyl, azaadamantanyl, oxepanyl, oxaspiro[4.5]decanyl, dioxaspiro[3.4]octnyl, oxaazaspiro[3.5]nonanyl, or dioxaazaspiro[4.4]nonanyl with one double bond. In some aspects, Cs-wheterocycloalkenyl is a aziridinyl, oxiranyl, thiiranyl, azetidinyl, diazetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, dioxolanyl, tetrahydrothiophenyl, oxathiolanyl, sulfolanyl, piperiinyl, piperazinyl, tetrahydropyranyl, dioxanyl, thianyl, dithianyl, morpholinyl, thiomorpholinyl, thiomorpholinyl dioxide, pyrrolizidinyl, decahydroisoquinolinyl, decahydroquinolinyl, tetrahydroquinolinyl, quinuclidinyl, azaadamantanyl, oxepanyl, oxaspiro[4.5]decanyl, dioxaspiro[3.4]octnyl, oxaazaspiro[3.5]nonanyl, or dioxaazaspiro[4.4]nonanyl with two double bonds. In some aspects, R41 is unsubstituted Cs-wheterocycloalkenyl. In some aspects, R41 is substituted Cs-wheterocycloalkenyl. In some aspects, the substituted Cs-wheterocycloalkenyl is substituted with one substituent. In some aspects, the substituted Cs-wheterocycloalkenyl is substituted with two substituents that are the same or different. In some aspects, the substituted Cs-wheterocycloalkenyl is substituted with three substituents that are the same or different. In some aspects, the substituted Cs-wheterocycloalkenyl is substituted with more than three substituents that are the same or different. When fR4i is substituted Cs-wheterocycloalkenyl, the substituent can be one substituent that is Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. When R41 is substituted Cs-wheterocycloalkenyl, the substituent can be two substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl. When R41 is substituted Cs-wheterocycloalkenyl, the substituent can2026.05.07 DESCRIPTION P000685WO
[0740] be three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. When R41 is substituted C3-10heterocycloalkenyl, the substituent can be more than three substituents that are each independently Ci-ealkyl, C2-6alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci- ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl.
[0741] Within the scope of the disclosure are compounds of formula X’ and salts thereof:
[0742]
[0743] wherein
[0744] L is Ci-ealk;
[0745] is a single bond or a double bond;
[0746] R41 is substituted or unsubstituted Ci-ealkyl; substituted or unsubstituted Ce-2oaryl; substituted or unsubstituted C5-2oheteroaryl; substituted or unsubstituted Cs- cycloalkyl, substituted or unsubstituted Cs- cycloalkenyl, substituted or unsubstituted Cs-wheterocycloalkyl, or substituted or unsubstituted Cs- heterocycloalkenyl.
[0747] R21 is H, Ci-ealkyl, Co-ealkCOOCi-ealkyl, Co-ealkOCOCi-ealkyl, Co-ealkCOOH, Ci-ealkyl-OH, Co-ealkOCi-ealkyl, Co-ealk-aryl, halogen, Co-ealkCONHCi-ealkyl, Co-ealkCONH-aryl, Co-ealkCONH-heteroaryl, Co-ealkCONH-cycloalkyl, Co-ealkCONH-heterocycloalkyl;
[0748] T is a bond, arylene, heteroarylene, alkynylene, alkenylene, or -O-;
[0749] R31 is H, halogen, -CN, Co-ealkCi-ealkyl, Co-ealkCOOCi-ealkyl, Co-ealkCOOCi-ealkene, Co.6alkCOOCi-ealkyne, Co-ealkOCOCi-ealkyl, Co-ealkOCOCi-ealkene, Co-ealkOCOCi-ealkyne, Co-6alkCOOH, Co-ealkCONHCi-ealkyl, Co-ealkCON(Ci-ealkyl)2, Co-6alkCONHOH, Ci-6alkyl-OH, Co- ealkOCi-ealkyl, Co-ealkOCi-ealkOCi-ealkyl, halogen, Co-ealk-cycloalkyl, Co-ealk-cycloalkenyl, Co-ealk-heterocycloalkyl, Co-ealk-heteroaryl, Co-ealk-aryl, Co-ealk-substituted aryl, Co-ealk-cycloalkyl, or C^alkenyl;
[0750] Q is CR51R51, wherein each R51 is independently H, Ci-ealkyl, alk0-6COOC1-6alkyl, alk0-6OCOC1-6alkyl, alk0-6COOH, C1-6alkyl-OH, or alk0-6OC1-6alkyl; and2026.05.07 DESCRIPTION P000685WO
[0751] n is an integer that is 1, 2, 3, or 4.
[0752] In preferred aspects of the disclosure are compounds of formula X’, L is Cialk (-CH2-). In other aspects, L is C2alk. In other aspects, L is Cealk. In other aspects, L is C4alk. In other aspects, L is Csalk. In other aspects, L is Cealk.
[0753] In some aspects of the disclosure, is a single bond, i.e. -. In some aspects of the disclosure, is a double bond, i.e..
[0754] In some aspects of the disclosure are compounds of formula X’ wherein R41 is substituted or unsubstituted Ci-ealkyL In some aspects, R41 is unsubstituted Ci-ealkyl, for example, unsubstituted methyl. In some aspects, R41 is unsubstituted ethyl. In some aspects, R41 is unsubstituted n-propyl. In some aspects, R41 is unsubstituted isopropyl. In some aspects, R41 is unsubstituted n-butyl. In some aspects, R41 is unsubstituted isobutyl. In some aspects, R41 is unsubstituted sec-butyl. In some aspects, R41 is unsubstituted tert-butyl. In some aspects, R41 is substituted Ci-ealkyl, for example, substituted methyl. In some aspects, R41 is substituted ethyl. In some aspects, R41 is substituted n-propyl. In some aspects, R41 is substituted isopropyl. In some aspects, R41 is substituted n-butyl. In some aspects, R41 is substituted isobutyl. In some aspects, R41 is substituted sec-butyl. In some aspects, R41 is substituted tert-butyl. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with one substituent. In some embodiments wherein R41 is substituted Ci- ealkyl, the Ci-ealkyl is substituted with two substituents that are the same or different. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with three substituents that are the same or different. In embodiments wherein R41 is substituted Ci- ealkyl, the Ci-ealkyl is substituted with more than three substituents that are the same or different. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with one substituent that is Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOC1. ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci. ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with two substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with three substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl. In some embodiments wherein R41 is substituted Ci-ealkyl, the Ci-ealkyl is substituted with more than three substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -2026.05.07 DESCRIPTION P000685WO
[0755] NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl.
[0756] In some aspects of the disclosure are compounds of formula X’ wherein R41 is substituted or unsubstituted Ce-2oaryl. In some aspects, R41 is unsubstituted C6-2oaryl, for example, unsubstituted phenyl. In some aspects, R41 is unsubstituted tolyl. In some aspects, R41 is unsubstituted xylyl. In some aspects, R41 is unsubstituted naphthyl. In some aspects, R41 is substituted C6-2oaryl, for example, substituted phenyl. In some aspects, R41 is substituted tolyl. In some aspects, R41 is substituted xylyl. In some aspects, R41 is substituted naphthyl. In some embodiments wherein R41 is substituted C6-2oaryl, the C6-2oaryl is substituted with one substituent. In some embodiments wherein R41 is substituted C6-2oaryl, the C6-2oaryl is substituted with two substituents that are the same or different. In some embodiments wherein R41 is substituted Ce-2oaryl, the C6-2oaryl is substituted with three substituents that are the same or different. In some embodiments wherein R41 is substituted Ce-2oaryl, the Ce-2oaryl is substituted with more than three substituents that are the same or different. In some embodiments wherein R41 is substituted Ce-2oaryl, the C6-2oaryl is substituted with one substituent that is Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci.ealkyl)Ci.ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted Ce-2oaryl, the Ce-2oaryl is substituted with two substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl. In some embodiments wherein R41 is substituted Ce-2oaryl, the Ce-2oaryl is substituted with three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NC1. ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted Ce-2oaryl, the Ce-2oaryl is substituted with three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOC1. ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci. ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl.
[0757] In some aspects of the disclosure are compounds of formula X wherein R41 is substituted or unsubstituted C5-2oheteroaryl. In some aspects, R41 is unsubstituted C5-2oheteroaryl, for example, unsubstituted pyridyl. In some aspects, R41 is unsubstituted pyrimidinyl. In some aspects, R41 is unsubstituted pyrazinyl. In some aspects, R41 is unsubstituted pyridazinyl. In some aspects, R41 is unsubstituted thienyl. In some aspects, R41 is unsubstituted furanyl. In some aspects, R41 is unsubstituted imidazolyl. In some aspects, R41 is unsubstituted2026.05.07 DESCRIPTION P000685WO
[0758] pyrazolyl. In some aspects, R41 is unsubstituted triazolyl. In some aspects, R41 is unsubstituted quinolinyl. In some aspects, R4I is unsubstituted isoquinolinyl. In some aspects, R4I is substituted C5-2oheteroaryl, for example, substituted pyridyl. In some aspects, R4I is substituted pyrimidinyl. In some aspects, R4I is substituted pyrazinyl. In some aspects, R4I is substituted pyridazinyl. In some aspects, R4I is substituted thienyl. In some aspects, R4I is substituted furanyl. In some aspects, R4I is substituted imidazolyl. In some aspects, R4I is substituted pyrazolyl. In some aspects, R4I is substituted triazolyl. In some aspects, R4I is substituted quinolinyl. In some aspects, R4I is substituted isoquinolinyl. In some embodiments wherein R4I is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with one substituent. In some embodiments wherein R4I is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with two substituents that are the same or different. In other embodiments wherein R4I is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with three substituents that are the same or different. In other embodiments wherein R4I is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with more than three substituents that are the same or different. In some embodiments wherein R4I is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with one substituent that is Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-6alkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted C5-20heteroaryl, the C5-20heteroaryl is substituted with two substituents that are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl. In some embodiments wherein R41 is substituted C5-20heteroaryl, the C5-20heteroaryl is substituted with three substituents that are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl. In some embodiments wherein R41 is substituted C5-20heteroaryl, the C5-20heteroaryl is substituted with more than three substituents that are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl.
[0759] In some aspects of the disclosure are compounds of formula X’ wherein R4I is substituted or unsubstituted Cs- cycloalkyl. In some aspects, R4I is unsubstituted Cs- cycloalkyl. For example, in some aspects, R4I is unsubstituted cyclopropyl. In some aspects, R4I is unsubstituted cyclobutyl. In some aspects, R4I is unsubstituted cyclopentyl. In some aspects, R4I is unsubstituted cyclohexyl. In some aspects, R4I is unsubstituted cycloheptanyl. In2026.05.07 DESCRIPTION P000685WO
[0760] some aspects, R41 is unsubstituted cyclooctanyl. In some aspects, R41 is unsubstituted adamantanyl. In some aspects, R41 is unsubstituted bicyclo[2.2.1]heptanyl. In some aspects, R4I is unsubstituted bicyclo[2.2.2.octanyl. In some aspects, R4I is unsubstituted spiro[3.3]heptanyl. In some aspects, R4I is unsubstituted spiro[4.4]nonanyl. In some aspects, R4I is unsubstituted spiro[2.4]heptanyl. In some aspects, R4I is unsubstituted spiro[3.4]octanyl. In some aspects, R4I is unsubstituted bicyclo[4.2.0]octanyl. In some aspects, R4I is unsubstituted bicyclo[4.3.0]nonanyl. In some aspects, R4I is unsubstituted bicyclo[4.4.0]decanyl. In some aspects, R4I is unsubstituted bicyclo[3.1.0]hexanyl. In some aspects, R4I is unsubstituted bicyclo[3.2.0]heptanyl. In some aspects, R4I is unsubstituted bicyclo[3.3.0]octanyl. In some aspects, R4I is unsubstituted bicyclo[4.1.0]heptanyl. In some aspects, R4I is unsubstituted tetrahydronapthalenyl. In some aspects, R4I is unsubstituted dihydroindenyl. In some aspects, R4I is substituted Cs- cycloalkyl. For example, in some aspects, R4I is substituted cyclopropyl. In some aspects, R4I is substituted cyclobutyl. In some aspects, R4I is substituted cyclopentyl. In some aspects, R4I is substituted cyclohexyl. In some aspects, R4I is substituted cycloheptanyl. In some aspects, R4I is substituted cyclooctanyl. In some aspects, R4I is substituted adamantanyl. In some aspects, R4I is substituted bicyclo[2.2.1]heptanyl. In some aspects, R4I is substituted bicyclo[2.2.2.octanyl. In some aspects, R4I is substituted spiro[3.3]heptanyl. In some aspects, R4I is substituted spiro[4.4]nonanyl. In some aspects, R4I is substituted spiro[2.4]heptanyl. In some aspects, R4I is substituted spiro[3.4]octanyl. In some aspects, R4I is substituted bicyclo[4.2.0]octanyl. In some aspects, R4I is substituted bicyclo[4.3.0]nonanyl. In some aspects, R4I is substituted bicyclo[4.4.0]decanyl. In some aspects, R4I is substituted bicyclo[3.1.0]hexanyl. In some aspects, R4I is substituted bicyclo[3.2.0]heptanyl. In some aspects, R4I is substituted bicyclo[3.3.0]octanyl. In some aspects, R4I is substituted bicyclo[4.1.0]heptanyl. In some aspects, R4I is substituted tetrahydronapthalenyl. In some embodiments wherein R4I is substituted C3-10cycloalkyl, the C3-10cycloalkyl is substituted with one substitutuent. In some embodiments wherein R41 is substituted C3-10cycloalkyl, the C3-10cycloalkyl is substituted with two substituents that are the same or different. In some embodiments wherein R4I is substituted Cs- cycloalkyl, the Cs- cycloalkyl is substituted with three substituents that are the same or different. In Some embodiments wherein R4I is substituted Cs- cycloalkyl, the Cs- cycloalkyl is substituted with more than three substituents that are the same or different. In some aspects wherein the R4I is substituted with one substituent, the substituent is Ci- ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, and OC1-6haloalkyl. In some aspects wherein the R4I is substituted with two substituents, the substituents can be two substituents are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -2026.05.07 DESCRIPTION P000685WO
[0761] NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl. In some aspects wherein the R41 is substituted with three substituents, they are each indepenently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci.ealkyl)Ci.ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In other embodiments, when R41 is substituted C3- cycloalkyl, the Cs- cycloalkyl substituted with more than three substituents are are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci- ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl.
[0762] In some aspects of the disclosure are compounds of formula X’ wherein R41 is substituted or unsubstituted Cs- cycloalkenyl. In some aspects, R41 is unsubstituted Cs- cycloalkenyl. In some aspects, R41 is unsubstituted cyclopropenyl. In some aspects, R41 is unsubstituted cyclobutenyl. In some aspects, R41 is unsubstituted cyclopentenyl. In some aspects, R41 is unsubstituted cyclohexenyl. In some aspects, R41 is unsubstituted cycloheptenyl. In some aspects, R41 is unsubstituted cyclooctenyl. In some aspects, R41 is unsubstituted adamantenyl. In some aspects, R41 is unsubstituted bicyclo[2.2.1]heptenyl. In some aspects, R41 is unsubstituted bicyclo[2.2.2.octenyl. In some aspects, R41 is unsubstituted spiro[3.3]heptenyl. In some aspects, R41 is unsubstituted spiro[4.4]nonenyl. In some aspects, R41 is unsubstituted spiro[2.4]heptenyl. In some aspects, R41 is unsubstituted spiro[3.4]octenyl. In some aspects, R41 is unsubstituted bicyclo[4.2.0]octenyl. In some aspects, R41 is unsubstituted bicyclo[4.3.0]nonenyl. In some aspects, R41 is unsubstituted bicyclo[4.4.0]decenyl. In some aspects, R41 is unsubstituted bicyclo[3.1.0]hexenyl. In some aspects, R41 is unsubstituted bicyclo[3.2.0]heptenyl. In some aspects, R41 is unsubstituted bicyclo[3.3.0]octenyl. In some aspects, R41 is unsubstituted bicyclo[4.1.0]heptenyl. In some aspects, R41 is unsubstituted dihydronapthalenyl. In some aspects, R41 is substituted C3-locycloalkenyl. In some aspects, R41 is substituted cyclopropenyl. In some aspects, R41 is substituted cyclobutenyl. In some aspects, R41 is substituted cyclopentenyl. In some aspects, R41 is substituted cyclohexenyl. In some aspects, R41 is substituted cycloheptenyl. In some aspects, R41 is substituted cyclooctenyl. In some aspects, R41 is substituted adamantenyl. In some aspects, R41 is substituted bicyclo[2.2.1]heptenyl. In some aspects, R41 is substituted bicyclo[2.2.2.octenyl. In some aspects, R41 is substituted spiro[3.3]heptenyl. In some aspects, the R41 is substituted spiro[4.4]nonenyl. In some aspects, the R41 is substituted spiro[2.4]heptenyl. In some aspects, R41 is substituted spiro[3.4]octenyl. In some aspects, R41 is substituted bicyclo[4.2.0]octenyl. In some aspects, R41 is substituted bicyclo[4.3.0]nonenyl. In some aspects, R41 is substituted bicyclo[4.4.0]decenyl. In some aspects, R41 is substituted bicyclo[3.1.0]hexenyl. In some aspects, R41 is substituted2026.05.07 DESCRIPTION P000685WO
[0763] bicyclo[3.2.0]heptenyl. In some aspects, R41 is substituted bicyclo[3.3.0]octenyl. In some aspects, R41 is substituted bicyclo[4.1.0]heptenyl. In some aspects, R41 is substituted dihydronapthalenyl. In some embodiments wherein R41 is substituted Cs- cycloalkenyl, the Cs- cycloalkenyl is substituted with one substituent. In some embodiments wherein R41 is substituted Cs- cycloalkenyl, the Cs- cycloalkenyl is substituted with two substituents that are the same or different. In some embodiments wherein R41 is substituted Cs- cycloalkenyl, the Cs- cycloalkenyl is substituted with three substituents that are the same or different. In some embodiments wherein R41 is substituted Cs- cycloalkenyl, the Cs- cycloalkenyl is substituted with more than three substituents that are the same or different. When R41 is substituted Cs- cycloalkenyl, the substituent can be one substituent that is Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-6alkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OC1-ehaloalkyl. When R41 is substituted Cs- cycloalkenyl, the substituent can be two substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl. When R41 is substituted Cs- cycloalkenyl, the substituent can be three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NC1. ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl. When R41 is substituted Cs- cycloalkenyl, the substituent can be more than three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOC1. ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci. ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl.
[0764] In some aspects of the disclosure are compounds of formula X’ wherein R41 is substituted or unsubstituted Cs-wheterocycloalkyl. In some aspects, R41 is unsubstituted C3-loheterocycloalkyl. In some aspects, R41 is unsubstituted aziridinyl. In some aspects, R41 is unsubstituted oxiranyl. In some aspects, R41 is unsubstituted thiiranyl. In some aspects, R41 is unsubstituted azetidinyl. In some aspects, R41 is unsubstituted diazetidinyl. In some aspects, R41 is unsubstituted oxetanyl. In some aspects, R41 is unsubstituted thietanyl. In some aspects, R41 is unsubstituted pyrrolidinyl. In some aspects, R41 is unsubstituted pyrazolidinyl. In some aspects, R41 is unsubstituted imidazolidinyl. In some aspects, R41 is unsubstituted tetrahydrofuranyl. In some aspects, R41 is unsubstituted dioxolanyl. In some aspects, R41 is unsubstituted tetrahydrothiophenyl. In some aspects, R41 is unsubstituted oxathiolanyl. In some aspects, R41 is unsubstituted sulfolanyl. In some aspects, R41 is unsubstituted piperiinyl. In some aspects, R41 is unsubstituted piperazinyl. In some aspects, R41 is unsubstituted tetrahydropyranyl. In some aspects, R41 is unsubstituted dioxanyl. In2026.05.07 DESCRIPTION P000685WO
[0765] some aspects, R41 is unsubstituted thianyl. In some aspects, R41 is unsubstituted dithianyl. In some aspects, R4I is unsubstituted morpholinyl. In some aspects, R4I is unsubstituted thiomorpholinyl. In some aspects, R4I is unsubstituted thiomorpholinyl dioxide. In some aspects, R4I is unsubstituted pyrrolizidinyl. In some aspects, R4I is unsubstituted decahydroisoquinolinyl. In some aspects, R4I is unsubstituted decahydroquinolinyl. In some aspects, R4I is unsubstituted tetrahydroquinolinyl. In some aspects, R4I is unsubstituted quinuclidinyl. In some aspects, R4I is unsubstituted azaadamantanyl. In some aspects, R4I is unsubstituted oxepanyl. In some aspects, R4I is unsubstituted oxaspiro[4.5]decanyl. In some aspects, R4I is unsubstituted dioxaspiro[3.4]octnyl. In some aspects, R4I is unsubstituted oxaazaspiro[3.5]nonanyl. In some aspects, R4I is unsubstituted dioxaazaspiro[4.4]nonanyl. In some aspects, R4I is substituted Cs-wheterocycloalkyl. In some aspects, R4I is substituted aziridinyl. In some aspects, R4I is substituted oxiranyl. In some aspects, R4I is substituted thiiranyl. In some aspects, R4I is substituted azetidinyl. In some aspects, R4I is substituted diazetidinyl. In some aspects, R4I is substituted oxetanyl. In some aspects, R4I is substituted thietanyl. In some aspects, R4I is substituted pyrrolidinyl. In some aspects, R4I is substituted pyrazolidinyl. In some aspects, R4I is substituted imidazolidinyl. In some aspects, R4I is substituted tetrahydrofuranyl. In some aspects, R4I is substituted dioxolanyl. In some aspects, R4I is substituted tetrahydrothiophenyl. In some aspects, R4I is substituted oxathiolanyl. In some aspects, R4I is substituted sulfolanyl. In some aspects, R4I is substituted piperiinyl. In some aspects, R4I is substituted piperazinyl. In some aspects, R4I is substituted tetrahydropyranyl. In some aspects, R4I is substituted dioxanyl. In some aspects, R4I is substituted thianyl. In some aspects, R4I is substituted dithianyl. In some aspects, R4I is substituted morpholinyl. In some aspects, R4I is substituted thiomorpholinyl. In some aspects, R4I is substituted thiomorpholinyl dioxide. In some aspects, R4I is substituted pyrrolizidinyl. In some aspects, R4I is substituted decahydroisoquinolinyl. In some aspects, R4I is substituted decahydroquinolinyl. In some aspects, R4I is substituted tetrahydroquinolinyl. In some aspects, R4I is substituted quinuclidinyl. In some aspects, R4I is substituted azaadamantanyl. In some aspects, R4I is substituted oxepanyl. In some aspects, R4I is substituted oxaspiro[4.5]decanyl. In some aspects, R4I is substituted dioxaspiro[3.4]octnyl. In some aspects, R4I is substituted oxaazaspiro[3.5]nonanyl. In some aspects, R4I is substituted dioxaazaspiro[4.4]nonanyl. In those embodiments wherein R4I is substituted Cs-wheterocycloalkyl, the Cs-wheterocycloalkyl is substituted with one substitutent. In some embodiments wherein R4I is substituted Cs-wheterocycloalkyl, the C3-loheterocycloalkyl is substituted with two substituents that are the same or different. In some embodiments wherein R4I is substituted Cs-wheterocycloalkyl, the Cs-wheterocycloalkyl is substituted with three substituents that are the same or different. In some embodiments wherein R4I is substituted Cs-wheterocycloalkyl, the Cs-wheterocycloalkyl is substituted with2026.05.07 DESCRIPTION P000685WO
[0766] more than three substituents that are the same or different. When R41 is substituted C3-loheterocycloalkyl, the substituent can be one substituent that is C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl. When R41 is substituted C3-10heterocycloalkyl, the substituents can be two substituents that are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci- ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. When R41 is substituted Cs-wheterocycloalkyl, the substituents can be three substituents that are each independently Ci-ealkyl, 02-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi. ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. When R41 is substituted Cs-wheterocycloalkyl, the substituents can be more than three substituents that are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl.
[0767] In some aspects of the disclosure are compounds of formula X’ wherein R41 is substituted or unsubstituted Cs-wheterocycloalkenyl. According to the disclosure, a Cs-wheterocycloalkenyl moiety is a Cs-wheterocycloalkyl moiety with one or more double bonds. In some aspects, Cs-wheterocycloalkenyl is a aziridinyl, oxiranyl, thiiranyl, azetidinyl, diazetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, dioxolanyl, tetrahydrothiophenyl, oxathiolanyl, sulfolanyl, piperiinyl, piperazinyl, tetrahydropyranyl, dioxanyl, thianyl, dithianyl, morpholinyl, thiomorpholinyl, thiomorpholinyl dioxide, pyrrolizidinyl, decahydroisoquinolinyl, decahydroquinolinyl, tetrahydroquinolinyl, quinuclidinyl, azaadamantanyl, oxepanyl, oxaspiro[4.5]decanyl, dioxaspiro[3.4]octnyl, oxaazaspiro[3.5]nonanyl, or dioxaazaspiro[4.4]nonanyl with one double bond. In some aspects, Cs-wheterocycloalkenyl is a aziridinyl, oxiranyl, thiiranyl, azetidinyl, diazetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, dioxolanyl, tetrahydrothiophenyl, oxathiolanyl, sulfolanyl, piperiinyl, piperazinyl, tetrahydropyranyl, dioxanyl, thianyl, dithianyl, morpholinyl, thiomorpholinyl, thiomorpholinyl dioxide, pyrrolizidinyl, decahydroisoquinolinyl, decahydroquinolinyl, tetrahydroquinolinyl, quinuclidinyl, azaadamantanyl, oxepanyl, oxaspiro[4.5]decanyl, dioxaspiro[3.4]octnyl, oxaazaspiro[3.5]nonanyl, or dioxaazaspiro[4.4]nonanyl with two double bonds. In some aspects, R41 is unsubstituted Cs-wheterocycloalkenyl. In some aspects, R41 is substituted Cs-wheterocycloalkenyl. In some aspects, the substituted Cs-wheterocycloalkenyl is substituted with one substituent. In some aspects, the substituted Cs-wheterocycloalkenyl is substituted with two substituents that are the same or different. In some aspects, the substituted C3-2026.05.07 DESCRIPTION P000685WO
[0768] wheterocycloalkenyl is substituted with three substituents that are the same or different. In some aspects, the substituted Cs- heterocycloalkenyl is substituted with more than three substituents that are the same or different. When fR₄₁ is substituted C₃-₁₀heterocycloalkenyl, the substituent can be one substituent that is Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. When R41 is substituted Cs-ioheterocycloalkenyl, the substituent can be two substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl. When R41 is substituted Cs- heterocycloalkenyl, the substituent can be three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. When R41 is substituted C3-10heterocycloalkenyl, the substituent can be more than three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci- ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl.
[0769] In some aspects of the disclosure are compounds of formula X’ wherein R21 is H. In some aspects R21 is Ci-ealkyl. In some aspects R21 is Co-ealkCOOCi-ealkyl. In some aspects R21 is Co-ealkOCOCi-ealkyl. In some aspects R21 is Co-ealkCOOH. In some aspects R21 is Ci-ealkyl-OH. In some aspects R21 is Co-ealkOCi-ealkyl. In some aspects R21 is Co-ealk-aryl. In some aspects R21 is halogen. In some aspects R21 is Co-ealkCONHCi-ealkyl. In some aspects R21 is Co-ealkCONH-aryl. In some aspects R21 is Co-ealkCONH-heteroaryl. In some aspects R21 is Co-ealkCONH-cycloalkyl. In some aspects R21 is Co-ealkCONH-heterocycloalkyl.
[0770] In some aspects of the disclosure are compounds of formula X’ wherein T is a bond. In some aspects of the disclosure, T is arylene. In some aspects of the disclosure, T is heteroarylene. In some aspects of the disclosure, T is alkynylene. In some aspects of the disclosure, T is alkenylene. In some aspects of the disclosure, T is -O-.
[0771] In some aspects of the disclosure are compounds of formula X’ wherein R31 is H. In some aspects of the disclosure R31 is halogen. In some aspects of the disclosure R31 is -CN. In some aspects of the disclosure R31 is Co-ealkCi-ealkyl. In some aspects of the disclosure R31 is Co-ealkCOOCi-ealkyl. In some aspects of the disclosure R31 is Co-ealkCOOCi-ealkene. In some aspects of the disclosure R31 is Co-ealkCOOCi-ealkyne. In some aspects of the disclosure R31 is Co-ealkOCOCi-ealkyl. In some aspects of the disclosure R31 is Co-2026.05.07 DESCRIPTION P000685WO
[0772] ealkOCOCi.ealkene. In some aspects of the disclosure R31 is Co-ealkOCOCi-ealkyne. In some aspects of the disclosure R31 is Co-ealkCOOH. In some aspects of the disclosure R31 is Co-ealkCONHCi-ealkyl. In some aspects of the disclosure R31 is Co-6alkCON(Ci-6alkyl)2. In some aspects of the disclosure R31 is Co-ealkCONHOH. In some aspects of the disclosure R31 is Ci- ealkyl-OH. In some aspects of the disclosure R31 is Co-ealkOCi-ealkyl. In some aspects of the disclosure R31 is Co-ealkOCi-ealkOCi-ealkyl. In some aspects of the disclosure R31 is halogen. In some aspects of the disclosure R31 is Co-ealk-cycloalkyl. In some aspects of the disclosure R31 is Co-ealk-cycloalkenyl. In some aspects of the disclosure R31 is Co-6alk-heterocycloalkyl. In some aspects of the disclosure R31 is Co-6alk-heteroaryl. In some aspects of the disclosure R31 is Co-ealk-aryl. In some aspects of the disclosure R31 is Co-ealk-substituted aryl. In some aspects of the disclosure R31 is Co-ealk-cycloalkyl. In some aspects of the disclosure R31 is C^alkenyl;
[0773] Within the scope of the disclosure are compounds of formula X’-A and salts thereof:
[0774]
[0775] In preferred aspects of the disclosure are compounds of formula X’-A wherein L is Cialk (-CH2-). In other aspects, L is C2alk. In other aspects, L is Csalk. In other aspects, L is C4alk. In other aspects, L is Csalk. In other aspects, L is Cealk.
[0776] In some aspects of the disclosure are compounds of formula X’-A, wherein, is a single bond, i.e. -. In some aspects of the disclosure, is a double bond, i.e.
[0777] In some aspects of the disclosure are compounds of formula X’-A wherein R41 is substituted or unsubstituted Ci-ealkyl. In some aspects, R41 is unsubstituted Ci-ealkyl, for example, unsubstituted methyl. In some aspects, R41 is unsubstituted ethyl. In some aspects, R41 is unsubstituted n-propyl. In some aspects, R41 is unsubstituted isopropyl. In some aspects, R41 is unsubstituted n-butyl. In some aspects, R41 is unsubstituted isobutyl. In some aspects, R41 is unsubstituted sec-butyl. In some aspects, R41 is unsubstituted tert-butyl. In some aspects, R41 is substituted Ci-ealkyl, for example, substituted methyl. In some aspects, R41 is substituted ethyl. In some aspects, R41 is substituted n-propyl. In some aspects, R41 is2026.05.07 DESCRIPTION P000685WO
[0778] substituted isopropyl. In some aspects, R41 is substituted n-butyl. In some aspects, R41 is substituted isobutyl. In some aspects, R4I is substituted sec-butyl. In some aspects, R4I is substituted tert-butyl. In some embodiments wherein R4I is substituted Ci-ealkyl, the Ci-ealkyl is substituted with one substituent. In some embodiments wherein R4I is substituted Ci- ealkyl, the Ci-ealkyl is substituted with two substituents that are the same or different. In some embodiments wherein R4I is substituted Ci-ealkyl, the Ci-ealkyl is substituted with three substituents that are the same or different. In embodiments wherein R4I is substituted Ci- ealkyl, the Ci-ealkyl is substituted with more than three substituents that are the same or different. In some embodiments wherein R4I is substituted Ci-ealkyl, the Ci-ealkyl is substituted with one substituent that is Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi. ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci. ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R4I is substituted Ci-ealkyl, the Ci-ealkyl is substituted with two substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R4I is substituted Ci-ealkyl, the Ci-ealkyl is substituted with three substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl. In some embodiments wherein R4I is substituted Ci-ealkyl, the Ci-ealkyl is substituted with more than three substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl.
[0779] In some aspects of the disclosure are compounds of formula X’-A wherein R4I is substituted or unsubstituted Ce-2oaryl. In some aspects, R4I is unsubstituted Ce-2oaryl, for example, unsubstituted phenyl. In some aspects, R4I is unsubstituted tolyl. In some aspects, R4I is unsubstituted xylyl. In some aspects, R4I is unsubstituted naphthyl. In some aspects, R4I is substituted Ce-2oaryl, for example, substituted phenyl. In some aspects, R4I is substituted tolyl. In some aspects, R4I is substituted xylyl. In some aspects, R4I is substituted naphthyl. In some embodiments wherein R4I is substituted Ce-2oaryl, the C6-2oaryl is substituted with one substituent. In some embodiments wherein R4I is substituted C6-2oaryl, the C6-2oaryl is substituted with two substituents that are the same or different. In some embodiments wherein R4I is substituted Ce-2oaryl, the C6-2oaryl is substituted with three substituents that are the same or different. In some embodiments wherein R4I is substituted Ce-2oaryl, the Ce-2oaryl is substituted with more than three substituents that are the same or different. In some2026.05.07 DESCRIPTION P000685WO
[0780] embodiments wherein R41 is substituted Ce-2oaryl, the Ce-2oaryl is substituted with one substituent that is Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci.ealkyl)Ci.ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted C6-2oaryl, the Ce-2oaryl is substituted with two substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl. In some embodiments wherein R41 is substituted Ce-2oaryl, the Ce-2oaryl is substituted with three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NC1. ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted Ce-2oaryl, the Ce-2oaryl is substituted with three substituents that are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOC1. ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci. ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl.
[0781] In some aspects of the disclosure are compounds of formula X’-A wherein R41 is substituted or unsubstituted C5-2oheteroaryl. In some aspects, R41 is unsubstituted C5-2oheteroaryl, for example, unsubstituted pyridyl. In some aspects, R41 is unsubstituted pyrimidinyl. In some aspects, R41 is unsubstituted pyrazinyl. In some aspects, R41 is unsubstituted pyridazinyl. In some aspects, R41 is unsubstituted thienyl. In some aspects, R41 is unsubstituted furanyl. In some aspects, R41 is unsubstituted imidazolyl. In some aspects, R41 is unsubstituted pyrazolyl. In some aspects, R41 is unsubstituted triazolyl. In some aspects, R41 is unsubstituted quinolinyl. In some aspects, R41 is unsubstituted isoquinolinyl. In some aspects, R41 is substituted C5-2oheteroaryl, for example, substituted pyridyl. In some aspects, R41 is substituted pyrimidinyl. In some aspects, R41 is substituted pyrazinyl. In some aspects, R41 is substituted pyridazinyl. In some aspects, R41 is substituted thienyl. In some aspects, R41 is substituted furanyl. In some aspects, R41 is substituted imidazolyl. In some aspects, R41 is substituted pyrazolyl. In some aspects, R41 is substituted triazolyl. In some aspects, R41 is substituted quinolinyl. In some aspects, R41 is substituted isoquinolinyl. In some embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with one substituent. In some embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with two substituents that are the same or different. In other embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with three substituents that are the same or different. In other embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with more than three substituents that are the same or different. In some embodiments wherein R41 is substituted2026.05.07 DESCRIPTION P000685WO
[0782] C5-2oheteroaryl, the C5-2oheteroaryl is substituted with one substituent that is Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-6alkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In some embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with two substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl. In some embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with three substituents that are each independently Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl. In some embodiments wherein R41 is substituted C5-2oheteroaryl, the C5-2oheteroaryl is substituted with more than three substituents that are each independently Ci- ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or OC1-6haloalkyl.
[0783] In some aspects of the disclosure are compounds of formula X’-A wherein R41 is substituted or unsubstituted Cs- cycloalkyl. In some aspects, R41 is unsubstituted Cs- cycloalkyl. For example, in some aspects, R41 is unsubstituted cyclopropyl. In some aspects, R41 is unsubstituted cyclobutyl. In some aspects, R41 is unsubstituted cyclopentyl. In some aspects, R41 is unsubstituted cyclohexyl. In some aspects, R41 is unsubstituted cycloheptanyl. In some aspects, R41 is unsubstituted cyclooctanyl. In some aspects, R41 is unsubstituted adamantanyl. In some aspects, R41 is unsubstituted bicyclo[2.2.1]heptanyl. In some aspects, R41 is unsubstituted bicyclo[2.2.2.octanyl. In some aspects, R41 is unsubstituted spiro[3.3]heptanyl. In some aspects, R41 is unsubstituted spiro[4.4]nonanyl. In some aspects, R41 is unsubstituted spiro[2.4]heptanyl. In some aspects, R41 is unsubstituted spiro[3.4]octanyl. In some aspects, R41 is unsubstituted bicyclo[4.2.0]octanyl. In some aspects, R41 is unsubstituted bicyclo[4.3.0]nonanyl. In some aspects, R41 is unsubstituted bicyclo[4.4.0]decanyl. In some aspects, R41 is unsubstituted bicyclo[3.1.0]hexanyl. In some aspects, R41 is unsubstituted bicyclo[3.2.0]heptanyl. In some aspects, R41 is unsubstituted bicyclo[3.3.0]octanyl. In some aspects, R41 is unsubstituted bicyclo[4.1.0]heptanyl. In some aspects, R41 is unsubstituted tetrahydronapthalenyl. In some aspects, R41 is unsubstituted dihydroindenyl. In some aspects, R41 is substituted Cs- cycloalkyl. For example, in some aspects, R41 is substituted cyclopropyl. In some aspects, R41 is substituted cyclobutyl. In some aspects, R41 is substituted cyclopentyl. In some aspects, R41 is substituted cyclohexyl. In some aspects, R41 is substituted cycloheptanyl. In some aspects, R41 is substituted2026.05.07 DESCRIPTION P000685WO
[0784] cyclooctanyl. In some aspects, R41 is substituted adamantanyl. In some aspects, R41 is substituted bicyclo[2.2.1]heptanyl. In some aspects, R4I is substituted bicyclo[2.2.2.octanyl. In some aspects, R4I is substituted spiro[3.3]heptanyl. In some aspects, R4I is substituted spiro[4.4]nonanyl. In some aspects, R4I is substituted spiro[2.4]heptanyl. In some aspects, R4I is substituted spiro[3.4]octanyl. In some aspects, R4I is substituted bicyclo[4.2.0]octanyl. In some aspects, R4I is substituted bicyclo[4.3.0]nonanyl. In some aspects, R4I is substituted bicyclo[4.4.0]decanyl. In some aspects, R4I is substituted bicyclo[3.1.0]hexanyl. In some aspects, R4I is substituted bicyclo[3.2.0]heptanyl. In some aspects, R4I is substituted bicyclo[3.3.0]octanyl. In some aspects, R4I is substituted bicyclo[4.1.0]heptanyl. In some aspects, R4I is substituted tetrahydronapthalenyl. In some embodiments wherein R4I is substituted C3-10cycloalkyl, the C3-10cycloalkyl is substituted with one substitutuent. In some embodiments wherein R41 is substituted C3-10cycloalkyl, the C3-10cycloalkyl is substituted with two substituents that are the same or different. In some embodiments wherein R4I is substituted Cs- cycloalkyl, the Cs- cycloalkyl is substituted with three substituents that are the same or different. In Some embodiments wherein R4I is substituted Cs- cycloalkyl, the Cs- cycloalkyl is substituted with more than three substituents that are the same or different. In some aspects wherein the R4I is substituted with one substituent, the substituent is Ci- ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, and OC1-6haloalkyl. In some aspects wherein the R4I is substituted with two substituents, the substituents can be two substituents are each independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi. ehaloalkyl. In some aspects wherein the R4I is substituted with three substituents, they are each indepenently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl. In other embodiments, when R4I is substituted C3- cycloalkyl, the Cs- cycloalkyl substituted with more than three substituents are are each independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci- ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, OCi-ealkyl, or OCi-ehaloalkyl.
[0785] In some aspects of the disclosure are compounds of formula X’-A wherein R4I is substituted or unsubstituted Cs- cycloalkenyl. In some aspects, R4I is unsubstituted Cs- cycloalkenyl. In some aspects, R4I is unsubstituted cyclopropenyl. In some aspects, R4I is unsubstituted cyclobutenyl. In some aspects, R4I is unsubstituted cyclopentenyl. In some aspects, R4I is unsubstituted cyclohexenyl. In some as...
Claims
2026.05.07 CLAIMS P000685WOCLAIMS1. Use of a compound of general Formula (I) or a salt thereof as a herbicide:(I)wherein Y is selected from O and S;xi and X2 are independently selected from N and C;X3 and X4 are independently selected from N, NR’”, CR’, C(=O), C(=S), O or S;W is –(x5)n–;each xs is independently selected from N, NRe, CR2, CR2R3, C(=O) and C(=S);n is an integer in the range 1 to 4;RA is absent or is selected from Re and R20;R’ is selected from hydrogen, CN, nitro, halide, ORe, SRe, NReR?, NReOR?, NReNRyRs, ONReR?, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;R’” is independently selected from Re and R20;wherein group RA may form a cyclic structure with any R’, or R’” on X3;R1 is selected from C1.20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-20 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl and C5-20 heteroaryl, any of which may be optionally substituted;wherein each R2 and R3 are independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NReR?, NReOR?, NReNR? Re, ONReR?, ON(=CRe), R20, OR20, SR20, NR6R20, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-102026.05.07 CLAIMS P000685WOcycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl and C5-20 heteroaryl any of which may be optionally substituted;wherein group R1 may form a cyclic structure with any of Re, R2R3 on adjacent unit x5;RG, R7 and Rs are independently selected from the group consisting of H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl and C5-20 heteroaryl, any of which may be optionally substituted; wherein Re may independently or together with R7form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl which may be optionally substituted;R20 is selected from the group consisting ofC(=O)Re,C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,C(=S)R6, C(=S)OR6, C(=S)NR6R7,CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).
2. Use according to claim 1 wherein Y is O and the compound is of formulawherein groups R1, W, RA and X1-X4 are as defined for formula (I) in claim 1.
3. Use according to claim 1 or 2 of formula2026.05.07 CLAIMS P000685WOwhereinY is selected from O and S;xi and X2 are selected from N and C;X3 and X4 are selected from N, NR’”, CR’, C(=O), C(=S), O or S;R’ is selected from hydrogen, CN, nitro, halide, ORe, SRe, NReR?, NReOR?, NReNRyRs, ONReR?, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;R’” is selected from Re and R20;RA is absent or is selected from Re and R20;wherein group RA may form a cyclic structure with R’ or R’” on X3;R1 is selected from C1.20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-20 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;wherein group R1 may form a cyclic structure with any of R2 or R3 (if present);wherein each R2 and each R3 (if present) are independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NReR?, NReOR?, NReNR? Re, ONReR?, ON(=CRe), R20, OR20, SR20, NR6R2O,, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl any of which may be optionally substituted;RG, R? and Rs are independently selected from the group consisting of H, Ci-e alkyl, C2-6alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl,2026.05.07 CLAIMS P000685WOCe-2o aryl, C5-20 heteroaryl which may be optionally substituted; wherein Re may independently or together with R7form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl, any of which may be optionally substituted;R20 is selected from the group consisting ofC(=O)Re,C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,C(=S)R6, C(=S)OR6, C(=S)NR6R7,CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).
4. Use according to any one of the preceding claims wherein the compound is selected from any one of the formulae (A) to (H):2026.05.07 CLAIMS P000685WOwherein Y is selected from O and S;W is –(x5)n–;each xs is independently selected from N, NRe, CR2, CR2R3, C(=O) and C(=S);n is an integer in the range 1 to 4;RA (if present) is selected from Re and R20;R’ (if present) is selected from hydrogen, CN, nitro, halide, ORe, SRe, NReR7, NReOR?, NReNRyRs, ONReR7, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;R’” (if present) is selected from Re and R20;R1 is selected from C1.20 alkyl, C2-20 alkenyl, C2-2oalkynyl, C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-20 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;wherein group R1 may form a cyclic structure with any of R2 or R3 (if present);wherein each R2 and each R3 (if present) are independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NReR?, NReOR?, NReNR? Re, ONReR?, ON(=CRe), R20, OR20, SR20, NR6R2O,, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl any of which may be optionally substituted;RG, R? and Rs are independently selected from the group consisting of H, Ci-e alkyl, C2-6alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce-2o aryl, C5-20 heteroaryl which may be optionally substituted; wherein Re may independently or together with R? form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl any of which may be optionally substituted;R20 is selected from the group consisting ofC(=O)Re,C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,2026.05.07 CLAIMS P000685WOS(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,C(=S)R6, C(=S)OR6, C(=S)NR6R7,CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).
5. Use according to any preceding claim, wherein the optional substituents are independently selected from one or more of oxo, CN, nitro, halogen, OR8, SR8, NR8R7, NR8OR7, NR8NR7R8, R2O, OR2O, SR2O, NR8R2O, Ci-6 alkyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C8-2o aryl, Cs-2o heteroaryl, C2-6 alkenyl and C2.8alkynyl which may themselves be optionally substituted.
6. Use according to any preceding claim wherein RA is selected from the group consisting of hydrogen, C1.10 alkyl, C1.10 haloalkyl, C2- alkene, C2- alkyne, any of which may be optionally substituted; preferably wherein RA is selected from the group consisting of Ci- alkyl, Ci- haloalkyl, C2- alkene, C2- alkyne, any of which may be optionally substituted; wherein RA is preferably H.
7. Use according to any preceding claim wherein R1 is -(CR2R8)m-Alk wherein m is in the range 0 to 4, R2and R3 are independently selected from H and Ci-8alkyl which is optionally substituted and Aik is selected from optionally substituted Ci-8alkyl, C3-10 cycloalkyl and C3-10 heterocycloalkyl, preferably optionally substituted cyclopentyl, cyclohexyl or cycloheptyl.
8. Use according to any one of claims 1 to 6 wherein R1 is -(CR2R8)m-Aryl wherein m is in the range 0 to 4, R2and R3 are independently selected from H and Ci-8alkyl which is optionally substituted, and Aryl is C8-2o aryl or Cs-2o heteroaryl which may be optionally substituted; preferably wherein Aryl is phenyl, which is optionally substituted in the ortho and / or para positions, preferably substituted with halide.
9. Use according to claim 7 or 8 wherein m is 1.
10. Use according to any preceding claim wherein X3 is NR’”, preferably wherein R’” is C(=O)R8, preferably wherein R8is C1-6 alkyl.2026.05.07 CLAIMS P000685WO11. Use according to any preceding claim, wherein X4 is CR’, wherein R’ is preferably selected from halide.
12. Use according to any preceding claim, wherein each X5 is CR2 or CR2R3, preferably wherein each R3 (if present) is H, more preferably wherein each R2 is selected from H, optionally substituted aryl or optionally substituted heteroaryl.
13. Use according to any preceding claim wherein the compound is of formula (HA) or (IIIA):(HA) (IIIA)wherein R1 is selected from C1.20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-20 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;wherein group R1 may form a cyclic structure with any of R2;wherein each R2 is independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NReR7, NReOR7, NReNR7Rs, ONReR7, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;RG, R7 and Rs are independently selected from the group consisting of H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted; wherein Re may independently or together with R7form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl, which may be optionally substituted;R20 is selected from the group consisting ofC(=O)Re,C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,2026.05.07 CLAIMS P000685WOS(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,C(=S)R6, C(=S)OR6, C(=S)NR6R7,CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).
14. Use according to claim 13 wherein the compound is of formula:wherein each R2is independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NR6R7, NR6OR7, NR6NR7R8, ONR6R7, ON(=CR8), R2o, OR2o, SR2o, NR8R2o, Ci-6 alkyl, C2-6 alkenyl, C2.8alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C8-2o aryl, Cs-2o heteroaryl which may be optionally substituted;Re, R7and R8are independently selected from the group consisting of H, C1-6 alkyl, C2.8alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C8-2o aryl, Cs-2o heteroaryl which may be optionally substituted; wherein R8may independently or together with R7form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl which may be optionally substituted;R20 is selected from the group consisting ofC(=O)Re,C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,C(=S)R6, C(=S)OR6, C(=S)NR6R7,CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).2026.05.07 CLAIMS P000685WO15. A compound having herbicidal activity of formula (X):(X)wherein Y is selected from O and S;xi and X2 are independently selected from N and C;X3 and X4 are independently selected from N, NR’”, CR’, C(=O), C(=S), O or S;W is –(x5)n–;each xs is independently selected from N, NRe, CR2, CR2R3, C(=O) and C(=S);n is an integer in the range 1 to 4;RA is absent or is selected from Re and R20;R’ is selected from hydrogen, CN, nitro, halide, ORe, SRe, NReR?, NReOR?, NReNRyRs, ONReR?, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;R’” is selected from Re and R20;wherein group RA may form a cyclic structure with any R’ or R’” on X3;R1 is selected from C1.20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-20 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;wherein each R2 and R3 are independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NReR?, NReOR?, NReNR? Re, ONReR?, ON(=CRe), R20, OR20, SR20, NR6R20, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;2026.05.07 CLAIMS P000685WOwherein group Ri may form a cyclic structure with any of Re, R2 or R3 on adjacent unit x5;Re, R7 and Rs are independently selected from the group consisting of H, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted; wherein Re may independently or together with R7form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl, any of which may be optionally substituted;R20 is selected from the group consisting ofC(=O)Re,C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,C(=S)R6, C(=S)OR6, C(=S)NR6R7,CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6);16. A compound according to claim 15 wherein the herbicidal activity is having >40% visual injury to AMARE & / or LOLMU, & / or POAAN, & / or ECHCG, & / or STEME, & / or CHEAL, at a rate of <1000 g / ha when applied pre-emergence within a glasshouse environment.
17. A compound according to claim 15 or 16 which has any of the features of the compound as defined in claims 2 to 14.
18. A compound according to any one of claims 15 to 17 wherein the compound of formula (X) is not any one of the following:2026.05.07 CLAIMS P000685WO19. A compound according to any one of claims 15 to 18 which does not comprise the following core (C):cording to any one of claims 15 to 19 wherein the formula (X) haswherein Y is selected from O and S;W is –(x5)n–;each xs is independently selected from N, NRe, CR2, CR2R3, C(=O) and C(=S);2026.05.07 CLAIMS P000685WOn is an integer in the range 1 to 4;wherein Ri is selected from C1.20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-20 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;wherein each R2 and R3 are independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NR8R7, NR8OR7, NReNR7R8, ONR8R7, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted;RG, R7 and Rs are independently selected from the group consisting of H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted; wherein Re may independently or together with R7form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl which may be optionally substituted;R20 is selected from the group consisting ofC(=O)Re,C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,C(=S)R6, C(=S)OR6, C(=S)NR6R7,CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).
21. A compound according to claim 20 wherein formula (X) has structure A(1) or A(2):2026.05.07 CLAIMS P000685WOA(2)wherein Ri is selected from C1.20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-20 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;wherein each R2 is independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NReR?, NReOR?, NReNRyRs, ONReR?, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted;RG, R7, Rs and R20 are as defined in claim 20 for formula (A).
22. A compound according to any one of claims 15 to 21 wherein R1 is not C6-20 aryl or C5- 20 heteroaryl, which may be optionally substituted.
23. A compound according to any one of claims 15 to 17 wherein the formula (X) has structure (B):wherein Y is selected from O and S;W is –(x5)n–;each X5 is independently selected from N, NRe, CR2, CR2R3, C(=O) and C(=S);n is an integer in the range 1 to 4;RA is selected from Re and R20;R’ is selected from hydrogen, CN, nitro, halide, ORe, SRe, NReR?, NReOR?, NReNR? Re, ONReR?, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;2026.05.07 CLAIMS P000685WOwherein Ri is selected from C1.20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-20 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;wherein each R2 and R3 are independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NReR7, NReOR7, NReNR7R8, ONReR7, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted;Re, R7 and Rs are independently selected from the group consisting of H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted; wherein Re may independently or together with R7form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl which may be optionally substituted;R20 is selected from the group consisting ofC(=O)Re,C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,C(=S)R6, C(=S)OR6, C(=S)NR6R7,CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).
24. A compound according to claim 23 wherein the structure (B) is B(1) or B(2):2026.05.07 CLAIMS P000685WOwherein RA, R’ and R1 are as defined in claim 22 for formula (B);each R2 is independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NReR?, NReOR?, NReNRyRs, ONReR?, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, which may be optionally substituted.
25. A compound according to any one of claims 15 to 17 wherein formula (X) has structure (C):(C)wherein Ri is selected from C1.20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C3-20 cycloalkyl, C3-20 heterocycloalkyl, C3-20 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;R’is Cl;R’” is independently selected from Re and R20;RG, R7 and Rs are independently selected from the group consisting of H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted; wherein Re may independently or together with R? form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl, any of which may be optionally substituted;2026.05.07 CLAIMS P000685WOR20 is selected from the group consisting ofC(=O)Re,C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,C(=S)R6, C(=S)OR6, C(=S)NR6R7,CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).
26. A compound according to claim 25 of structure C(1) or C(2):wherein Ri, R’ and R’” are as defined for formula (C) in claim 25;each R2 is independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NR6R7, NR6OR7, NR6NR7R8, ONR6R7, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, any of which may be optionally substituted;27. A compound according to any one of claims 15 to 26 whereinR1 is -(CR2R3)m-Alk or -(CR2R3)m-Aryl;wherein m is in the range 0 to 4, R2 and R3 are independently selected from H and Ci-e alkyl which is optionally substituted; Aik is selected from optionally substituted cyclopentyl, cyclohexyl and cycloheptyl; and Aryl is C6-20 aryl or C5-20 heteroaryl which may be optionally substituted; preferably wherein Aryl is phenyl, which is optionally substituted in the ortho and / or para positions, preferably substituted with halide.
28. A compound of general Formula (I’) or a salt thereof:2026.05.07 CLAIMS P000685WOwherein Y is selected from O and S;W is –(x5)n–;each X5 is independently selected from N, NRe, CR2, CR2R3, C(=O) and C(=S);n is an integer in the range 1 to 4;R1 is -(CH2)m-Z wherein Z is selected from C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl and C3-10 heterocycloalkenyl, wherein Z may be optionally substituted and m is an integer in the range 1 to 4;wherein each R2 and R3 are independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NReR7, NReOR7, NReNR7Rs, ONReR7, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl any of which may be optionally substituted;RG, R7 and Rs are independently selected from the group consisting of H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted; wherein Re may independently or together with R7form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl which may be optionally substituted;R20 is selected from the group consisting ofC(=O)Re,C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,C(=S)R6, C(=S)OR6, C(=S)NR6R7,2026.05.07 CLAIMS P000685WOCR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).
29. A compound according to claim 28 wherein Y is O and the compound is of formulawherein groups R1 and W are as defined for formula (I’) in claim 28.
30. A compound according to claim 28 or 29, wherein the optional substituents are independently selected from one or more of oxo, CN, nitro, halogen, OR8, SR8, NR8R7, NR8OR7, NR8NR7R8, R20, OR20, SR20, NR6R20, C1-6 alkyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl, C2-6 alkenyl and C2-6 alkynyl which may themselves be optionally substituted.
31. A compound according to any one of claims 28 to 30 wherein R1 is -(CH2)m-C3-io cycloalkyl wherein the cycloalkyl may be optionally substituted and m is an integer in the range 1 to 4, preferably wherein the cycloalkyl group is selected from optionally substituted cyclopentyl, cyclohexyl and cycloheptyl groups.
32. A compound according to any one of claims 28 to 31 wherein m is 1.
33. A compound according to any one of claims 28 to 32, wherein X5 is CR2 or CR2R3, preferably wherein R3 (if present) is H, more preferably wherein R2 is selected from H, C6-20 aryl and C5-20 heteroaryl.
34. A compound according to any one of claims 28 to 33, wherein the compound is of formula (HA’) or (II IA’):2026.05.07 CLAIMS P000685WO(HA’) (IIIA’)wherein Ri is as defined in any of claims 28 to 33;wherein each R2 is independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NReR7, NReOR7, NReNR7R8, ONReR7, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl any of which may be optionally substituted;RG, R7 and Rs are independently selected from the group consisting of H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted; wherein Re may independently or together with R7form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl which may be optionally substituted;R20 is selected from the group consisting ofC(=O)Re,C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,C(=S)R6, C(=S)OR6, C(=S)NR6R7,CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).
35. A compound according to claim 34 wherein the compound is of formula:wherein each R2 is independently selected from the group consisting of hydrogen, CN, nitro, halide, ORe, SRe, NReR7, NReOR7, NReNR7R8, ONReR7, ON(=CRe), R20, OR20, SR20, NR6R20, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted;2026.05.07 CLAIMS P000685WORG, R7and Rs are independently selected from the group consisting of H, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, C6-20 aryl, C5-20 heteroaryl which may be optionally substituted; wherein Re may independently or together with R7form a C3-10 cycloalkyl, C3-10 heterocycloalkyl, C3-10 cycloalkenyl, C3-10 heterocycloalkenyl, Ce- aryl or C5-10 heteroaryl which may be optionally substituted;R20 is selected from the group consisting ofC(=O)Re,C(=O)OR6, C(=O)NR6R7, C(=O)NR6C(=O)R7, C(=O)C(=O)R6, C(=O)C(=O)OR6, C(=O)C(=O)NR6R7, C(=O)NR7S(=O)OR6, C(=O)NR6OR7, (C=O)SR6,S(=O)R6, S(=O)2R6, S(=O)OR6, S(=O)2OR6, S(=O)NR6R7, S(=O)2NR6R7, S(=O)2NR7COR6, S(=O)(=NR8)NR6R7, S(=O)(=NR6)R7, S(=NR6)R7,SC(=O)R6, SC(=O)OR6, SC(=O)NR6R7,C(=S)R6, C(=S)OR6, C(=S)NR6R7,CR7(=NR6), CR7(=N-OR6), COR7(=N-OR6), CNR7R8(=N-OR6), CR8(=N-NR7R6).
36. A compound according to any one of claims 28 to 35 wherein each R2, where present, is H.
37. A compound which is selected from:2026.05.07 CLAIMS P000685WO2026.05.07 CLAIMS P000685WO2026.05.07 CLAIMS P000685WO2026.05.07 CLAIMS P000685WO2026.05.07 CLAIMS P000685WO2026.05.07 CLAIMS P000685WO39. A compound according to any one of claims 28 to 38 which has herbicidal activity.
40. Use of a compound as defined in any one of claims 28 to 39 in agriculture, preferably as a herbicide.
41. An agricultural composition comprising a compound of formula (I) as defined in any one of claims 1 to 14 or a compound of formula (X) as defined in any one of claims 15 to 27 or a compound of formula (I’) as defined in any one of claims 28 to 36, or a compound as defined in claim 37 or 38, and one or more agriculturally acceptable formulation adjuvants.
42. An agricultural composition according to claim 41 which is a herbicidal composition.
43. An agricultural composition according to claim 41 or 42 further comprising at least one additional herbicide.
44. A method of controlling weeds at a locus comprising application to the locus of a weed controlling amount of a composition according to any one of claims 41 to 43.
45. A compound of formula XI or a salt thereof or a compound of formula Xl-A or a salt thereof:whereinL is C1-6alk; andR41 is substituted or unsubstituted C1-6alkyl; substituted or unsubstituted C6-20aryl; substituted or unsubstituted C6-20heteroaryl; substituted or unsubstituted C3-10cycloalkyl, substituted or unsubstituted C3-10cycloalkenyl, substituted or unsubstituted C3-10heterocycloalkyl, or substituted or unsubstituted C3-10heterocycloalkenyl.
46. The compound of claim 45, or a salt thereof, of formula XI2026.05.07 CLAIMS P000685WO48. The compound of any one of claims 45 to 47, wherein L is C1alk (CH2).
49. The compound of any one of claims 45 to 48, wherein R41 is unsubstituted C3-10cycloalkyl.
50. The compound of any one of claims 45-48, wherein R41 is substituted C3-10cycloalkyl.
51. The compound of claim 49 or claim 50, wherein the C3-10cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl, cyclooctanyl, adamantanyl, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2.octanyl, spiro[3.3]heptanyl, spiro[4.4]nonanyl, spiro[2.4]heptanyl, spiro[3.4]octanyl, bicyclo[4.2.0]octanyl, bicyclo[4.3.0]nonanyl, bicyclo[4.4.0]decanyl, bicyclo[3.1.0]hexanyl, bicyclo[3.2.0]heptanyl, bicyclo[3.3.0]octanyl, bicyclo[4.1.0]heptanyl, tetrahydronapthalenyl, or dihydroindenyl.
52. The compound of claim 51, wherein the C3-10cycloalkyl is substituted with one or more of C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, OC1-6haloalkyl.
53. The compound of claim 51, wherein the C3-10cycloalkyl is substituted with one of C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, OC1-6haloalkyl.
54. The compound of claim 51, wherein the C3-10cycloalkyl is substituted with two substituents, each of which is independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, OC1-6haloalkyl.
55. The compound of any one of claims 45-48, wherein R41 is unsubstituted C3-10cycloalkenyl.2026.05.07 CLAIMS P000685WO56. The compound of any one of claims 45-48, wherein R41 is substituted C3-10cycloalkenyl.
57. The compound of claim 55 or claim 56, wherein the C3-10cycloalkenyl is cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, adamantenyl, bicyclo[2.2.1]heptenyl, bicyclo[2.2.2.octenyl, spiro[3.3]heptenyl, spiro[4.4]nonenyl, spiro[2.4]heptenyl, spiro[3.4]octenyl, bicyclo[4.2.0]octenyl, bicyclo[4.3.0]nonenyl, bicyclo[4.4.0]decenyl,bicyclo[3.1.0]hexenyl, bicyclo[3.2.0]heptenyl, bicyclo[3.3.0]octenyl, bicyclo[4.1.0]heptenyl, or dihydronapthalenyl.
58. The compound of claim 57, wherein the C3-10cycloalkenyl is substituted with one or more of C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, OC1-6haloalkyl.
59. The compound of claim 57, wherein the C3-10cycloalkenyl is substituted with one of C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, OC1-6haloalkyl.
60. The compound of claim 57, wherein the C3-10cycloalkenyl is substituted with two substituents, each of which is independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, OC1-6haloalkyl.
61. The compound of any one of claims 45-48, wherein R41 is unsubstituted C3-10heterocycloalkyl.
62. The compound of any one of claims 45-48, wherein R41 is substituted C3-10heterocycloalkyl.
63. The compound of claims 61 or claim 62, wherein the C3-10heterocycloalkyl is aziridinyl, oxiranyl, thiiranyl, azetidinyl, diazetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, dioxolanyl, tetrahydrothiophenyl, oxathiolanyl, sulfolanyl, piperiinyl, piperazinyl, tetrahydropyranyl, dioxanyl, thianyl, dithianyl, morpholinyl, thiomorpholinyl, thiomorpholinyl dioxide, pyrrolizidinyl, decahydroisoquinolinyl, decahydroquinolinyl, tetrahydroquinolinyl, quinuclidinyl, azaadamantanyl, oxepanyl, oxaspiro[4.5]decanyl, dioxaspiro[3.4]octnyl, oxaazaspiro[3.5]nonanyl, or dioxaazaspiro[4.4]nonanyl.
64. The compound of claim 63, wherein the C3-10heterocycloalkyl is substituted with one or more of C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, OC1-6haloalkyl.2026.05.07 CLAIMS P000685WO65. The compound of claim 63, wherein the C3-10heterocycloalkyl is substituted with one of C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, OC1-6haloalkyl.
66. The compound of any one of claims 45-48, wherein R41 is unsubstituted C3-10heterocycloalkenyl.
67. The compound of any one of claims 45-48, wherein R41 is substituted C3-10heterocycloalkenyl.
68. The compound of claim 67, wherein the C3-10heterocycloalkenyl is substituted with one or more of C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, OC1-6haloalkyl.
69. The compound of claim 67, wherein the C3-10heterocycloalkenyl is substituted with one of C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, OC1-6haloalkyl.
70. The compound of any one of claims 45-48, wherein R41 is unsubstituted C1-6alkyl.
71. The compound of any one of claims 45-48, wherein R41 is substituted C1-6alkyl.
72. The compound of claim 71, wherein the C1-6alkyl is substituted with one or more of C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, OC1-6haloalkyl.
73. The compound of any one of claims 45-48, wherein R41 is unsubstituted C6-20aryl.
74. The compound of any one of claims 45-48, wherein R41 is substituted C6-20aryl.
75. The compound of claim 74, wherein the aryl is substituted with one or more of C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, OC1-6haloalkyl.
76. The compound of any one of claims 45-48, wherein R41 is unsubstituted C6-20heteroaryl.
77. The compound of any one of claims 45-48, wherein R41 is substituted C6-20heteroaryl.
78. The compound of claim 77, wherein the C6-20heteroaryl is substituted with one or more of C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl,-NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, OC1-6haloalkyl.
79. A compound of formula XII or a salt thereof:2026.05.07 CLAIMS P000685WOwhereinL is C1-6alk; andR41 is substituted or unsubstituted Ci-ealkyl; substituted or unsubstituted Ce-2oaryl; substituted or unsubstituted C5-2oheteroaryl; substituted or unsubstituted C3- cycloalkyl, substituted or unsubstituted Cs- cycloalkenyl, substituted or unsubstituted Cs-wheterocycloalkyl, or substituted or unsubstituted C3- 1 oheterocycloalkenyl.
80. The compound of claim 79, wherein L is C1alk (CH2).
81. The compound of claim 79 or claim 80, wherein R41 is unsubstituted C3-10cycloalkyl.
82. The compound of claim 79 or claim 80, wherein R41 is substituted C3-10cycloalkyl.
83. The compound of claim 81 or claim 82, wherein the C3-10cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl, cyclooctanyl, adamantanyl, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2.octanyl, spiro[3.3]heptanyl, spiro[4.4]nonanyl, spiro[2.4]heptanyl, spiro[3.4]octanyl, bicyclo[4.2.0]octanyl, bicyclo[4.3.0]nonanyl, bicyclo[4.4.0]decanyl, bicyclo[3.1.0]hexanyl, bicyclo[3.2.0]heptanyl, bicyclo[3.3.0]octanyl, bicyclo[4.1.0]heptanyl, tetrahydronapthalenyl, or dihydroindenyl.
84. The compound of claim 83, wherein the C3-10cycloalkyl is substituted with one or more of C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, OC1-6alkyl, or. OC1-6haloalkyl.
85. The compound of any one of claim 79 or claim 80, wherein R41 is unsubstituted C3-10cycloalkenyl.
86. The compound of any one of claim 79 or claim 80, wherein R41 is substituted C3-10cycloalkenyl.
87. The compound of claim 85 or claim 86, wherein the C3-10cycloalkenyl is cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, adamantenyl, bicyclo[2.2.1]heptenyl, bicyclo[2.2.2.octenyl, spiro[3.3]heptenyl, spiro[4.4]nonenyl, spiro[2.4]heptenyl, spiro[3.4]octenyl, bicyclo[4.2.0]octenyl, bicyclo[4.3.0]nonenyl, bicyclo[4.4.0]decenyl,bicyclo[3.1.0]hexenyl, bicyclo[3.2.0]heptenyl, bicyclo[3.3.0]octenyl, bicyclo[4.1.0]heptenyl, or dihydronapthalenyl.2026.05.07 CLAIMS P000685WO88. The compound of claim 87, wherein the C3-10cycloalkenyl is substituted with one or more of C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, OC1-6haloalkyl.
89. The compound of claim 88, wherein the C3-10cycloalkenyl is substituted with one of C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, OC1-6haloalkyl.
90. The compound of claim 88, wherein the C3-10cycloalkenyl is substituted with two substituents, each of which is independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, OC1-6haloalkyl.
91. The compound of any one of claim 79 or claim 80, wherein R41 is unsubstituted C3-10heterocycloalkyl.
92. The compound of any one of claim 79 or claim 80, wherein R41 is substituted C3-10heterocycloalkyl.
93. The compound of claims 91 or claim 92, wherein the C3-10heterocycloalkyl is aziridinyl, oxiranyl, thiiranyl, azetidinyl, diazetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, dioxolanyl, tetrahydrothiophenyl, oxathiolanyl, sulfolanyl, piperiinyl, piperazinyl, tetrahydropyranyl, dioxanyl, thianyl, dithianyl, morpholinyl, thiomorpholinyl, thiomorpholinyl dioxide, pyrrolizidinyl, decahydroisoquinolinyl, decahydroquinolinyl, tetrahydroquinolinyl, quinuclidinyl, azaadamantanyl, oxepanyl, oxaspiro[4.5]decanyl, dioxaspiro[3.4]octnyl, oxaazaspiro[3.5]nonanyl, or dioxaazaspiro[4.4]nonanyl.
94. The compound of claim 93, wherein the C3-10heterocycloalkyl is substituted with one or more of C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, OC1-6haloalkyl.
95. The compound of claim 93, wherein the C3-10heterocycloalkyl is substituted with one of C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, OC1-6haloalkyl.
96. The compound of claim 93, wherein the C3-10heterocycloalkyl is substituted with two substituents, each of which is independently C1-6alkyl, C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, OC1-6haloalkyl.2026.05.07 CLAIMS P000685WO97. The compound of any one of claim 79 or claim 80, wherein R41 is unsubstituted C3-10heterocycloalkenyl.
98. The compound of any one of claim 79 or claim 80, wherein R41 is substituted C3-10heterocycloalkenyl.
99. The compound of claim 98, wherein the Cs-wheterocycloalkenyl is substituted with one or more of Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci- ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-6alkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl.
100. The compound of claim 98, wherein the Cs-wheterocycloalkenyl is substituted with one of Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, - NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl.
101. The compound of claim 98, wherein the Cs-wheterocycloalkenyl is substituted with two substituents, each of which is independently Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NC1. ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OC1. ehaloalkyl.
102. The compound of any one of claim 79 or claim 80, wherein R41 is unsubstituted C1-6alkyl.
103. The compound of any one of claim 79 or claim 80, wherein R41 is substituted C1-6alkyl.
104. The compound of claim 103, wherein the C1-6alkyl is substituted with one or more of C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, OC1-6haloalkyl.
105. The compound of any one of claim 79 or claim 80, wherein R41 is unsubstituted C6-20aryl.
106. The compound of any one of claim 79 or claim 80, wherein R41 is substituted C6-20aryl.
107. The compound of claim 106, wherein the aryl is substituted with one or more of Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci- ehaloalkyl,-NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, OC1-6haloalkyl.
108. The compound of any one of claim 79 or claim 80, wherein R41 is unsubstituted Ce-2oheteroaryl.2026.05.07 CLAIMS P000685WO109. The compound of any one of claim 79 or claim 80, wherein R41 is substituted C6-2oheteroaryl.
110. The compound of claim 109, wherein the C6-2oheteroaryl is substituted with one or more of Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci- ealkyl, Ci-ehaloalkyl,-NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHC1-6alkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl.
111. A compound of formula XI 11 or a salt thereof or a compound of formula XI or a salt thereof:whereinL is C1-6alk; andR41 is substituted or unsubstituted Ci-ealkyl; substituted or unsubstituted Ce-2oaryl; substituted or unsubstituted C5-2oheteroaryl; substituted or unsubstituted C3- cycloalkyl, substituted or unsubstituted Cs- cycloalkenyl, substituted or unsubstituted Cs-wheterocycloalkyl, or substituted or unsubstituted C3- 1 oheterocycloalkenyl.
112. The compound of claim 111, or a salt thereof, of formula XIII113. The compound of claim 111, or a salt thereof, of formula XIV114. The compound of any one of claims 111-113, wherein L is Cialk (CH2).2026.05.07 CLAIMS P000685WO115. The compound of any one of claims 111-113 wherein R41 is unsubstituted C3-10cycloalkyl.
116. The compound of any one of claims 111-113, wherein R41 is substituted C3- locycloalkyl.
117. The compound of claim 115 or claim 116, wherein the Cs- cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl, cyclooctanyl, adamantanyl, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2.octanyl, spiro[3.3]heptanyl, spiro[4.4]nonanyl, spiro[2.4]heptanyl, spiro[3.4]octanyl, bicyclo[4.2.0]octanyl, bicyclo[4.3.0]nonanyl, bicyclo[4.4.0]decanyl, bicyclo[3.1.0]hexanyl, bicyclo[3.2.0]heptanyl, bicyclo[3.3.0]octanyl, bicyclo[4.1,0]heptanyl, tetrahydronapthalenyl, or dihydroindenyl.
118. The compound of claim 117, wherein the Cs- cycloalkyl is substituted with one or more of Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci- ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-6alkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl.
119. The compound of any one of claims 111-113, wherein R41 is unsubstituted C3-10cycloalkenyl.
120. The compound of any one of claims 111-113, wherein R41 is substituted C3-10cycloalkenyl.
121. The compound of claim 119 or claim 120, wherein the C3-10cycloalkenyl is cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, adamantenyl, bicyclo[2.2.1]heptenyl, bicyclo[2.2.2.octenyl, spiro[3.3]heptenyl, spiro[4.4]nonenyl, spiro[2.4]heptenyl, spiro[3.4]octenyl, bicyclo[4.2.0]octenyl, bicyclo[4.3.0]nonenyl, bicyclo[4.4.0]decenyl,bicyclo[3.1.0]hexenyl, bicyclo[3.2.0]heptenyl, bicyclo[3.3.0]octenyl, bicyclo[4.1.0]heptenyl, or dihydronapthalenyl.
122. The compound of claim 121, wherein the Cs- cycloalkenyl is substituted with one or more of Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci- ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl.
123. The compound of any one of claims 111-113, wherein R41 is unsubstituted C3-10heterocycloalkyl.
124. The compound of any one of claims 111-113, wherein R41 is substituted C3-10heterocycloalkyl.
125. The compound of claims 123 or claim 124, wherein the Cs-wheterocycloalkyl is aziridinyl, oxiranyl, thiiranyl, azetidinyl, diazetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, dioxolanyl, tetrahydrothiophenyl,2026.05.07 CLAIMS P000685WOoxathiolanyl, sulfolanyl, piperiinyl, piperazinyl, tetrahydropyranyl, dioxanyl, thianyl, dithianyl, morpholinyl, thiomorpholinyl, thiomorpholinyl dioxide, pyrrolizidinyl, decahydroisoquinolinyl, decahydroquinolinyl, tetrahydroquinolinyl, quinuclidinyl, azaadamantanyl, oxepanyl, oxaspiro[4.5]decanyl, dioxaspiro[3.4]octnyl, oxaazaspiro[3.5]nonanyl, or dioxaazaspiro[4.4]nonanyl.
126. The compound of claim 125, wherein the Cs-wheterocycloalkyl is substituted with one or more of Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci- ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-6alkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl.
127. The compound of any one of claims 111-113, wherein R41 is unsubstituted C3-10heterocycloalkenyl.
128. The compound of any one of claims 111-113, wherein R41 is substituted C3-10heterocycloalkenyl.
129. The compound of claim 128, wherein the Cs-wheterocycloalkenyl is substituted with one or more of Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi- ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, - N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl.
130. The compound of any one of claims 111-113, wherein R41 is unsubstituted Ci- ealkyl.
131. The compound of any one of claims 111-113, wherein R41 is substituted Ci- ealkyl.
132. The compound of claim 131, wherein the Ci-ealkyl is substituted with one or more of 02-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, - NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-6alkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl.
133. The compound of any one of claims 111-113, wherein R41 is unsubstituted Ce- 2oaryl.
134. The compound of any one of claims 111-113, wherein R41 is substituted Ce- 2oaryl.
135. The compound of claim 134, wherein the aryl is substituted with one or more of Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci- ehaloalkyl,-NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, OC1-6haloalkyl.
136. The compound of any one of claims 111-113, wherein R41 is unsubstituted C6-20heteroaryl.2026.05.07 CLAIMS P000685WO137. The compound of any one of claims 111-113, wherein R41 is substituted Ce- 2oheteroaryl.
138. The compound of claim 137, wherein the C6-2oheteroaryl is substituted with one or more of Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci- ealkyl, Ci-ehaloalkyl,-NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-6alkyl)Ci-6alkyl, -NHC1-6alkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl.
139. A compound of formula XV or a salt thereofwhereinL is C1-6alk; andR41 is substituted or unsubstituted Ci -ealkyl; substituted or unsubstituted Ce-2oaryl;substituted or unsubstituted C5-20 heteroaryl; substituted or unsubstituted C3- locycloalkyl, substituted or unsubstituted Cs- cycloalkenyl, substituted or unsubstituted Cs-wheterocycloalkyl, or substituted or unsubstituted C3- 1 oheterocycloalkenyl.
140. The compound of 139, wherein L is Cialk (CH2).
141. The compound of claim 139 or claim 140, wherein R41 is unsubstituted C3-10cycloalkyl.
142. The compound of claim 139 or claim 130, wherein R41 is substituted C3- locycloalkyl.
143. The compound of claim 141 or claim 142, wherein the Cs- cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl, cyclooctanyl, adamantanyl, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2.octanyl, spiro[3.3]heptanyl, spiro[4.4]nonanyl, spiro[2.4]heptanyl, spiro[3.4]octanyl, bicyclo[4.2.0]octanyl, bicyclo[4.3.0]nonanyl, bicyclo[4.4.0]decanyl, bicyclo[3.1.0]hexanyl, bicyclo[3.2.0]heptanyl, bicyclo[3.3.0]octanyl, bicyclo[4.1,0]heptanyl, tetrahydronapthalenyl, or dihydroindenyl.
144. The compound of claim 143, wherein the Cs- cycloalkyl is substituted with one or more of Ci-ealkyl, C2-6alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-2026.05.07 CLAIMS P000685WOealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-6alkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl.
145. The compound of any one of claim 139 or claim 140, wherein R41 is unsubstituted Cs- cycloalkenyl.
146. The compound of any one of claim 139 or claim 140, wherein R41 is substituted Cs- cycloalkenyl.
147. The compound of claim 145 or claim 146, wherein the C3-10cycloalkenyl is cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, adamantenyl, bicyclo[2.2.1]heptenyl, bicyclo[2.2.2.octenyl, spiro[3.3]heptenyl, spiro[4.4]nonenyl, spiro[2.4]heptenyl, spiro[3.4]octenyl, bicyclo[4.2.0]octenyl, bicyclo[4.3.0]nonenyl, bicyclo[4.4.0]decenyl,bicyclo[3.1.0]hexenyl, bicyclo[3.2.0]heptenyl, bicyclo[3.3.0]octenyl, bicyclo[4.1.0]heptenyl, or dihydronapthalenyl.
148. The compound of claim 147, wherein the Cs- cycloalkenyl is substituted with one or more of Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci- ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl.
149. The compound of any one of claim 139 or claim 140, wherein R41 is unsubstituted Ce-wheterocycloalkyl.
150. The compound of any one of claim 139 or claim 140, wherein R41 is substituted Ce-wheterocycloalkyl.
151. The compound of claims 149 or claim 150, wherein the C3-10heterocycloalkyl is aziridinyl, oxiranyl, thiiranyl, azetidinyl, diazetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, dioxolanyl, tetrahydrothiophenyl, oxathiolanyl, sulfolanyl, piperiinyl, piperazinyl, tetrahydropyranyl, dioxanyl, thianyl, dithianyl, morpholinyl, thiomorpholinyl, thiomorpholinyl dioxide, pyrrolizidinyl, decahydroisoquinolinyl, decahydroquinolinyl, tetrahydroquinolinyl, quinuclidinyl, azaadamantanyl, oxepanyl, oxaspiro[4.5]decanyl, dioxaspiro[3.4]octnyl, oxaazaspiro[3.5]nonanyl, or dioxaazaspiro[4.4]nonanyl.
152. The compound of claim 151, wherein the Cs-wheterocycloalkyl is substituted with one or more of Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci- ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl.
153. The compound of any one claim 139 or claim 140, wherein R41 is unsubstituted Cs-ioheterocycloalkenyl.
154. The compound of any one of claim 139 or claim 140, wherein R41 is substituted Ce- heterocycloalkenyl.2026.05.07 CLAIMS P000685WO155. The compound of claim 154, wherein the Cs-wheterocycloalkenyl is substituted with one or more of Ci-ealkyl, C2-ealkenyl, halogen, oxo, OH, -OCOCi. ealkyl, -COO Ci-ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, - N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl.
156. The compound of any one of claim 139 or claim 140, wherein R41 is unsubstituted C1-6alkyl.
157. The compound of any one of 139 or claim 140, wherein R41 is substituted Ci- ealkyl.
158. The compound of claim 157, wherein the C1-6alkyl is substituted with one or more of C2-6alkenyl, halogen, oxo, OH, -OCOC1-6alkyl, -COO C1-6alkyl, C1-6haloalkyl, -NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, OC1-6haloalkyl.
159. The compound of any one of claim 139 or claim 140, wherein R41 is unsubstituted C6-20aryl.
160. The compound of any one of claim 139 or claim 140, wherein R41 is substituted C6-20aryl.
161. The compound of claim 160, wherein the aryl is substituted with one or more of Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci-ealkyl, Ci- ehaloalkyl,-NHCOOC1-6alkyl, -NC1-6alkylCOOC1-6alkyl, -N(C1-6alkyl)C1-6alkyl, -NHC1-6alkyl, NH2, or OC1-6alkyl, OC1-6haloalkyl.
162. The compound of any one of claim 139 or claim 140, wherein R41 is unsubstituted Ce-2oheteroaryl.
163. The compound of any one of claim 139 or claim 140, wherein R41 is substituted C6-20heteroaryl.
164. The compound of claim 163, wherein the Ce-2oheteroaryl is substituted with one or more of Ci-ealkyl, C^alkenyl, halogen, oxo, OH, -OCOCi-ealkyl, -COO Ci- ealkyl, Ci-ehaloalkyl, -NHCOOCi-ealkyl, -NCi-ealkylCOOCi-ealkyl, -N(Ci-ealkyl)Ci-ealkyl, -NHCi-ealkyl, NH2, or OCi-ealkyl, OCi-ehaloalkyl.
165. A compound of formula X’ or a salt thereof or a compound of formula X’-A or a salt thereof2026.05.07 CLAIMS P000685WOL is Ci-ealk;is a single bond or a double bond;R41 is substituted or unsubstituted Ci-ealkyl; substituted or unsubstituted Ce-2oaryl; substituted or unsubstituted C6-2oheteroaryl; substituted or unsubstituted C3- cycloalkyl, substituted or unsubstituted Cs-wheterocycloalkyl, substituted or unsubstituted Cs- cycloalkenyl, or substituted or unsubstituted C3- 1 oheterocycloalkenyl;R21 is H, Ci-ealkyl, Co-ealkCOOCi-ealkyl, Co-ealkOCOCi-ealkyl, Co-ealkCOOH, Ci-ealkyl- OH, Co-ealkOCi-ealkyl, Co-ealk-aryl, halogen, Co-ealkCONHCi-ealkyl, Co- ealkCONH-aryl, Co-ealkCONH-heteroaryl, Co-ealkCONH-cycloalkyl, Co- ealkCONH-heterocycloalkyl;T is a bond, arylene, heteroarylene, alkynylene, alkenylene, or -O-;R31 is H, halogen, -CN, Co-ealkCi-ealkyl, Co-ealkCOOCi-ealkyl, Co-ealkCOOCi-ealkene, Co-ealkCOOCi-ealkyne, Co-ealkOCOCi-ealkyl, Co-ealkOCOCi-ealkene, Co-6alkOCOCi-6alkyne, Co-ealkCOOH, Co-ealkCONHCi-ealkyl, Co-ealkCON(Ci-6alkyl)2, Co-ealkCONHOH, Ci-ealkyl-OH, Co-ealkOCi-ealkyl, Co-ealkOCi-ealkOCi- ealkyl, halogen, Co-ealk-cycloalkyl, Co-ealk-cycloalkenyl, Co-ealk- heterocycloalkyl, Co-6alk-heteroaryl, Co-ealk-aryl, Co-ealk-substituted aryl, Co- ealk-cycloalkyl, or C^alkenyl;Q is CR51R51, wherein each R51 is independently H, Ci-ealkyl, alko-eCOOCi-ealkyl, alko- eOCOCi-ealkyl, alko-eCOOH, Ci-ealkyl-OH, or alko-eOCi-ealkyl; andn is an integer that is 1, 2, 3, or 4.
